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Background: Living kidney donor transplantation is the ideal treatment for many 
patients with kidney failure. However, the living donor evaluation process has been 
criticized by patients and healthcare providers as inefficient. In the present research, we 
evaluated the inefficiency of the living donor evaluation process. 
Methods: We conducted a scoping review of the literature and obtained data from large 
administrative datasets (1256 living donors) and medical chart review (849 prospectively 
recruited living donors across 12 transplant centres plus retrospective analysis of 1065 
living donor candidates from a single centre).  
Results: The median time to complete the entire evaluation was 9-11 months for donors 
and 4.3 months for candidates who were declined or withdrew from the evaluation. Up to 
35% of recipients who could potentially have received a pre-emptive transplant (avoided 
dialysis entirely) started dialysis before transplantation, costing the healthcare system 
$8.1M for dialysis alone. Shortening the evaluation time by only 10% translated to an 
annual cost savings of at least $1.3M in Ontario due to averted dialysis costs and up to 38 
intended recipients each year could have received a transplant they otherwise did not 
receive (17% increase in living donor transplantation). The cost to the healthcare system 
was $3,641 for the donor evaluation, $11,695 for the donor surgery (including 
perioperative costs), and $933 for the first year post-donation. There are many reasons 
that may contribute to a longer living donor evaluation. Donation through kidney paired 
donation prolonged the time until donation by 6 months. The evaluation time was 
doubled if the intended recipient started dialysis part-way through the donors’ evaluation. 
Finally, every month delay in the recipient referral extended the time until donation by 
0.4-0.9 months and increased the likelihood that the recipient would start dialysis before 
transplant. Between-centre differences were observed for evaluation times and donation 
costs. 
Conclusions: The living donor evaluation is time-consuming, resulting in potentially 




and the healthcares system. Potential strategies to improve the efficiency of this process 
include eliminating unnecessary or redundant tests, evaluating multiple donor candidates 
simultaneously, performing 1-day evaluations, and promoting earlier recipient referrals. 
Keywords 
Living kidney donation; efficiency; evaluation; pre-emptive transplant; costs; living 
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Chapter 1  
1 Background 
The kidneys are mainly responsible for eliminating wastes and excess fluids through 
urine production. For a healthy adult, the kidneys filter more than 90 milliliters of blood 
every minute per 1.73 m2 (normalized for body surface area), a feat that declines 
naturally with age.1 Chronic kidney disease (CKD) is defined as a sustained filtration rate 
of less than 60mL/min/1.73 m2, resulting in ionic imbalances that can lead to mineral 
bone disorders and cardiovascular complications that will ultimately result in kidney 
failure (e.g. a filtration rate <5 mL/min/1.73 m2) and death if left untreated.2–5 Filtering 
the blood through dialysis is currently the best technological means of mimicking the 
native kidney, but is associated with a variety of complications (morbidity and mortality 
is high) and is time and resource intensive for both patients and providers.6–8 For some 
patients, their kidney disease can be managed and disease progression can be effectively 
slowed through medication (e.g. phosphate binders), dietary restrictions (e.g. limiting 
fluid intake; low-protein diet), lifestyle changes (e.g. smoking cessation), or early 
detection (e.g. through screening of high-risk patients).9–11 For others, the progression to 
kidney failure is sudden and unpredictable, requiring rapid initiation of dialysis.12 
Adequately preparing patients for dialysis takes months of planning related to sustaining 
dialysis access and choosing the right modality for the patient that includes location (e.g. 
at home or in the clinic), type (e.g., hemodialysis or peritoneal dialysis), and the 
frequency and timing of dialysis sessions. Compared with dialysis, kidney transplantation 
is associated with increased longevity, improved quality of life, and results in substantial 
cost savings to the healthcare system beginning as early as 1 year after 
transplantation.5,13–16 Among kidney transplants performed in the United States between 
1996 and 2005, grafts remained viable for a median of 10-27 years depending on the type 
of donor.17 Thus, kidney transplantation offers patients with end-stage kidney disease the 
best chance for dialysis-free survival. Despite this, the number of transplantable kidneys 
available from deceased donors does not meet the need, and there is opportunity to 




1.1 Some statistics on kidney disease and transplantation* 
The incidence of kidney failure in Ontario has risen steadily from 180 to 219 per million 
population between 2006 and 2015 (Figure 1).18 As the risk factors for CKD continue to 
rise (particularly obesity, hypertension, and diabetes), the burden of CKD and kidney 
failure among Canadians is also expected to rise; the most common causes of CKD are 
diabetes (38%), renal vascular disease (14%), and glomerulonephritis (11%).18,19 
 
Figure 1: Incident end-stage kidney disease patients by province/territory, Canada 
(excluding Quebec), 2006 to 2015. Source: Canadian Organ Replacement Register, 2016, 
Canadian Institute for Health Information; Statistics Canada. 
Despite the benefits of transplantation, dialysis is typically the first treatment given: 76% 
of patients with kidney failure received hemodialysis and 21% received peritoneal 
dialysis over the last decade (Figure 2).18 In 2015, 41% (15,037/36,251) of Canadians 
living with end-stage kidney disease were living with a functioning transplant, which is 
only a modest rise from the 39% observed in 2006.18 
                                                 
 
*
 All statistics derived from the Canadian Organ Replacement Register (CORR) exclude Quebec because 





















Figure 2: Incident end-stage kidney disease patients by initial treatment, Canada 
(excluding Quebec), 2006 to 2015 (percentage of total). Source: Canadian Organ 
Replacement Register, 2016, Canadian Institute for Health Information; Statistics Canada. 
 
Most kidney transplants across Canada are made possible by deceased donors (60%) 
(Figure 3).18 The rate of living kidney donation has stagnated or even declined since 2006 
and remains well below the rate of deceased donation.20–23 This trend was observed 
across Canadian provinces, and by 2015 the proportion of all kidney transplants that were 
enabled by a living donor was 41% in Manitoba, 40% in British Columbia, 37% in 
Alberta, 37% in Ontario, and 26% in Nova Scotia.18 On an international stage, Canada 
ranked below the United States and Norway on the number of living donor transplants 













2005 2007 2009 2011 2013 2015










Figure 3: Number and proportion of kidney transplants enabled by living and 
deceased donors. Source: Canadian Organ Replacement Register, 2016, Canadian Institute for 
Health Information; Statistics Canada. 
1.2 Living donor kidney transplantation 
Living donation is preferred over deceased donation because it can be planned (i.e., 
scheduled), wait-time is reduced, and organ ischemic time† is reduced, leading to better 
recipient outcomes.5,24,25 Between 2013 and 2015, the median time spent on dialysis until 
transplant was 4.0 years from a deceased donor and 1.6 years from a living donor (Figure 
4).18 Considering the potential for pre-emptive transplantation (transplant occurring 
before dialysis onset), this falls to 0.84 years for living donation (deceased donation 
remained at 4.0 years).18  
Pre-emptive transplantation is recognized by many healthcare professionals as the ideal 
treatment for patients with kidney failure.26 Pre-emptive transplantation avoids 
complications related to dialysis (e.g. infection of dialysis catheters) and promotes better 
survival as the time on dialysis is minimized.7,27–30 Despite this, pre-emptive transplants 
                                                 
 
†
 The time spent without oxygen, usually due to removal of the organ from the body’s blood supply (e.g. 
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only occurred in 3% of Canadians, a proportion that has remained stable from 2006 
through 2015 (Figure 2).18 Pre-emptive transplants are mostly made possible by living 
donors due to deceased donor allocation systems that distribute organs and tissues by 
need (e.g. by time spent on the wait-list, and this generally only accrues after dialysis 
initiation).31 
 
Figure 4: Median time on dialysis before transplant (years), excluding pre-emptive 
transplantation. Source: Canadian Organ Replacement Register, 2016, Canadian Institute for 
Health Information; Statistics Canada. 
1.2.1 Barriers to living kidney donation 
Several barriers to living kidney donation have been identified, including difficulties in 
identifying potential donors (“The Ask”), financial barriers associated with donation, a 
lack of knowledge of the long-term medical and psychological risks to donors, a lack of 
patient and provider education, socioeconomic and demographic factors leading to 
disparities in access to living donor transplantation (i.e., cultural, geographical, financial 
barriers), a lack of social support, and a lack of general knowledge about living kidney 
donation.32–44 While these areas of research tackle critical barriers that may improve 
living kidney donation rates or the number of living donor candidate evaluations 

















received relatively little attention and is the focus of this research: the living kidney donor 
evaluation process is too long, difficult to complete, and is inefficient.45 
1.2.2 Efficiency of the living donor candidate evaluation process 
Prior donors and recipients have strongly advised that it is necessary to “be your own 
advocate”, shedding light on the frustration and difficulty of navigating the healthcare 
system and completing the living donor evaluation process.46,47 Several donors view the 
evaluation as the worst phase of the donation experience.47,48 Recommendations from a 
recent international consensus conference cite the efficiency of the evaluation as a high-
priority area for research.49,50 These sentiments were further promulgated in the 2017 
Kidney Disease: Improving Global Outcomes (KDIGO) Guideline on the Evaluation and 
Care of Living Kidney Donors and the United Kingdom’s guidelines on Living Donor 
Kidney Transplantation.51,52 Despite these recent advances, recommendations to improve 
the efficiency of the evaluation are not supported by evidence and are predominantly 
based on the ideas of key opinion leaders.49 More work is needed to understand the 
current state of the evaluation process, the gaps in care created by an inefficient 
evaluation, and tractable solutions to improve the evaluation process. 
1.2.3 Thesis breakdown 
In Chapter 2, I briefly describe the main components that are required to complete a 
thorough living donor evaluation. Chapter 3 is a targeted discussion on various 
components of the evaluation where efficiency improvements have been recommended. 
Chapter 4 follows with a scoping review of the literature to understand the knowledge 
gaps and summarize the research conducted on the efficiency of the living donor work-
up.  
Chapter 5 describes the specific aims of the thesis. Chapter 6-10 follow with original 
work to satisfy these aims. Finally, Chapter 11 provides an overall discussion of the work 
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Chapter 2  
2 Evaluation and Selection of the Living Kidney Donor 
Candidate‡  
The purpose of this chapter is to describe the main components of the living donor 
evaluation. Although an efficient evaluation is not the subject matter, this chapter is a 
useful source of reference for the remainder of the thesis. 
2.1 Introduction 
The practice of living donor kidney transplantation is based on the principle that the 
benefits to the recipient outweigh the minimal risks to the carefully evaluated and 
selected living donor. Living kidney donors should undergo a rigorous evaluation and 
selection process to ensure that the short- and long-term risks to the donor are minimized. 
In addition to this, the benefits and risks to the intended recipient are also considered. 
From the recipient perspective, an aim is to select donors who will provide adequate graft 
function while minimizing the transmission of any donor-derived diseases, such as 
infections or malignancy. To mitigate potential conflict of interest, it is recommended 
that the evaluations of the donor candidate and the intended recipient be performed by 
separate, independent healthcare teams.1–5  
Multiple guidelines assist clinicians in the complex process of donor evaluation and 
selection. A systematic review of these clinical practice guidelines found that while many 
recommendations were consistent, important variations exist and many appeared to lack 
methodological rigor.6 The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) 
‘Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors’ 
provides a comprehensive set of best practice recommendations based on a systematic 
                                                 
 
‡
 A version of this chapter has been accepted for publication as a subsection of a book chapter. Steven 
Habbous was responsible for completing this subsection of the book chapter: Lam NN, Habbous S, Garg 




evidence review, de novo evidence generation, and expert opinion when evidence was 
lacking.1 When possible, the guideline recommends that transplant programs establish 
numeric thresholds for short- and long-term post-donation risks above which the program 
will not accept the candidate for donation. It also demonstrates how tools can be 
developed to help estimate a donor candidate’s risk of long-term complications such as 
end-stage kidney disease based on their individualized set of pre-donation demographic 
and health characteristics. 
A central goal of the KDIGO guideline is to promote “consistent, transparent and 
defensible decision-making” based on comparisons of individualized, quantitative 
estimates of donor risks “to a transplant program’s acceptable risk threshold”.1 Risk 
threshold is defined as the upper limit of acceptable risk established by a program for 
donor candidate selection. Under this framework, when a candidate’s estimated risk is 
above the acceptable threshold, the transplant program is justified in declining the 
candidate and can ground its decision in a quantitative framework. When a donor 
candidate’s estimated risk is below the acceptable risk threshold, the transplant program 
should accept a donor candidate, and it should be the candidate’s decision whether to 
proceed with living kidney donation after being informed of the risks. Once established, 
acceptable risk thresholds should be applied consistently and transparently for all donor 
candidates evaluated at a program. The KDIGO framework was informed by a systematic 
evidence review.7 The KDIGO group also developed a tool to quantify a donor 
candidate’s risk of post-donation complications such as end-stage kidney disease. This 
tool projects the 15-year and lifetime risk of renal failure based on level of predonation 
glomerular filtration rate (GFR) and other baseline demographic and health factors.8 For 
practical applications, the resulting risk models were incorporated into an online risk 
prediction tool (http://www.transplantmodels.com/esrdrisk. The tool serves as an 
example, and can be improved with future research efforts for various types of living 
kidney donors worldwide.  
The evaluation process should include a comprehensive history, physical exam, 
laboratory and radiological investigations, and specialist consultations. Aspects of the 




components and what is considered required or additional testing. Depending on local 
resources and policies, transplant programs may also choose to evaluate multiple donors 
for an intended recipient either simultaneously or sequentially. The 2017 KDIGO living 
kidney donor guideline recommends that all donor candidates should be evaluated using 
the same criteria, regardless of who the intended recipient is.1  
2.2 Kidney function 
The purpose of evaluating GFR in kidney donor candidates is to detect kidney disease 
and to project long-term outcomes for the candidate and their recipient should they 
proceed with donation. Recommended methods for evaluating GFR in donor candidates 
are based on the 2012 KDIGO CKD guideline.9,10 Considering practicality, test 
availability, and costs, the 2017 KDIGO living donor guideline recommends initial 
estimated GFR (eGFR) based on serum creatinine (eGFRcr) and confirmation using one 
or more of the following measurements according to their availability: measured GFR 
(mGFR) from clearance of exogenous radio-labeled filtration markers, measured 
creatinine clearance (mCrCl) based on collecting a timed (24-hour) urine specimen, 
eGFR based on serum creatinine and cystatin (eGFRcr-cys), or repeated eGFRcr; the 
latter being the least preferred approach.1,9,10 Although mGFR or mCrCl is required for 
donor evaluation in the United States according to Organ Procurement and 
Transplantation Network (OPTN) policy, a timed urine collection for albumin excretion 
rate (AER) is not required (i.e., measurement of urine protein or albumin may be 
performed on a random “spot” urine sample). In countries where clearances are required 
for assessment of GFR, an efficient strategy may be to omit timed urine collections and 
rely on mGFR using clearance of an exogenous filtration marker and a random urine 
albumin-to-creatinine ratio (ACR). In countries where clearance measures are not 
required for assessment of GFR, transplant programs could obtain eGFRcr, eGFRcr-cys, 
and urine ACR prior to a candidate donors’ visit to the center.11  
The 2017 KDIGO living kidney donor guideline recommends a GFR ≥90 mL/min/1.73 
m2 as an acceptable level of kidney function for donation, while donor candidates with 




with GFR 60-89 mL/min/1.73 m2 should be individualized based on demographic and 
health profiles. 
2.3 Albuminuria 
Elevated protein in the urine (proteinuria) may suggest the presence or risk of developing 
kidney disease due to increased permeability of the glomeruli to protein, and/or an 
inability of the renal tubules to reabsorb protein. Until acceptable standardization 
methods are available for quantifying deficiencies in tubular reabsorption, urine albumin 
remains the most reliable indicator of kidney disease, standardized to urinary creatinine 
as the ACR. The 2017 KDIGO living kidney donor guideline recommends initial 
evaluation using ACR in a random urine specimen with confirmation by AER (from a 
timed urine specimen) or otherwise a second random urinary ACR. Donor candidates 
with an AER >100 mg/d (or ACR >30 mg/mmol) should not donate. Such candidates 
have microalbuminuria and are at an elevated risk of developing chronic kidney disease 
in their lifetime.12 Candidates with an AER <30 mg/d (or ACR <3 or below the 
detectable limit of the assay) may be acceptable for donation, while the decision to 
approve donor candidates with AER 30 to 100 mg/d should be individualized based on 
demographic and health profiles in relation to the transplant program’s acceptable risk 
threshold. 
2.4 Hematuria 
The persistent presence of blood in the urine (hematuria) is another indicator for the 
presence or risk of developing kidney disease. Presence of hematuria is established by 
visualizing 2-5 red blood cells per high-powered field on microscopic evaluation. 
“Persistence” is established if hematuria is observed in more than 50% of urine samples 
obtained from 2-3 separate occasions. When hematuria is persistent, further investigation 
is warranted which many include a urine culture for bacterial or fungal infection (this 
may be treated without affecting candidacy), a 24-hour urine kidney stone panel, a 
cystoscopy, imaging to rule out a urinary tract malignancy, and a kidney biopsy to rule 
out underlying kidney disease (thin basement membrane disease may not be a 




2.5 Kidney stones 
A renal calculus in the donor’s remaining kidney may affect kidney function if it results 
in ureteral obstruction. Reassuringly, living kidney donors do not appear to have an 
increased risk of kidney stones requiring treatment with surgical intervention compared 
to healthy, matched non-donor controls (median follow-up of 8 years).15 Evaluation of 
kidney stones in living kidney donor candidates includes a history from the candidate, 
laboratory investigations, including persistent microscopic hematuria, and renal imaging 
such as computed tomography. If suspected, further investigations may be performed, 
including parathyroid hormone measurements and 24-hour urine collections for 
metabolic testing. A history of previous stones does not necessarily rule out donation, 
particularly small, unilateral, non-recurrent stones.1 There is also the option to remove 
small kidney stones at the time of procurement prior to transplantation.16 
2.6 Hyperuricemia, gout, and metabolic bone disease 
Compared to non-donor controls, living kidney donors have an increased risk of gout 
(3.4% versus 2.0% in non-donor controls, a median 8 years after donation).17 This may be 
due to the reduced ability of a single kidney to excrete excess uric acid, a precursor to 
gout. Although a comprehensive gout assessment is not usually conducted for all 
candidates, pre-donation serum urate is frequently ordered alongside other biochemical 
indicators of metabolic kidney disease, including inorganic phosphate, calcium, and 
parathyroid hormone. Living kidney donor nephrectomy may lower the concentration of 
1,25-dihydroxyvitamin D and phosphate and raise the concentration of parathyroid 
hormone, with no appreciable effect on the concentration of calcium. Whether these 
changes in bone mineral metabolism alter skeletal fracture risk in living kidney donors is 
an open question. To date, a single study of over 2,000 living kidney donors (median age 
43 years) matched to a segment of the general population selected for good health has 
found that after a median follow-up of 6.6 years (maximum 17.7 years), the rate of 




2.7 Blood pressure 
Sustained elevated blood pressure is a common cause of kidney disease, and conversely, 
kidney disease may accelerate the development of high blood pressure. Candidates with 
hypertension are eligible for donation only if their blood pressure can be controlled with 
anti-hypertensive medications and that they are without end-organ damage related to their 
hypertension.1 The systolic and/or diastolic blood pressure thresholds and the nature of 
the anti-hypertensive medications used (e.g. number of agents, class of drugs, and dosage 
used) to disqualify a candidate may vary across programs and according to other 
candidate characteristics. Blood pressure measurements should be performed on at least 
two separate occasions by trained personnel. An ambulatory (e.g. 24-hour) blood pressure 
monitor may be used if hypertension is suspected. Donor candidates with hypertension 
that can be controlled to less than 140/90 mmHg using 1 or 2 antihypertensive agents, 
and who do not have evidence of target organ damage, may be acceptable for donation. 
The decision to approve donation in persons with hypertension should be individualized 
based demographic and health profiles in relation to the transplant program’s acceptance 
risk threshold. 
2.8 Metabolic and lifestyle risk factors 
Obesity is a strong risk factor for diabetes, cardiovascular disease, and kidney disease. 
Living donor nephrectomy is more difficult for patients with excess visceral fat, 
increasing the risk of perioperative complications including infection, blood loss, and 
delayed wound healing.19 Various body mass index (BMI) cut-points have been reported 
in the literature as absolute or relative contraindications to donation. Elevated serum 
glucose or glucose intolerance are also strong risk factors for diabetes. Apart from 
personal and family history assessments of diabetes (childhood, adult-onset, gestational), 
glycosylated hemoglobin and serum and urinary glucose are typically measured early in 
the assessment of all candidates. Fasting glucose and glucose tolerance tests are 
recommended for high-risk candidates (e.g. high random glucose, positive family 
history). According to the 2017 KDIGO living kidney donor guideline, donor candidates 
with type 1 diabetes mellitus should not donate. The decision to approve donor 




demographic and health profiles in relation to the transplant program’s acceptance 
threshold. Donor candidates with prediabetes and type 2 diabetes should be counseled 
that their condition may progress over time and may lead to end-organ complications.1 
Less evidence is available to comment on the influence of predonation lipids (e.g. 
cholesterol, triglycerides, and high-density and low-density lipoproteins) and smoking on 
donor candidacy, although notably, smoking was a strong risk factor for kidney failure in 
healthy persons.8 While candidates should be educated and encouraged to modify their 
dietary and smoking habits, eligibility based on these factors may vary across programs. 
Smoking should be considered as part of comprehensive risk assessment. 
2.9 Screening for transmissible infections 
To minimize the risk of viral transmission from the donor to the recipient, the evaluation 
should include assessment of prior history of infections, recent travel history, and 
virology screens early in the evaluation and again within the 2-4 weeks of donation to 
minimize the window of infection.20,21 The 2017 KDIGO living kidney donor guideline 
recommends screening for human immunodeficiency virus, hepatitis B and C, Epstein-
Barr virus, cytomegalovirus, syphilis, urinary tract infection, and other potential 
infections based on geography and environmental exposures.1 If a donor candidate is 
found to have a potentially transmissible infection, then the donor candidate, the intended 
recipient and transplant team should weigh the risks and benefits of proceeding with 
donation, and develop a management plan if the decision is to proceed with donation. 
2.10 Cancer screening 
All candidates should be up-to-date with local cancer screening guidelines according to 
age, sex, and family history. Donors with active cancer are generally not eligible to 
donate. Donors with a prior history of successfully treated cancer with a high risk of 
reoccurrence may be excluded from donation because anti-neoplastic agents may be 
nephrotoxic, and because transmission of cancer from the donor to the recipient can have 
serious consequences to the immunocompromised recipient.22 Candidates with a prior 
history of cancer with a low risk of reoccurrence may be considered on a case-by-case 




(III or higher) or small (T1a) renal cell carcinoma curable by nephrectomy) may be 
acceptable for donation, and the donor and recipient provide consent for the cancer to be 
resected at the time of donor nephrectomy.23,24 
2.11 Genetic kidney diseases 
If the donor candidate is biologically related to the intended recipient, the cause of the 
recipients’ kidney disease should be well understood before accepting the candidate. 
Candidates with a genetic kidney disease generally are not eligible to become donors. If a 
candidate has a family history of a genetic kidney disease, the candidate may be eligible 
to donate if the risk of developing kidney disease after donation is acceptably low and the 
risks are discussed with the candidate. Genetic diseases that may be assessed during the 
donor candidate evaluation include autosomal dominant polycystic kidney disease, 
APOL1-related kidney disease, atypical hemolytic uremic syndrome, Alport syndrome, 
Fabry disease, familial focal segmental glomerulosclerosis, and autosomal dominant 
tubulointerstitial kidney disease.  
If a donor candidate is of sub-Saharan African ancestry, testing for APOL1 risk alleles 
may be offered.25,26 The presence of two APOL1 risk alleles increases the lifetime chance 
of developing kidney failure even in the absence of donation. The effects of kidney 
donation on this risk are unknown, but are a topic of active research. 
2.12 Pregnancy 
While donation does not preclude future pregnancy and child-bearing, patients are not 
evaluated or do not donate while they are pregnant. A history of hypertensive disorders 
related to pregnancy (e.g. preeclampsia, gestational hypertension) increase the risk of 
developing kidney failure later in life, and the severity, timing, and frequency of these 
conditions should be considered before determining the potential donor’s candidacy. 
2.13 Psychosocial assessment 
The 2017 KDIGO living kidney donor guideline recommends that a psychosocial 




recipient), in the absence of the intended recipient (to reliably assess voluntariness), and 
by a professional independent from the care of the intended recipient. A thorough 
psychosocial assessment should minimize the incidence of poor psychosocial outcomes 
postdonation by careful selection or treatment (e.g. counseling).51 Quality of life is 
generally positive postdonation, but there have been instances of regret, depression, and 
financial hardships.52,53 
2.14 Conclusion 
This chapter summarized the main components of the living donor assessment, as well as 
quantitative and qualitative issues related to donor eligibility. With this background, 
concerns of efficiency can be discussed while completing a thorough evaluation. 
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Chapter 3  
3 Optimizing efficiency in the evaluation of living donor 
candidates: Best practices and implications§ 
 
3.1 Introduction 
Compared with chronic dialysis, kidney transplantation is associated with increased 
survival, improved quality of life, and reduced costs to the healthcare system.1–5 Living 
donor transplant is preferred over deceased donor transplant because the surgery can be 
scheduled when the recipient is in optimal health, without the wait for a deceased donor 
kidney to become available, potentially avoiding the need to start dialysis (pre-emptive 
transplantation), with a better graft survival than deceased donor kidney 
transplantation.6,7 Despite these benefits to the recipient, in most regions the rate of living 
kidney donation has been stagnant over the last decade and remains well below the rate 
of deceased donation.8–12 Thus, there is interest in safely increasing the number of living 
donor kidney transplants. 
There are many recognized barriers to living kidney donation. One barrier that has 
received little attention, and is the focus of this review, is inefficiencies in the living 
kidney donor evaluation process.13 A study in Ireland reported that the donor evaluation 
process can exceed 2 years, leading to donor fatigue and eventual dropout.14 A multi-
center Canadian and Australian study reported a median evaluation time (from evaluation 
start until donation) of 10.3 months (Chapter 6).15 Notably, most donors feel that even 6 
months is too long for this process.16 The United Kingdom has set a target to complete 
the donor evaluation in under 5 months, but in current practice this target may not be 
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achievable in many programs.17 Although donor candidate withdrawal rates can reach 
30% in some centers, it is difficult to quantify how many of these withdrawals are 
attributable to a prolonged evaluation process.18,19 An international consensus conference 
highlighted the efficiency of the evaluation as a research priority.20,21 The 2017 Kidney 
Disease: Improving Global Outcomes (KDIGO) Guideline on the Evaluation and Care of 
Living Kidney Donors recommends that transplant programs conduct efficient donor 
evaluations, meeting the needs of donor candidates, intended recipients, and the 
transplant program.22 However, due to a lack of supporting evidence, this 
recommendation is ungraded.22 In this review, we examine reasons why the living kidney 
donor evaluation may be inefficient, and make recommendations to optimize this process.  
3.2 The Donor Candidate Evaluation 
A thorough evaluation will result in donor selection that will optimize the medical and 
psychosocial outcomes of the donor candidate and their intended recipient. Minimizing 
donor risk is one of the main objectives of the living donor candidate evaluation and is 
the reason why donors and recipients often have different healthcare teams responsible 
for their care.23,24  
A schematic of an overview of the evaluation process is shown in Figure 5. Typically, the 
donor candidate must contact the transplant program by phone, internet, or in person to 
express their interest in donation and initiate the evaluation process. Then, donor 
candidates complete a standard medical-social questionnaire and initial compatibility 
testing with an intended recipient (e.g. blood group). Following this, there is a more 
comprehensive set of laboratory and diagnostic investigations (Table 1). Candidates also 
meet with members of the transplant team in consultation, including nephrologists, 
surgeons, and psychosocial experts (e.g. social workers, psychologists). Candidates who 
meet the transplant center’s eligibility criteria and make an informed decision to proceed 
will then be scheduled for nephrectomy.  
For each of these steps, we offer recommendations that may lead to improved efficiencies 
with respect to reducing costs and/or the time to completion, drawing on the literature 




the minimal number of tests needed, use the least costly alternative, and avoid redundant 
or repeat testing. The living donor evaluation process is typically graded, organized to 
progress from less invasive and less costly tests to more invasive and costly tests, as 
needed.25,26 To improve technical efficiency, the process should attempt to maximize the 
number of successful donations with respect to the number of donor candidates who start 
the evaluation process. The process should also attempt to maximize the number of 
completed evaluations with respect to the number of donor candidates who start the 
evaluation (regardless of donation). 
 
Figure 5: General flow of the living donor evaluation process with potential 
efficiency improvements 
a Could also provide a living donor toolkit, with frequently asked questions, testimonials from previous 
donors, and details about the donation process 
b Automated data quality checks to ensure it is filled out completely 
c Care is needed to avoid evaluating the donor candidate too far ahead in case the recipient is never 
referred 
d Encourage multiple candidates to initiate the process  
e Can also have online tests to ensure the donor candidate understands the information provided to them 
 
3.2.1 First contact 
The donor candidate must self-refer to a living donor program. At first contact, the living 




identify any absolute contraindications (e.g. type 1 diabetes mellitus) or issues that must 
be resolved before the evaluation can proceed (e.g. very high body mass index, 
uncontrolled hypertension). One strategy to improve the efficiency of the first contact 
stage is to provide information on absolute contraindications on a trusted website to 
reduce contacts from ineligible donor candidates and the associated workload on living 
donor coordinators.27,28 Also, renal program staff working with patients with kidney 
failure and their families can provide basic education on absolute contraindications when 
discussing living kidney donation. 
Table 1: Tests related to the living donor evaluation 
Test Indication Paina 
Time to 
complete 
Time to results 
(approximately
) 
Location of test 
Initial screening  
    
First contact all 0 various immediately digital 
Medical-social questionnaire all 0 various 7 days digital or paper 
 
 
    
Compatibility testing  
    
ABO blood typing  all 1 5 min 1 day local lab 
HLA typing all 1 5 min 1 day hospital 
Biological crossmatching all 1 5 min 5 days hospital 
 
 
    
Blood  
    
Blood chemistry all 1 5min 1 day local lab 
Virology all 1 5min 1 day local lab 
Oral glucose tolerance test if indicated 1.5 2 hours 2 days local lab 
 
 
    
Urine  
    
Random urine test all 1 5 min 1 days local lab 
24-hour urine test program-
specificb 
2 24 hours 1 day local lab 
 
 
    
Imaging/other  
    
24-hour blood pressure monitor if indicated 2 24 hours 1 day home 
Electrocardiogram all 1 5 min 1 day local lab 
Chest x-ray all 1 10 min 1 day local lab 
Echocardiogram if indicated 1 1 hour 7 days hospital 
Renal ultrasound all 1 45 min 2 days local lab 
Renal imaging (CT or MR) all 2 1 hour 2 days hospital 
Nuclear renogram for split GFR if indicated 2 1.5 hours 2 days hospital 
Nuclear GFR if indicated 2 4.5 hours 2 days hospital 
Cystoscopy if indicated 3 15 min 1 day hospital 




Cancer screening if indicated 1-2 ? ? hospital or clinic 
 
 
    
Consults  
    
Nephrology consult all 1 1 hour 1 to 5 days hospital 
Surgical consult all 1 45 min 1 to 5 days hospital 
Social worker consult program-
specificb 
2 1.5 hours 5-6 days hospital or phone (at 
least one in person) 
Cardiology consult if indicated 1 1 hour 7 days hospital 
GFR – glomerular filtration rate; CT – computed tomography; MR – magnetic resonance; HLA – human leukocyte 
antigen 
a a subjective measure of invasiveness or pain based on our opinion (1 – least; 3 – most) 
b all or if indicated, depending on the program’s standard procedure 
 
At this stage, there is also an opportunity to prioritize donor work-up when multiple 
donor candidates come forward for the same recipient. The donor candidate that is 
assessed first should be the one who is most likely to donate (i.e., has fewer 
comorbidities, has a closer relationship to the intended recipient, is biologically 
compatible). Most living donor programs perform sequential evaluations (i.e. work up 
one donor at a time). Although this is a cost-saving strategy with regard to donor 
evaluation costs, if the primary candidate does not donate, then the potential recipient 
will have consumed more healthcare resources related to their disease while waiting 
longer for the next donor to be approved. Currently, there is no evidence that sequential 
donor evaluations are more cost-effective than simultaneous donor evaluations. 
3.2.2 Medical-social Questionnaire 
A questionnaire is the most effective way to obtain information on the donor candidate’s 
medical and psychosocial history, family history, and social habits (e.g. behaviour 
associated with transmissible infections, substance use). Results from the questionnaire 
can identify risk factors to both the donor and the recipient and inform the content of the 
evaluation or the order of tests. For example, some donors may require additional tests or 
consultations, while others may require a psychosocial assessment earlier than usually 
offered by the program.  
The medical-social questionnaire can be done at the time of first contact or can be 




programs, a coordinator completes this questionnaire over the phone or in person with the 
donor candidate. While such a process can be time-consuming and resource intensive, it 
has the advantage of allowing coordinators to answer any initial questions the donor 
candidate may have, as well as gather further information on their medical history, if 
positive. Other programs provide this questionnaire on their website to be downloaded or 
completed online by the candidate; however, online submission may create a backlog of 
completed questionnaires that cannot be reviewed by healthcare staff in a reasonable 
amount of time. The length of the questionnaire varies across programs. For example, 
individual programs in Canada can modify a standardized questionnaire that includes at 
least 50 questions.29 In contrast, a quality improvement initiative in Ireland developed a 
short (one-page) questionnaire with yes/no responses for ease of administration.14 
However, it is unclear whether the length of this questionnaire influences the time to 
complete the evaluation.  
3.2.3 Compatibility Testing 
Donor and recipient ABO blood typing, human leukocyte antigen typing, and cross-
match testing are required to minimize the risk that the donor kidney will be rejected by 
the intended recipient.30–32 If multiple donor candidates come forward for the same 
recipient, then it may be prudent to prioritize candidates who are more immunologically 
compatible. 
For biologically incompatible pairs, alternatives include kidney paired donation 
(incompatible donor-recipient pairs exchange with each other) or performing 
incompatible transplants with desensitization protocols (a treatment option that removes 
antibodies from the recipient and aggressively suppresses the immune system).33,34 Due 
to the costs and medical risks associated with desensitization, kidney paired donation is 
often the preferred option. However, kidney paired donation poses other challenges that 
may impact the efficiency of living donation, such as finding and organizing multiple 
exchanges with hard-to-match transplant candidates.35–38 Matching cycles are conducted 
intermittently (e.g. every 3-4 months), which may prolong the time until donation can 
occur and impose a barrier for some donor candidates.39 A recent study of 849 living 




donation by 6.6 months (Chapter 6).15 Furthermore, many donor candidates are unable or 
unwilling to travel to donate due to financial or time constraints or lack of family support. 
To address this barrier, one strategy is to transport the donor’s kidney to the recipient’s 
transplant hospital, recognizing that this may increase the cold ischemia time.40,41 
Medically suitable but biologically incompatible donors should be counseled early about 
the advantages and disadvantages of paired donation programs and be given the option to 
stop their evaluation early if they are not willing or able to proceed.  
3.2.4 Laboratory and Radiologic Testing 
For convenience, most initial blood and urine tests can be performed at local laboratories, 
rather than at the transplant center. These tests are typically performed before the donor 
candidate visits the transplant center for the first time, and the results can guide the 
remainder of the evaluation.42 For example, if a donor candidate has persistent 
microscopic hematuria on multiple urinalyses, further work-up would be recommended 
to rule out infection, renal calculi, malignancy, and renal pathology. To rule out bladder 
malignancy, consultation with a urologist for consideration of cystoscopy is routine; 
however, for low-risk patients (i.e., <35 years of age), this step may be unnecessary given 
its low yield.43 Moreover, cardiac evaluations (e.g., cardiology consultations, 
echocardiograms, nuclear stress tests) may not be necessary for donor candidates who 
have good exercise tolerance, yet guidelines are vague on this topic.43 
A 24-hour urine collection is used to measure the donor candidate’s creatinine clearance 
(an indicator of kidney function); however, results may be inaccurate in the setting of 
over- or under-collection.44 Currently, there is no consensus on how many 24-hour urine 
tests should be performed (range 0-2 tests considered as part of the standard work-up).15 
Although there is no evidence that eliminating this test from the evaluation process 
results in more timely completion, it may reduce the burden on donor candidates.15  
Due to its relatively low cost and high availability, renal ultrasound may provide the first 
image of the kidney in some regions. Renal ultrasound can identify cysts, kidney stones, 
and other anomalous findings in adjacent anatomy that require further investigation (i.e., 




magnetic resonance (MR) angiography, is a critical part of the living donor evaluation 
and may be reserved for a later phase of the evaluation because of its higher costs and 
wait times in some regions. CT or MR angiography provides higher resolution than renal 
ultrasound, enabling more accurate mapping of the renal vasculature, which is necessary 
to plan the donation surgery.48,49 Nuclear renogram has been recommended to measure 
the split kidney function to determine which kidney should be donated, if indicated by 
differential kidney dimensions identified earlier in the evaluation. Due to the graded 
nature of the evaluation, advanced (and costly) imaging modalities are usually performed 
later. When donor candidates do not proceed to this stage of the evaluation (i.e., declined 
or withdrew), these tests would not be needed and fewer resources would be used to 
complete the evaluation. Even in the setting of a 1-day evaluation, the CT scan may be 
scheduled later in the day and subject to cancellation following review of earlier test 
results by the consulting nephrologist or surgeon.14  
Other efforts to improve the efficiency of the living donor evaluation process have 
focused on eliminating the need for some tests, such as an assessment of split function 
with nuclear renogram. Some investigators have suggested using CT volumetry to 
estimate split kidney function instead of nuclear renogram.50,51 Others have devised an 
algorithm to omit the measured glomerular filtration rate (GFR) test to assess the total 
kidney function: donor candidates whose estimated kidney function (based on serum 
creatinine and/or cystatin C) is sufficiently high or sufficiently low that the measured 
GFR will not change the decision on the candidate’s eligibility may proceed or be 
declined without the need for measured GFR.52,53 
3.2.5 Consults 
All programs require donor candidates to receive consultation with a nephrologist and a 
surgeon, with less agreement on routine consultation with a psychosocial specialist.54 
Some programs have systems in place to permit all initial testing and imaging as well as 
consultations to be scheduled for the same visit. This is intended to reduce the travel 
burden for donor candidates, particularly for those who live far from the transplant 
center, but may also permit a one-day donor evaluation as a routine process for all donor 




months across Canada and Australia.14 Another strategy to improve the efficiency of the 
consultations may be to delay the surgical consult in patients without a significant history 
of abdominal surgery, who have a healthy weight, and no abnormalities on initial testing. 
In this way, the surgeon would only see patients who are more likely to proceed with 
nephrectomy. 
3.2.6 Donor Nephrectomy 
CT angiography is generally regarded as one of the late-phase tests in the evaluation, and 
may further delay the evaluation as there may be a significant waiting time to book a CT 
angiogram in some regions. One potential solution is to negotiate dedicated time with 
radiology, and so the living donor program can expect a given number of spots for living 
donor assessments each week. The average time from CT until donation was reported to 
be 4.8 months across Canadian and Australian centers, ranging from 3-8 months.15 If 
these delays are attributable to difficulties scheduling the operating room (OR), then 
efforts should be made to book the OR as early as possible, considering the needs of the 
donor candidate, the recipient, and the OR staff. Donor candidates often express times of 
the year when they can (or prefer to) donate so the recovery process will not greatly 
interfere with their work, dependent care, or other responsibilities. In situations where 
this leaves ample time for an evaluation, booking the OR should not be a factor delaying 
the time until donation. Conversely, if an expedited work-up is necessary, then the living 
donor program should work with the surgeons and the OR staff to book the ORs once the 
donor and recipient are likely to be approved (rather than waiting until the actual 
approval date). Alternatively, the living donor program could negotiate having a standing 
time in the OR schedule to accommodate the expected number of donations each year. 
3.2.7 Other Aspects of the Evaluation 
3.2.7.1 When does the living donor evaluation actually start? 
Most programs do not start the living donor evaluation until the recipient has at least been 
referred to the transplant program. Some programs may additionally require that the 
recipient is approved for transplant. This latter strategy is a cost-conscious one, avoiding 




this may delay the time until transplant, which will be particularly costly for recipients 
who are on dialysis. Although the optimal strategy to initiate the living donor work-up is 
unknown, the funding model and payer perspective are important considerations, as cost 
savings in one domain (fewer living donor evaluations) may not be reconciled by cost 
savings in another (less time on dialysis). In either case, earlier recipient referrals are 
expected to translate into earlier transplants. 
3.2.7.2 Navigators as part of the evaluation  
Donors are healthier than the general population, and may therefore be unfamiliar with 
healthcare systems. The use of prior recipients as navigators has been shown to be 
effective at increasing the number of steps completed as part of the evaluation for 
recipient candidates.55 In Ontario, a pilot Transplant Ambassador Program is being 
launched: by connecting potential donor and recipient candidates with prior donors and 
recipients, candidates will be better positioned to make decisions about donation or 
transplantation and will be better informed about navigating the evaluation process. The 
Transplant Ambassador Program is expected to increase the number of living donor 
candidates contacting programs and the number of evaluation tests completed, but will 
also be positioned to assess the impact of donor ambassadors on the timeliness of 
donation.56 
3.2.7.3 Cost to the living donor  
The out-of-pocket costs to the donor to participate in and complete the evaluation have 
been recognized as a substantial barriers to living kidney donation.57–59 Although 
reimbursement for at least some of these costs helps some donor candidates, others are 
still disadvantaged because reimbursement may occur some time after the evaluation is 
complete, be limited to only to those who complete an evaluation, or include only a 
portion of costs incurred (e.g., costs of travel and lodging, but not lost wages).59–63 A pre-
paid credit card for valid expenses or validated hospital parking may remove this barrier 
and allow candidates to complete the evaluation in a timely manner. Telemedicine is also 




live far from the transplant center. However, the effectiveness of such strategies has not 
yet been demonstrated. 
3.2.7.4 Evaluating center is not the same as the center where 
donation is intended 
The donor candidate is typically assessed at their home program, and if approved, their 
chart is sent to the intended donor recovery program for review. Differences in program-
specific evaluation and selection criteria may result in inefficiencies, particularly when 
the home program may not perform tests routinely done by the recovery center. This may 
lead to additional or redundant testing after the candidate has already been approved by 
the home center. To ameliorate this, for donor candidates enrolled in the Canadian kidney 
paired donation program, a minimum set of required tests has been established by 
consensus.29 However, for donor candidates who are not in the kidney paired donation 
program, this remains a potential source of inefficiency, and a uniform set of criteria for 
donor selection and evaluation should be adopted, regardless of donation strategy (direct 
donation, simple exchanges, national paired donation programs). 
3.3 The intersection of efficiency and quality 
Numerous quality indicators are reported by governmental health authorities each year 
that may be used to provide benchmarks or serve as indicators of quality, equity, or 
effectiveness. Common metrics include the number of deaths after an intended recipient 
has been approved for transplant but has not yet received one, the time spent on the wait-
list, the number of patients on dialysis, the number of living and deceased donor kidney 
transplants performed, and the burden of disease on the healthcare budget.64 A prolonged 
living donor evaluation will adversely affect most of these outcomes, but there are 
additional indicators that are important, yet not reported (Figure 6). If the intended 
recipient could receive a pre-emptive transplant, then this may avoid complications of 
kidney failure, reduce costs, and increase quality-adjusted life expectancy.65–69 A new 
study at five centers in Ontario, Canada found that one-third of living donor transplant 
recipients initiated dialysis prior to receiving their living kidney donor transplant, despite 




may increase the number of pre-emptive transplants.14,70 In a similar vein, if the intended 
recipient dies while the living donor is being evaluated, this can also have long-term 
implications on the psychosocial health of the donor candidate. Finally, since most 
programs do not remove transplant candidates from the deceased donor wait-list because 
they have a living donor, deceased donor kidney transplantation is a competing treatment 
option that prevents another recipient from receiving that deceased donor organ, if the 
deceased donor organ is accepted in favor of living donation.7 These outcomes are also 
not routinely reported. 
 
Figure 6 Potential implications of an inefficient living donor evaluation process. 
Once the living donor begins the evaluation and the intended recipient is approved 
for transplant, a prolonged evaluation may result in adverse consequences for the 
intended recipient, including dialysis initiation, transplantation from a deceased 
donor instead, or ineligibility resulting from death or illness. 
3.4 Recommendations for future research 
It is clear that an inefficient living donor evaluation can have substantive unintended 
consequences that have not yet been consistently measured and reported to date. The 
rather nebulous definition of “efficiency” complicates measurement using any single 
metric and likely requires multiple complementary indices.15 However, we propose a 
working definition: an efficient evaluation is one that is completed in as little time as 
possible, results in optimal outcomes, and meets the expectations of patients and 




Quality indicators are needed for quality improvement projects.14,71 Such indicators 
should be defined clearly and measured to enable comparisons between and within 
transplant programs. They should be measured retrospectively to provide an 
environmental scan and allow benchmarking, and also prospectively to facilitate 
monitoring in continuous audit-feedback loops. We recommend a few quality indicators, 
such as the total time until donation, among others15,70, but a systematic approach is 
needed to generate a more complete list and define measures operationally (i.e., these 
metrics may require uniform definition of the evaluation start date, or a minimum time 
sufficient to complete an average donor’s evaluation). We recommend that all 
stakeholders (patients, healthcare providers, insurers, and policy-makers) be involved in 
this process and remain engaged to identify, design, and implement solutions to improve 
the efficiency of the donor evaluation process. A more efficient living donor evaluation is 
expected to improve the living donor experience, increase the rate of living donor kidney 
transplants, improve recipient health, and reduce healthcare expenditures. 
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Chapter 4  
4 The efficiency of evaluating candidates for living kidney 
donation: a scoping review** 
 
4.1 Introduction 
An efficient living donor candidate evaluation is completed in as little time as possible 
and meets the needs of the donor candidate, the intended recipient, and the healthcare 
system. An inefficient evaluation process can result in missed opportunities for 
preemptive transplants if the intended recipient’s kidney disease progresses.1,2 If an 
intended recipient is approved for transplant but the evaluation of their living donor is 
delayed because of an inefficient healthcare process, this may cause anxiety and 
frustration for the recipient and the donor.3 Finally, there may also be missed 
opportunities for living donor transplants if the intended recipient receives a deceased 
donor kidney transplant while their donor is being actively evaluated.4 
A need to improve the efficiency of the living kidney donor candidate evaluation is 
featured in reports from patient advocacy groups, a recent consensus conference in the 
United States (U.S.), the 2017 Kidney Disease Improving Global Outcomes (KDIGO) 
international practice guideline, and a report from the National Health Services in the 
United Kingdom (U.K.) targeting an 18-week evaluation, where possible.5–8 However, 
while advocating for efficiency, these reports do not provide any recommendations on 
how efficiency can be achieved. 
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A review that summarizes existing information on the efficiency of the donor candidate 
evaluation can provide a necessary foundation for quality improvement.9 As a 
multidimensional construct (including the time to complete the evaluation, patient 
outcomes, and resource use), an efficient evaluation process may not easily be 
summarized in a single systematic review of a focused question. Instead, we undertook a 
scoping review to map the available literature to themes related to an efficient living 
kidney donor candidate evaluation. We also reviewed the websites of living donor 
programs from four countries to describe the information provided to candidates about 
the nature and length of the evaluation process. 
4.2 Methods 
4.2.1 Literature review:  
We followed the recommendations of the Joanna Briggs Institute for conducting and 
reporting scoping reviews.10 On September 12, 2017, one author (S.H.) searched 
bibliographic databases using the search terms “living AND kidney AND donor AND 
(assessment OR evaluation OR practice OR screening OR selection OR efficient OR 
efficiency)” [Medline (n=2,801 citations via PubMed), PsychInfo (n=58), EMBASE 
(n=2,899 via OVID), and ABI Inform Collection (n=5)]. Search terms were chosen based 
on terms associated with known articles of interest. Articles were restricted to human 
studies published in English from 2000 onwards. Conference abstracts were excluded. 
Studies were not restricted by age or country. Google searches and reference lists of 
relevant articles were screened and manually added if appropriate, regardless of 
publication date. The title, abstract, or full-text of an article was used to sort the literature 
into themes related to the efficiency of living kidney donor evaluations. We then 
summarized the findings within each theme, focusing on how they could be used to guide 
future efficiency improvements. Articles only considering how accepting donors with 





4.2.2 Living donor program websites:  
From May to August 2017, we searched the websites of living donor programs in 
Canada, U.S., U.K., and Australia for information related to an efficient evaluation 
process. 
4.2.3 Statistical methods 
Meta analysis was performed using the metaprop package in STATA v13.0 using a 
random-effects model. Confidence intervals were calculated using exact methods. 
4.3 Results 
A total of 4,706 articles were available for screening after duplicates were deleted. After 
applying the exclusion criteria, 273 articles were available for mapping (Figure 7). Five 
relevant themes emerged through the mapping process: 1) surveys of living donor 
program practices (eight studies); 2) renal imaging for the living donor assessment (159 
studies); 3) kidney function assessment (56 studies); 4) the flow of living donor 
candidates through the evaluation process (38 studies); and 5) the living donor experience 





Figure 7: Summary of literature search, study inclusion and mapping for scoping 
review. 
4.3.1 Studies surveying living donor programs 
Eight surveys of multiple transplant programs were conducted in the U.S.11–14, U.K.15,16, 
France17, and Europe18 (Table 2). These surveys revealed some similarities in the 
evaluation and selection of living donor candidates, but also some notable differences in 




efficiency of the living donor evaluation process was not an objective of any of the 
surveys. 
Table 2: Survey of living donor programs 
Reference Country Number of centres responding 
Average number 
of living donor 
transplants per 
centre each year 
Bia 199512 USA 173/231 (75%) 13 
Lumsdaine 199916 UK 29/31 (94%) 4.7 
Gabolde 200118 France 36/46 (78%) 1.6 
Mandelbrot 200713 
or Rodrigue 200714 
USA 132/205 (64%) 39 
Lennerling 201219 Europe 113 programs over 40 countries median <50 
Brar 201215 USA 72/181 (40%) median ~80 
Arunachalam 
201317 
UK 44/74 (59%) includes transplant and 
non-transplant centres 
69 
Table: Studies surveying living donor programs 
4.3.1.1 Number of donors evaluated simultaneously 
Several donor candidates may come forward at the same time for the same recipient. This 
may increase to dozens of candidates when recipients share their need for a living donor 
on social media, which is often public.21 One survey from the U.K. reported that 50% of 
centres evaluate one donor candidate at a time, while 20% evaluate 2 or more 
simultaneously (although it was not reported what the policy is among the remaining 
30%).16 Detail on the relative rigor of the evaluations was not reported (e.g. one 
candidate evaluated quicker; full versus partial evaluation for one or all candidates). 
Further research is needed on the optimal use of resources in evaluating multiple donor 
candidates simultaneously versus sequentially. 
4.3.1.2 Removal from the deceased donor wait-list  
Some intended recipients are on a waitlist for a deceased donor kidney while the 
evaluation of their living donor candidate is underway. In such cases, a prolonged living 
donor evaluation may result in a deceased donor transplant and the loss of a kidney from 
a potential living donor at that time. A recent survey of 44 transplant centres from the 




living donor kidney transplant date is scheduled (16 centres), when the candidate is 
approved for donation (eight centres), when the final crossmatch is complete (five 
centres), or on the actual day of the living donor transplant (one centre).16 The U.S., 
Organ Procurement and Transplantation Network policy now requires potential recipients 
of all organ types (living or deceased) to be registered on the waiting list prior to their 
transplant, although listing status may be inactive to prevent offers of a deceased donor 
(policy 3 in reference).22 
4.3.1.3 Receipt of a formal psychosocial evaluation  
Survey responses suggest a formal psychosocial evaluation is required for all donor 
candidates by 74% of programs in the U.S. (survey from 2007), 60% in Europe (survey 
from 2001), and 53% in France (survey from 2013).13,17,18 Whether these assessments 
were conducted by a psychiatrist, psychologist, or social worker varied. Programs that do 
not routinely conduct a formal psychosocial evaluation may do so if underlying problems 
were identified or suspected during the evaluation, or if the donor was unrelated to the 
intended recipient. The 2017 KDIGO guideline recommends that all candidates receive 
an in-person psychosocial evaluation (an ungraded recommendation due to insufficient 
evidence).7 As of 2013, a psychosocial evaluation is required during the assessment of 
donors (rather than candidates) in the U.S., which can be conducted by any of the 3 
aforementioned professionals (policy 14 in reference).22 We are unaware of whether these 
policies impacted the efficiency of the living donor work-up. 
4.3.1.4 Time for smoking cessation or abstinence  
The requirements related to smoking have become less stringent over time. Most centres 
do not routinely exclude active smokers (36% of French centres exclude only heavy 
smokers; only 2% of U.S. centres require documentation of cessation), but instead urge 
donors to stop (or reduce) smoking for some period of time before donation.13,17 
4.3.1.5 Time to complete evaluation 
The time to complete the donor evaluation was mentioned briefly in two surveys from the 




an appropriate window by nine programs (although the start and end dates of the 
evaluation were not defined).15,16 
4.3.1.6 Other differences 
Living donor programs also varied on donor eligibility criteria. These issues relate to the 
age of an acceptable candidate, acceptable limits for hypertension, and other components 
of the evaluation. As these issues relate to the safety of the evaluation rather than 
efficiency, we describe these differences briefly in Appendix A. 
4.3.2 Renal imaging studies 
A total of 159 studies reported on renal imaging modalities in the candidate evaluation. 
Most of these studies considered the accuracy of computed tomography (CT) and 
magnetic resonance (MR) angiography to define the renal vasculature compared with the 
actual vascular findings observed during surgery (CT was more common than MR).16,23 
Correctly charting the vascular network and characterizing any abnormalities as benign 
(i.e., cysts, lesions, small excisable tumors or stones) is a critical function of CT or MR 
imaging in the living donor evaluation and is necessary to ensure donor and recipient 
safety.24 Regarding efficiency, CT or MR imaging is generally performed later in the 
evaluation because these tests are costly and expose donor candidates to mild risks 
related to contrast media or ionizing radiation.12,16,25,26 In some centres there may be a 
waiting time to receive such testing. 
If a clinically important size discrepancy between the left and right kidney is observed 
(i.e., >1 cm or >10% difference from prior imaging), then a nuclear renogram may be 
performed to assess the relative function of each kidney, called the “split renal function” 
(if significantly different then the donor may be left with the higher-functioning kidney). 
All living donors complete a CT or MR scan as part of the evaluation (Figure 8A). 
Because of the expected relationship between kidney size and function (larger kidney = 
more nephrons = higher function), 18 studies assessed whether the relative kidney 
volume determined by CT can be used as a surrogate for relative function as determined 
by nuclear renography (Figure 8B). Most authors concluded that CT volumetry could 




for some candidates. Given such consistent reporting, a systematic review and meta-
analysis was conducted separately (including these studies and more), which reported a 
moderate correlation between split renal volume by CT scan and split renal volume by 
nuclear renogram (Pearson’s r=0.74, beta=0.76 by linear regression).27 For predicting a 
clinically significant size difference between the two kidneys, CT had a specificity of 
88% and negative predictive value of 86% (sensitivity 35%; positive predictive value 
40%).27 
 
Figure 8 Improving the efficiency of the evaluation: The use of split renal volume 
measured by computed tomography to replace split renal function measurement by 
nuclear renogram. A) The current renal imaging protocol at many transplant 
centres, where the computed tomography (CT) scan and nuclear renogram are both 
performed for donor candidates. Both exams may be conducted on the same day, 
but this is not necessary. B) The proposed renal imaging protocol, where the nuclear 




4.3.3 Studies measuring predonation kidney function 
Acceptable living donor candidates must have sufficient predonation kidney function to 
minimize the risks associated with living with one kidney. Glomerular filtration rate 
(GFR) measured using a radionuclide (mGFR) is the current gold standard, but is a 
resource-intensive test, is not always readily available, exposes donor candidates to 
potentially harmful radioisotopes, and may be subject to systematic bias and 
measurement error.28 Because of this, GFR is estimated (eGFR) early in the evaluation 
using serum creatinine (a biomarker that can be measured from a simple blood test).7,29,30 
Confirmation using another test can be performed later, including a second eGFR from 
creatinine with/without cystatin-c, measured creatinine clearance, or mGFR.7,31 
Fifty-six studies focused on measuring or estimating GFR in kidney donor candidates. 
Most studies compared the accuracy of various equations to estimate kidney function or 
predict postdonation kidney function. In contrast, two studies were identified that directly 
addressed the role of GFR in an efficient living donor evaluation.32,33 In the presence of 
imprecision and biases among existing methods, Huang et al.32 developed an algorithm to 
determine whether mGFR could be unnecessary for some candidates based on high 
predictive value of eGFR, age, sex, and race for measuring kidney function. The rationale 
behind this algorithm is presented in Figure 9. The authors recommend that the second 
eGFR (the first confirmatory test, or “post-test probability 2” in Figure 9) be performed 
using both serum creatinine and cystatin-c. However, two validation studies used a 
second eGFR based only on serum creatinine since cystatin-c is not routinely 
available.33,34 Huang et al. estimated that at least 53% of donors in the U.S. from 2009-
2015 would not have required a mGFR based on an eGFR high enough to assure a mGFR 
≥90 ml/min/1.73 m2. In one validation study, 27% of mGFR could have been avoided, 
but a post-test probability cut-point >98% (rather than 95% in the original study) was 
required to achieve 100% sensitivity.33 In a second validation study, 14% of mGFR could 
have been avoided, but a post-test probability cut-point >99.98% was required to achieve 







Figure 9: Algorithm to remove measured glomerular filtration rate (GFR) by 
radionuclide for some donor candidates. Threshold is an arbitrary cut-point 
generated by the data to permit 100% sensitivity. Algorithm described by Huang et 
al.32 mGFR – measured GFR; eGFR – estimated glomerular filtration rate using 
serum creatinine (eGFRCr) or serum creatinine and cystatin c (eGFRCr-Cys). GFR – 
glomerular filtration rate; eGFR – estimated GFR; mGFR – measured GFR; Cr – 
serum creatinine; Cys – cystatin C; eGFRCr – eGFR estimated using serum 
creatinine only; eGFRCr-Cys – eGFR estimated using both serum creatinine and 
cystatin C 
4.3.4 Studies describing the flow of living donors through the 
evaluation process 
A total of 38 studies reported on the number of donor candidates evaluated by their 
programs.2,3,35–73 We summarized these results, tabulating the proportion who donated, 




transplant from a deceased donor or died or became too ill to receive a transplant, and the 
time required to evaluate candidates. 
The proportion of living donor candidates who ultimately donated ranged from 8% to 
86%, averaging 37% across studies (Figure 10). Although the definition of the numerator 
and denominator varied, no difference was observed when we excluded any study. 
 
Figure 10: Forest plot with proportion of donor candidates who donated. Studies 
were pooled using a random effects model. There was significant variability (I2 = 
99.5%, p<0.0001). ES – effect size (a proportion); CI – confidence interval. 
Twenty-four (63%) studies reported a loss of intended recipients due to illness or death 
(range 1-7%) or receipt of a deceased donor kidney (1-21%) (Table 3). Although these 




donor transplant was feasible (i.e., the donor candidate may have come forward only a 
few weeks before, which was not enough time to complete a thorough evaluation). It is 
possible that up to 21% of potential recipients could have received a living donor 
transplant if the evaluation was quicker. This is, however, an upper theoretical limit and 
the true loss of potential living donor transplants remains unknown without more data. A 
recent study projected that a more efficient living donor evaluation process (i.e., donor 
evaluation completed three months sooner) may result in a 20% increase in the total 
number of living donor kidney transplants performed, translating to substantial healthcare 
system cost savings through avoided dialysis.4 These findings are supported by a recent 
quality improvement project that reduced the time to complete the living donor 
assessment using a one-day donor assessment model.2 
Table 3: Summary of studies reporting on the loss of potential donor candidates due 
to recipient illness or death or competition from deceased donor transplantation 
Reference Transplant centre Time period 
Loss of potential donor candidates 
due to recipient 
illness or death 




Leicester General Hospital, 
Leicester UK 
1994-1998 
1 no longer eligible after 
surgeon consult (recipient 
cancer), but no indication of 
recipient death or loss 





University of Heidelberg 
Hospital, Germany 
1997-2002 NR 
3 (7%) (in subset of 45 
candidates) 
Calder 200440 St. George’s Hospital, UK 1997-2001 2 (1%) (death only) 13 (7%) 
McCurdie 
200541 
University of Cape Town 
and Groote Shuur 
Hospital, South Africa 
Jan 2000-Mar 
2003 
4 (3%) 25 (21%) 
Kayler 200542 
Thomas Jefferson 
University Hospital, PA 
Jan 2000-April 
2003 
NR 64 (6%) (estimated) 
Tuohy 200644 
Beth Israel Deaconess 
Medical Center, NY, USA 
2000-2003 
12 donors were approved but recipient too sick or died or 
received a transplant (unsure of donor source); for donors who 
did not initiate medical work-up (definition of this is unclear, 
n=120), 18 recipients died/too sick and 84 already transplanted 
(unsure of donor source) 
Akoh 200846 




7 (2%) (death only) 34 (9%) 
Larsen 200948 Rigshospitalet, Denmark 
Jan 2002-Dec 
2006 
NR (recipient unfit for 
transplant in 5 (4%), but no 
indication of deaths or loss 
due to illness) 
NR 
Reese 200949 
Hospital of the University 
of Pennsylvania 
Dec 2006 – March 
2008 
NR 












59 (6%) recipient reasons 









5 (2%) [illness only, no 
indication of death] 
5 (2%) 
Lapasia 201053 Stanford, CA 
Oct 2007-March 
2009  







6/135 recipients N/A (recipients only) 
Norman 201156 




14-20% of those excluded 
donors (death only) 
23-28% of those excluded 
Moore 201257 
Vanderbilt University 
Medical Center, TN, USA 
Jan 2004-July 1 
2009 
35 (11%) (combined death, 
illness or incompatible) 
NR 
Weng 201259 
Saint Barnabas Medical 




56 (5%) 36 (3%) 
Gozdowska 
201362 
Poland 2007-2011 NR (assume zero deaths) 17 (14%) 
Romagnoli 
201363 










33 (3%) 75 (8%) 
Alsulaiman 
201667 




17 (10%) combined 
Muturi 201769 
Kenyatta National Hospital, 
Kenya 
2010-2014 
4/84 (5%) deaths (records 
available for only 84) 








42 (7%) NR 
Bailey 201771 
Multiple centres in England 
and Wales 
Aug 8, 2014-Jan 
31, 2016 
32 (4%) 34 (4%) 




London Health Sciences 
Centre, London, Ontario 
Canada 
Jan 2013 – Dec 
2016 
4 (1%) with a donor in the 
evaluation 
13 (4%) with a donor in the 
evaluation 
NR – not reported; N/A – not applicable 
*these were studies primarily mapped to the living donor experience with the living donor evaluation 
Seventeen studies (45%) reported evaluation times using various metrics, estimated using 
data or stated anecdotally. Common evaluation times included the time until approval to 
donate, donation, or rejection, although the definition of the starting point varied (Table 
4).35,47,48,65,72 The time until donation ranged from 4-14 months across studies and 
transplant programs. One report described a single recipient who received a kidney from 
her father (before) and her mother (after) the living donor evaluation process was 
redesigned to be completed in one day.3 The results of this redesign were highly positive, 
showing a reduction in the evaluation time from 2 years to 3 months, an increase in the 




donor kidney transplants per million population from <5 to >32, and a reduction in the 
prevalence of patients on dialysis.2 









Hospital, Leicester UK 
1994-1998 time until donation: mean 9.3 (SD 6.5) months 
Trevitt 200137 
Barts and The London 
NHS Trust, London, 
UK 
1997-1999 
~4 months from the time of initial crossmatch until donation (estimated 
from graph) 
Calder 200440 
St. George’s Hospital, 
UK 
1997-2001 
process designed to take a minimum of 3 months (some with <3 months if 




University and Sir 
Charles Gairdner 
Hospital 
Not reported most cases between 1-2 years, shortest was 6 months 
Ferriman 
200847 
Royal Free Hospital, 
London UK 






median 4 (IQR 1-24) months time until approval; median 3 (IQR 0-9) 



















Medical Center in 
Livingston, N.J., USA 









Belfast City Hospital, 
UK 
Not reported 








process designed to take a minimum of 2 months, but not measured 
Bailey 201771 
Multiple centres in 
England and Wales 
Aug 8, 2014-Jan 
31, 2016 
median 308 days for donors; median 61 days for non-donors 
Graham 
20172 
Ireland 2010-2015 2-3 months for work-up 
Habbous 
201872 
Multiple centres in 
Canada and Australia 
Sept 2009-Jan 
2015 
median 10.3 months (total evaluation time), 7.9 months (time until 
approval), 0.7 months from approval until donation, 4.8 months from 






median 132 days from first contact until decision; median 204 days from 











time from evaluation start until donation was a median 9.2 (6.1, 14.0) 
months; time until withdrawal or decline was a median 4.3 (1.4, 9.1) 
months 
*these were studies primarily mapped to the living donor experience with the living donor evaluation 




4.3.5 Studies describing the living donor experience 
Twelve studies asked prior donors about their experience with donation.3,45,55,74–82 One of 
the most common comments related to the evaluation process was that the evaluation was 
lengthy, and a prolonged evaluation was a source of strain on both the donor and the 
recipient: 
“It just has to be soon as possible because we are not able to do 
anything right now. X (the recipient) is so bad that we never know in 
advance if we can carry out the plans we’ve made but have to wait and 
see on the day.”74 
 
“... it actually disrupted our whole life ... I had to keep taking time off 
work ... like each time we went for tests ... when ... they were going to 
have the first operation, I took holidays and then it was cancelled and 
then I tried to ring my boss and get back to work again so I could save 
my holidays. It was pretty hard ... you sort of have to try and switch off 
your family life to get on with the job.”45 (mother donating to her child) 
 
“At the first appointment, we were told that the process takes 
approximately 9 or 10 months, and all I could think of was whether we 
had this amount of time, as our daughter’s kidney was failing and she 
was determined not to have dialysis if she could avoid it.”3 
 
“I wish the process could be quicker, there are people dying and it 
shouldn’t take so long to get checked out as a donor.”81 
 
The length of time needed to reconsider the act of donation (the ‘cooling off’ period) 
varies by donor, but three months may be sufficient for most.76 Some donors have 
expressed wanting less time to think about the decision to donate because of the 
additional anxiety it produces: “the longer you wait, the longer you worry about it”.76 
Once the decision is made, donors often want the surgical procedure as quickly as 
possible. Several donors blamed the healthcare system for conducting an inefficient and 
poorly executed evaluation process (concerning an evaluation time of six months or 
longer).55,74 Moreover, the time between donor approval and donor surgery was 
prolonged for several donors, which injected an additional source of anxiety for both the 
donor and recipient.45,74 
Some donors reported being frustrated that a prolonged evaluation resulted in their 




reported donor responses in favor of preemptive transplant (i.e., better for recipient 
health), while others favoured transplant after some time on dialysis (i.e., more likely for 
the recipient to be compliant with medications and to better understand the value of a 
kidney).76 
 
4.4 Information on living donor program websites 
We reviewed the websites for 296 living donor programs in Canada, U.S., U.K., and 
Australia (Appendix B), focusing on issues related to an efficient living donor evaluation. 
4.4.1.1 Time to complete the evaluation  
9/296 (3%) of the websites provided information on the duration of the donor evaluation 
process, time until results are obtained, and the time to complete the evaluation (i.e., 
number of days of testing at the hospital). Most websites only provided a low level of 
information, stating either the number of days of testing required or the total evaluation 
time. Some representative examples are listed in Table 5. Twenty-one programs 
acknowledged the evaluation may take up to 6 months, sometimes providing very broad 
ranges (e.g. 6-12 months; 1-6 months; 3-18 months; up to 6 months). Others described 
evaluations <4 months. Although some of these may accurately represent the efficiency 
of the program, we are only aware of published data from one centre (2-3 months in 
Belfast City Hospital, Ireland, U.K.).2 One website stated a time of two months from 
donor approval to surgery (Ohio State University Medical Center). 
Ten transplant programs indicated that evaluation testing is completed in 1 day for most 
candidates (depending on the candidates’ age; older candidates may require additional 
testing). Eleven programs indicated up to 2 days were required, and 6 programs indicated 





Table 5: Representative information from the websites of living kidney donor 
programs on the time to complete the evaluation process 
Country City, province Hospital Example Quality
a 
Canada London, Ontario London Health 
Science Centre 
2-3 days for tests; 3-6 months for results; 6+ 
months total from start to surgery date 
moderate 
USA Portland, Oregon Oregon Health and 
Science University 
1 day for evaluation, 2-3 months plus a few weeks 
to schedule surgery 
moderate 
UK Belfast, Ireland Belfast City 
Hospital 
1 day (1 full day, starts at 8am; the day’s schedule 
provided); most results reported within a few days. 
While our priority is always to make sure donation 
is as safe as possible for the donor, we can actually 
complete all of this within 2-3 months if necessary. 
There may be an appropriate delay before you have 
the 1-day assessment process if we need additional 
information or blood tests. Other times it may be 
too early for you to have other investigations 
depending on the person that you are hope to give a 
kidney to 
moderate 
Canada Toronto, Ontario Toronto General 
Hospital 
2-3 months, (3-6 months before surgery can be 
scheduled) 
low 
USA Columbus, Ohio Ohio State 
University Medical 
Center 





St. Paul’s Hospital 3+ months very low 
USA Hershey, 
Pennsylvania 
Penn State Milton 
S Hershey Medical 
Center 
4-6 months very low 
UK Leeds, England Leeds St James's 
University Hospital 
3-6 months very low 
a the quality of reporting was subjective, based on the relative detail of information provided 
 
4.4.1.2 Medical history form online  
Seventy-two websites provided their medical history intake form online (71 from the 
U.S.). Of these, 49 (68%) could be completed and submitted directly to the program 
coordinators online. Twenty-two of these used the same third-party system (Breeze 
Transplant™) to facilitate collection of the online health history questionnaire. 
4.4.1.3 Number of candidates evaluated simultaneously 
Twenty-five websites stated their general procedure for assessing candidates when more 
than one comes forward at the same time. Most stated the preferred candidate is the one 
who is a better match (although the definition of “match” was not described), and few 




programs stated only evaluating one candidate at a time, but screened up to 10 candidates 
at the outset.  
4.5 Discussion 
There is limited data on the efficiency of the living donor evaluation in the literature and 
the websites of living donor programs. Based on available information, we summarized 
several areas that have the potential to improve the living donor evaluation process, 
which may promote better recipient outcomes, improve donor satisfaction, and reduce 
costs to the healthcare system. 
A prolonged living donor evaluation may cause anxiety for donor candidates who want to 
minimize the dialysis time for the intended recipient (including avoiding dialysis 
altogether).55,76 There is a paucity of information on the duration of the living donor 
evaluation, but existing studies report evaluation times that are often long, used different 
definitions of the evaluation start and end date, and rarely report more than one indicator. 
For example, the time between donor approval and actual donation can take weeks in 
some programs and months in others.48,72 Together with the time until approval, this can 
explain some of the differences between the total time until donation between different 
programs or can reveal hidden differences between programs who have similar total 
evaluation times.72 Thus, more accurate estimates of the time to complete an evaluation 
(using multiple metrics) are needed to facilitate quality improvement. Moreover, the 
potential implications of a prolonged evaluation on recipient outcomes were infrequently 
reported or were reported with insufficient detail to draw conclusions or use as a reliable 
indicator for benchmarking. As a result, it remains only speculative whether the loss of 
potential living donor kidney transplants due to recipient illness or death, due to receipt 
of a deceased donor kidney transplant, or due to donor candidate withdrawal could have 
been avoided if the evaluation was completed earlier.4 According to the websites of living 
donor programs, many programs can conduct the evaluation in a single visit to the 





The necessity of measuring GFR in donor candidates with a radionuclide has been 
debated. By eliminating unnecessary tests, the burden on candidates, the cost to the 
healthcare system, and the timeliness of the evaluation process can all be improved. 
Nuclear renography is useful to measure the split (left versus right) renal function. 
However, CT volumetry can conceivably replace nuclear renography to measure the 
relative function.27 Moreover, nuclear renography can be used to measure the GFR, 
which may be unnecessary if the candidate has an eGFR associated with a high post-test 
probability of having a level of GFR that permits or precludes donation.32 In the case 
where a radionuclide is used to measure the total renal function, the split renal function 
can be measured with little additional effort and cost. However, for programs that use 
different contrast media for these two related tests, this may provide one strategy for 
improvement.83,84 Better prediction of postdonation kidney function from predonation 
eGFR is needed, which may be enhanced by incorporating variables like predonation 
kidney volume.85,86 
This scoping review has two main strengths. First, it highlights gaps in knowledge that 
require further research, including the potential implications of an inefficient evaluation 
process on health and cost outcomes. Second, it identifies areas for potential 
improvement that warrant additional testing. However, there are a few limitations that 
must be recognized. First, given the difficulty in performing a targeted search on this 
topic, we may have missed relevant studies that were not captured by the search terms 
chosen, or excluded some efficiency indicators. Future work is needed to establish 
important and actionable metrics for quality improvement. Second, we did not assess the 
quality of the included studies, as few studies had the primary objective of evaluating the 
efficiency of the living donor evaluation. Third, we were unable to estimate the true cost 
of an inefficient living donor evaluation on transplant activity. Although we found an 
upper limit of 21% lost opportunities for transplant, this represents an upper limit because 
we could never know if donor candidates: 1) would have completed their evaluation; 2) 
would have been deemed eligible for donation; and 3) would have donated. Finally, the 
cost of a more efficient living donor evaluation was unavailable. One study projected the 
cost savings associated with a shorter time until living donor kidney transplantation, but 




modeled (Chapter 9).4 A second study used regression-based models to estimate the true 
cost of living kidney donation to the healthcare system for donors and potential 
candidates (Chapter 10).87 However, the cost of the living donor evaluation due to real-
world efficiency improvements remains to be estimated. 
In conclusion, there are promising opportunities to improve the efficiency of the living 
donor evaluation process. Better efforts are needed to define, collect, and report 
indicators of an efficient living donor evaluation for accountability, benchmarking, 
quality improvement, and research.9 Individual programs can learn from the processes 
used by other programs to improve their own practices (e.g. enable a 1-day evaluation), 
but this requires individual programs to be more transparent on their evaluation 
procedures. The evaluation should continue to focus on ensuring donor safety, including 
completing tests that are costly or time-consuming if they are necessary to complete a 
thorough evaluation for donor candidacy. 
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Chapter 5  
5 Research Objectives 
The overarching goal of this thesis is to fill the gaps in the existing literature and to 
inform stakeholders (e.g. patients, providers, and decision-makers) on the efficiency of 
the living kidney donor evaluation process. We project that reducing the donor evaluation 
time to 3-4 months is feasible for at least highly motivated healthy donors (i.e., those who 
are essentially waiting for medical clearance).1–3 We expect this to result in numerous 
benefits. First, a reduction in the donor evaluation time may result in fewer recipients 
starting dialysis before transplantation (e.g. more pre-emptive transplants), which will 
reduced the need for vascular access and the costs and complications associated with 
dialysis initiation.4,5 Second, we expect less time on dialysis overall, which will improve 
the health outcomes of recipients and reduce costs associated with maintenance dialysis 
to the healthcare system.6,7 Third, we expect fewer deaths on the transplant wait-list and 
increased living kidney donor transplantation rates, as fewer intended recipients are likely 
to receive a deceased donor transplant or lose eligibility for transplant entirely (e.g. 
through health deterioration).2 For this overarching goal to be feasible, we propose three 
research objectives to provide an environmental scan of the current state of the living 
kidney donor evaluation in Ontario. 
 
5.1 Objective 1: To understand and evaluate the living 
donor evaluation process 
The first aim of Objective 1 is to measure how long it takes the complete the living donor 
evaluation using multiple metrics. Multiple metrics (process and outcome indicators) are 
needed to fully understand a process and identify any bottlenecks.8,9 It is also critical to 
understand why different metrics vary across individuals and programs. Thus, the second 
aim of Objective 1 is to identify modifiable and non-modifiable factors associated with 




5.2 Objective 2: Implications of a prolonged living donor 
evaluation 
The process indicators used to measure the evaluation process should be linked to 
meaningful outcomes.10,11 Moreover, any improvements in the quality indicators should 
result in improved outcomes. Healthcare agencies are moving towards such an evidence-
based quality improvement strategy to improve the healthcare of its citizens.12,13 A recent 
study has suggested that a longer evaluation time is related to fewer pre-emptive 
transplants and living donor transplants overall, but no such work has been done in a 
Canadian context and numerous outcomes remain to be measured.2 Thus, for this 
Objective we will estimate some of the possible implications that a longer evaluation can 
have on transplant outcomes and financial outcomes. We will use real data to estimate 
how frequently the recipient starts dialysis despite having a living donor. To our 
knowledge, this is a metric that has not been reported before but has been asked of us by 
patients. We will also conduct scenario analyses to explore the potential implications of a 
quicker evaluation. 
5.3 Objective 3: Cost of living donor evaluation 
The cost of the living donor assessment is a key component to informing decisions on 
modifying the evaluation process. Examples include implementation of rapid 
assessments, which may result in more tests completed for candidates who do not donate 
or evaluating multiple candidates simultaneously rather than sequentially.2 These 
potential process designs may increase costs due to donor evaluations, but may also 
reduce costs by increasing living donation and reducing time on dialysis. Thus, an 
accurate assessment of the cost of living donation is needed, and this will be the goal of 
Objective 3. 
5.4 Future directions 
Once these objectives are complete, possible solutions to improve the living kidney donor 
evaluation process can be proposed, prioritized, and ultimately tested. This research 
therefore follows the framework of Six Sigma – a quality improvement guide that is 




problem (e.g. the living donor evaluation process is inefficient). Then we measure and 
analyze key indicators before and after improvements are made. Alongside interventions 
to address other barriers to living kidney donation as mentioned in the Introduction 
(1.2.1), successful quality improvement strategies following this research will result in 
increased transplantation rates and better transplant outcomes (health gains), substantial 
cost savings to the healthcare system (financial gains), and an improved living donor 
experience and overall quality of life (quality gains).16,17  
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Chapter 6  
6 Duration of Living Kidney Transplant Donor 




Kidney transplantation for patients with kidney failure is associated with improved 
survival and better quality of life at a fraction of the cost compared to dialysis.1–4 
Compared to deceased donor kidney transplantation, living donor kidney transplantation 
offers many advantages including superior rates of patient and graft survival and a shorter 
time until transplant.5  
The evaluation of a living kidney donor candidate begins when they contact a 
transplant center. What follows is a series of screening tests (questionnaires, blood and 
urine tests), diagnostic tests (ultrasound, chest x-ray), and specialist consultations 
(nephrologist, surgeon, and an assessment of psychosocial health).6–8 During the 
evaluation, a donor candidate often makes multiple trips to local clinics or the transplant 
center, and there may be frequent periods waiting for appointments or test results. We 
consider an efficient living donor candidate evaluation as one that is completed in as 
timely a manner as possible, is clinically appropriate, and promotes patient and provider 
satisfaction. At a recent international consensus conference, the efficiency of the donor 
evaluation was highlighted as a high-priority area for improvement.8,9 Not surprisingly, 
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several donors view the evaluation process as the worst phase of the donation 
experience.10,11 
In response to such concerns, the 2017 Kidney Disease: Improving Global 
Outcomes Guideline on the Evaluation and Care of Living Kidney Donors recommends 
transplant programs conduct as efficient a donor evaluation as possible, to meet the needs 
of donor candidates, intended recipients, and transplant programs.12 Guidelines from the 
United Kingdom set a more tangible goal: by the year 2020, all donor candidates should 
have the opportunity to complete their evaluation within 4-5 months whenever possible.13 
In order to put these recommendations into context we require knowledge of current 
performance. To date, the time to complete the living kidney donor evaluation has 
received limited attention as an outcome or as a focus for quality improvement.14,15 
To address this knowledge gap and advance a patient-driven research priority,16 
we estimated the time to complete the donor evaluation process using data from multiple 
transplant centers in two cohorts. We also assessed the variability in donor evaluation 
times between transplant centres, and individual and transplant centre factors associated 
with longer evaluation times.  
6.2 Methods 
6.2.1 Data sources 
Prospective cohort: Donors who donated between September 2009 and January 2015 
were prospectively enrolled from 16 transplant centers in Canada and Australia 
(Appendix C). Participants were recruited prior to donation, spoke and read English or 
French, and were deemed good candidates for post-donation follow-up. Data were 
obtained from medical records (evaluation test results, consultation notes, operative 
records) and questionnaires. No data on recipient characteristics were used for this study. 
All records were de-identified and sent to a coordinating center for abstraction and 
analysis. All participants provided written informed consent and centers obtained ethics 




Table 6: Comparison of prospective and retrospective cohorts 
Characteristic Prospective Cohort Retrospective Cohort 
Overall characteristics: 
Sample size: 849 1140 
Study design: Observational cohort Observational cohort 
Population: Prior living kidney donors  Prior living kidney donors 
Time period: September 2009 – January 2015 April 2004 – March 2014 
Cohort 
ascertainment: 
Identification by research personnel. 
Donors enrolled into the study prior to 
donation.  
Identification through TGLN databases 
through ICES 
Catchment area: 12 Canadian and 4 Australian transplant 
programs 
5 Ontario transplant programs 
Patient consent: Required Waived 
Ethics approval: #6056 (see Appendix D) Not applicable 
Observational 
period: 
First contact with transplant centre (proxy) 
until donation 
First contact with transplant centre 
(proxy) until donation 
Strengths and limitations: 
center-to-center 
variability 
16 transplant programs 5 transplant programs 
Outcomes total evaluation time, time until approval, 
time from approval until donation, time 
from CT until donation, time between 
consults 
total evaluation time, time from CT until 
donation, time between consults 
Key dates Evaluation start and approval dates derived 
by proxy (limitation) 
Evaluation start date derived by proxy; 
no approval date (limitation) 
Scope of data Individual-level factors available unique to 
this cohort, including smoking, BMI, blood 
pressure, kidney paired donation, marital 
status, education, employment (strength) 
Individual-level factors available unique 
to this cohort, particularly recipient data 
including demographics, kidney 
function, cause of illness, date of referral 
(strength) 
Data collection: Convenient sample of medical records; 
self-reported questionnaires (limitation) 
Comprehensive list of healthcare 
utilization in Ontario from ICES data 





Recipient data not available (limitation) Stratification by pre-emptive transplant 
and dialysis-dependent status (strength) 
TGLN – Trillium Gift of Life Network; ICES – Institute for Clinical Evaluative Sciences; CORR - Canadian Organ 





Retrospective cohort: We obtained linked healthcare administrative data for living donors 
who were evaluated and donated at one of Ontario’s five transplant centers between 
March 2004 and April 2014. Data were obtained from Ontario’s organ procurement 
organization Trillium Gift of Life Network17 and multiple datasets available at the 
Institute for Clinical Evaluative Sciences (ICES). All recipients were Ontario residents 
who received a first-time kidney transplant (described previously).18 This study was 
approved by the research ethics board at Sunnybrook Health Sciences Centre, Toronto, 
Canada (patient consent was waived; Table 6). A summary of each cohort is provided in 
Table 6. 
6.2.2 Measures of evaluation time 
Total evaluation time was defined as the time the donor started the evaluation until 
donation. Total approval time was defined as the time from evaluation start to the date 
the donor was approved to donate. Since the date the evaluation started and the date of 
approval were unavailable (and may not be well defined), we used tests relevant to the 
evaluation process to inform these dates (tests usually performed early or late in the 
evaluation; Table 7 for the prospective cohort; Habbous et al for the retrospective cohort 
– reproduced in Appendix E).18 Time to donation post-approval was defined as the time 
from approval to donation. Time from computed tomography (CT) until donation was 
defined as the time from first CT angiogram (to assess kidney anatomy and vasculature) 
until donation. Time between consults was defined as the period between the first and last 
of the nephrologist, surgeon, and psychosocial assessments (restricted to donors with all 
three consults). 
Table 7: Procedures for donors (N=849) 
Procedure 
N (%) with 
procedure 
N (%) as first 
procedure  
(all tests) 
N (%) as last 
procedurec 
Consultations    
Surgery consult 804 (95%) 10 (1%)* 496 (58%) 
Nephrologist consult 834 (98%) 14 (2%)* 132 (15%) 
Psychosocial consult 753 (89%) 22 (3%)* 28 (3%) 
Other health professional consult 323 (38%) 5 (<1%)* 93 (11%) 
Cardiac evaluation 211 (25%) 5 (<1%)* 8 (1%) 




Procedures    
Renal imaging 844 (99%)a 101 (12%) 9 (1%) 
Nuclear medicine (GFR) 692 (82%) 20 (2%) 23 (3%) 
24-hr blood pressure 227 (27%) 23 (3%) 16 (2%) 
Renal biopsy 22 (3%) 0 (0%)* 1 (<1%)d 
Cystoscopy 21 (2%) 0 (0%)* 2 (<1%) 
    
Laboratory tests    
Histocompatibility test 839 (99%) 346 (41%) – 
Spot urine test 839 (99%) 23 (3%) – 
Biochemistry 829 (98%) 4 (<1%) 42 (4%) 
Cholesterol (fasting) 702 (83%) 116 (14%) – 
24-hr urinalysis 708 (83%)b 96 (11%) 33 (4%) 
Oral glucose tolerance test 379 (45%) 43 (5%) 8 (1%) 
    
First contact datee 395 (46%) 21 (2%) – 
a any of renal/abdominal ultrasound (n=659) or CT angiogram (n=834) 
b 289 had one and 419 had two 24-hr urinalysis tests documented 
c only tests indicated in column without “–“ were considered as a possible last procedure to define 
approval date 
d exceeding 10 days prior to donation to ensure not an implant biopsy 
e the date the donor first phoned or emailed the transplant program, restricted to Ontario donors. 
This was only considered as the first procedure if no other appropriate test was identified. 
*not considered an appropriate start date (these donors were excluded from total evaluation time 
and time until approval)  
 
6.2.3 Individual-level and center-level characteristics 
We obtained individual-level donor, recipient, and transplant characteristics by 
abstracting medical records (prospective cohort) or linking across healthcare databases 
(retrospective cohort). Socio-demographic factors included age at donation, sex, marital 
status, race, and smoking status at the time of study recruitment. Individual-level 
socioeconomic factors included education, employment status, and rural residence. 
Neighbourhood-level median household income quintile was obtained from the 2006 
Canada Census (Canada only). Other socioeconomic indicators were assessed, including 
the Canadian Marginalization Index (Can-MARG) and the Australian Socio-economic 
Index for Areas (SEIFA); both derived using several variables from each country’s 2006 
Census.19,20 Pre-donation clinical factors included donor and recipient estimated 
glomerular filtration rate (eGFR) calculated using the CKD-EPI (Chronic Kidney Disease 




diastolic (DBP) blood pressure measurements prior to donation, donors were considered 
normotensive if SBP <120 mmHg and DBP <80 mmHg, pre-hypertensive if SBP 120 to 
<140 mmHg or DBP 80 to <90 mmHg, and hypertensive if SBP ≥140 mmHg or DBP 
≥90 mmHg. Other factors included the year of donation, distance to the transplant center 
(Euclidean distance between postal codes), the donors’ relationship to the intended 
recipient (which may differ from the actual recipient if the donation occurred through 
paired donation), participation in kidney paired donation, the surgical technique, the 
recipient’s referral date to a transplant centre for evaluation, and the recipient’s primary 
cause of kidney failure. 
Transplant center characteristics were obtained for the prospective cohort for the year 
2012 (mid-year and peak of participant recruitment), including transplant center volume 
(number of living and deceased donor kidney transplants) and resources (number of full-
time equivalent living donor nurse coordinators). 
6.2.4 Statistical analysis 
We present continuous data as mean (SD) or median (25th, 75th percentile). Differences 
between cohorts on categorical variables were compared using chi-squared tests from 
contingency tables. To evaluate individual-level predictors, we used generalized 
estimating equations to accommodate clustering by transplant center (identity link; 
normal distribution). Point estimates with 95% confidence intervals (CI) were presented. 
Multivariable models included all covariates yielding unadjusted p-values <0.2 (no 
selection algorithm was employed) or variables considered important. We used random-
effects models to explore transplant center-level factors associated with evaluation times 
(random intercept for transplant center; center-level factors were treated as fixed effects). 
Random effects models without any individual-level or center-level covariates 
(unconditional means models) were used to compute the proportion of the total variability 
in evaluation times that could be accounted for by differences between transplant centers 
(the intracluster correlation coefficient, ICC). We evaluated model fit using a variety of 
indices, which showed use of linear regression was appropriate (Pregibon link test 
p=0.19; Hosmer-Lemeshow test p=0.9, Pearson’s test p=1.0).22 We used Statistical 




NC, USA) and STATA v13.0 (StataCorp LP, Texas, USA). This study was conducted 
and reported per recommended guidelines (Appendix F). 
6.3 Results 
From the prospective cohort, 849/851 (99%) donors were included (two donated outside 
of Canada or Australia). Donors were recruited a median (25th, 75th percentile) 2.3 (1.3, 
7.5) weeks prior to donation. From the retrospective cohort, 1109/1140 (97%) living 
donors from Ontario were included (31 recipients could not be identified). The 
characteristics of the prospective and retrospective cohorts are presented in Table 8.  







 Donors Donors Recipients 
Demographic factors    
Mean age at donation, years 47.8 (11.4) 45.1 (11.0) 44.2 (14.4) 
    
Sex    
Female 558 (66%) 716 (63%) 415 (36%) 
Male 291 (34%) 424 (37%) 725 (64%) 
    
Smoking status at recruitment (within last 30 days)*    
Not smoking 624 (80%) na na 
Recently quit 47 (6%) na na 
Still smoking 107 (14%) na na 
    
Marital status    
Married/common-law 610 (78%) na na 
Not married 168 (22%) na na 
    
Race    
White 745 (88%) 428 (77%) 375 (75%) 
Non-white** 101 (12%) 131 (23%) 124 (25%) 
    
Socioeconomic factors    
Highest education    
University/college  451 (58%) na na 
Trades/high school or less 326 (42%) na na 
    
Employment status    
Full-time 499 (64%) na na 
Other 280 (36%) na na 
    
Residencea    
Urban 642 (81%) 959 (84%) 954 (87%) 
Rural 151 (19%) 181 (16%) 148 (13%) 
    
Median income quintileb    
5, highest 162 (26%) 257 (23%) 246 (22%) 
4 152 (24%) 289 (25%) 255 (23%) 
3 140 (23%) 239 (21%) 132 (21%) 
2 91 (15%) 183 (16%) 193 (18%) 
1, lowest 74 (12%) 172 (15%) 173 (16%) 
    




Pre-donation clinical factors    
estimated GFR, mL/min/1.73m2c    
≥90 548 (64%) 665 (62%) na 
80-89 177 (21%) 166 (15%) na 
<80  124 (15%) 251 (23%) na 
mean estimated GFR from serum creatinine, mL/min/1.73m2c 96 (14.0) 97.3 (14.9) 16.2 (8.4) 
mean measured (nuclear) GFR, mL/min/1.73m2c 108 (21.2) na na 
    
Recipient co-morbidities    
Cardiovascular disease na na 592 (53%) 
Ischemic heart disease/ coronary artery disease na na 123 (11%) 
Heart failure na na 86 (8%) 
Diabetes na na 222 (20%) 
Hypertension na na 925 (83%) 
    
Body mass index, kg/m2    
Underweight (<18.5) 9 (1%) na na 
Normal (18.5-24.9)  321 (38%) na na 
Pre-obese (25-29.9) 366 (43%) na na 
Obese (30-34.9) 134 (16%) na na 
Very obese (BMI ≥ 35) 16 (2%) na na 
mean body mass index, kg/m2 26.3 (3.90) na na 
    
Blood pressured    
Normal 420 (49%) na na 
Pre-hypertensive  405 (48%) na na 
Hypertensive 24 (3%) na na 
    
Other factors    
Relation to intended recipient    
First degree relative 408 (48%) 571 (50%) na 
Spouse 166 (20%) 246 (22%) na 
Other (friend, other relative) 200 (24%) 323 (28%) na 
Non-directed anonymous donation 68 (8%) na na 
    
Participated in Kidney Paired Donation    
No 748 (89%) na na 
Yes 91 (11%) na na 
    
Days until recipient referrale na na 26 (-81, 160) 
    
Surgery type performed    
Laparoscopic 705 (84%) na na 
Open 135 (16%) na na 
Presented as number (percent) or mean (standard deviation). 
a restricted to donors with a valid Canadian postal code. For donors in this table, rural status was derived from 
the second digit of the postal code (rural if zero, urban otherwise). Rural status is generally defined in the 
retrospective cohort as a municipality having <10,000 persons [990 (87%) of was urban with this definition]. 
b Median household income was obtained from the 2006 Canada Census 
c GFR –glomerular filtration rate estimated using the CKD-EPI equation; recipient estimated GFR was 
measured a median 0 (-14, 17) days before the donor evaluation start date; measured GFR was restricted to 
donors with a radioisotope measurement (n=555) 
d normal if systolic <120 mmHg or diastolic <80; pre-hypertensive if systolic 120-139 or diastolic 80-89; 
hypertensive if systolic ≥140 or diastolic ≥90 
e calculated as the time from the donor evaluation start date until the recipient referral date. Negative values 
mean the recipient was referred to the transplant center before the donor evaluation started.  
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation. 
** in the prospective cohort, non-whites included 58 (7%) Asians, 20 Aboriginals (2%), 17 Blacks (2%), and 6 
Hispanic/Latino (<1%). In the retrospective cohort, non-whites included 69 (12%) Asians, and 22 (4%) Blacks 
[the ethnicity of remaining donors was suppressed due to small cells (<6 individuals) to comply with privacy 
requirements to minimize the risk of re-identification.] 





For the prospective cohort, the mean (SD) age at donation was 47.8 (11.4) years, most 
donors were married (78%), white (88%), and female (66%). Many donors were educated 
(58% with a college or university degree), employed full time (64%), and were of high 
socioeconomic status (26% in the highest neighbourhood-income quintile). Most (87%) 
donors underwent a laparoscopic nephrectomy and 11% donated through kidney paired 
donation. In terms of health status indicators 18% were classified as obese (BMI ≥30 
kg/m2); and 2% were very obese (BMI ≥35 kg/m2); 64% had a pre-donation eGFR ≥90 
mL/min/1.73 m2. Most intended recipients were first-degree relatives (48%), while 8% 
were non-directed (anonymous).  
Donors from the retrospective cohort were similar to the prospective cohort with respect 
to age (mean 45.1 years), sex (63% female), residence (84% urban), income (23% in the 
highest neighbourhood-income quintile), pre-donation eGFR ≥90 mL/min/1.73 m2 
(64%), and relationship (50% were donations to a first-degree relative). However, 
Ontario donors were more likely to be non-white (23%) than donor participants in the 
prospective cohort (10%, p<0.001). Recipients in the retrospective cohort were similar to 
donors with respect to age, race, rural status, and neighbourhood-income quintile, but 
were more likely to be male (64% vs. 37%). Recipients were referred to a transplant 
centre a median (25th, 75th percentile) 26 (-81, 160) days after the start of their donor’s 
evaluation (recipient referral date was available for 290/1256 (23%) of recipients).  
6.3.1 Living kidney donor evaluation times 
The distribution of evaluation times across transplant centres from the prospective cohort 





Figure 11: Evaluation times by transplant centre. Boxplots showing the distribution 
of evaluation times stratified by transplant center. A) The total wait time was 
defined as the time the donor completed the evaluation, from first contact until 
donation surgery; B) total approval time was calculated as the time from first 
contact until the donor was approved to donate; C) the time to donor surgery after 
approval was calculated as the difference in total wait time and total approval time; 




between consults was defined as the period between the first and last nephrology, 
urology, and psychosocial consults (restricted to donors with all three consults). 
Vertical axis was truncated for readability. Box represents interquartile range (25th 
to 75th percentile). Horizontal line indicates median (50th percentile). Circle 
represents mean. Vertical lines represent the upper fence (75th percentile plus 1.5× 
interquartile range) and lower fence (25th percentile minus 1.5× interquartile 
range). Five Austrialian centers were combined and presented as a single center for 
this analysis.  
The median (25th, 75th percentile) total evaluation time in the prospective cohort was 10.3 
(6.5, 16.7) months (n=803) and varied across transplant centers (ICC=7.0%, p=0.04). 
Among the subgroup of Ontario participants, the median evaluation time was 10.7 (6.6, 
16.7) months, similar to the evaluation time from the retrospective cohort [median 10.8 
(7.3-19.4) months].  
In the prospective cohort, the median time until approval was 7.9 (4.6-14.1) months 
(n=745, ICC 13.2%, p=0.02) and from approval to donation was 0.7 (0.3, 2.4) months 
(n=745, ICC 20.6%, p=0.01). The approval date was not available in the retrospective 
cohort. 
The time from CT scan until donation was a median 4.8 (2.6, 9.2) months in the 
prospective cohort (n=839, ICC 2.9%, p=0.05), which was similar to the 4.9 (2.8, 8.8) 
months observed in the retrospective cohort (n=1054).  
Among donors who completed a nephrology, surgery, and psychosocial assessment in the 
prospective cohort, the median time between the first and last consultation was 3.0 (1.0, 
6.3) months (n=716, ICC 11.0%, p=0.03). In the retrospective cohort, the median time 




Table 9: Comparisons of the donor evaluation process between transplant centers in the prospective cohort 
 
Average time for different measures of the donor evaluation in months,  
median (25th, 75th percentile)a  
Frequency of 
24-hour urine 











Time from CT scan 
to donation, N=839 
Time between 
consults, N=716b  
All consults 
completed ≤2 
days, N=716b 0 1 2 
Center A 8.1 (5.4, 12.9) 5.6 (3.5, 12) 1.0 (0.3, 3.5) 3.4 (1.5, 7.6) 0.7 (0.3, 2.3) 15% 2 19 78 
Center B 11.3 (6.2, 16.4) 10.7 (5.8, 15.4) 0.4 (0.3, 0.7) 4.5 (2.7, 8.3) 4.8 (2.1, 9.1) 1.3% 6 78 16 
Center C 9.4 (6.6, 16.7) 8.8 (6.0, 15.4) 0.3 (0.2, 0.5) 5.5 (3.3, 12.3) 4.7 (2.5, 11.9) 0% 6 80 14 
          
Center D 9.3 (6.1, 14.1) 8.6 (5.3, 12.9) 0.5 (0.3, 1.0) 3.3 (1.6, 7.1) 4.3 (2.8, 8.5) 0% 0 0 100 
Center E 15.9 (11.4, 26.1) 15.2 (9.7, 25.3) 0.2 (0.1, 1.8) 6.2 (3.2, 10.2) 6.9 (4.6, 16.7) 0% 15 72 12 
Center F 11.9 (7.1, 14.9) 9.6 (7.7, 14.9) 0.5 (0.3, 1.0) 7.0 (3.4, 9.3) 5.1 (3.3, 7.9) 0% 2 7 91 
          
Center G 10.8 (7.6, 15.9) 8.5 (6.1, 14.7) 1.0 (0.3, 1.9) 5.9 (3.7, 8.4) 5.9 (4.6, 9.9) 0% 0 4 96 
Center H 11.1 (7.6, 17.4) 10.2 (5.8, 14.6) 0.5 (0.4, 2.3) 4.3 (2.3, 7.3) 2.0 (0.6, 4.8) 10%  0 13 87 
Center I 9.9 (6.2, 18.6) 3.8 (2.6, 5.3) 4.5 (2.3, 8.1) 6.9 (3.4, 15.8) 0.1 (0.0, 1.1) 50% 92 2 6 
          
Center J 14.4 (8.4, 23.7) 13.6 (7.8, 23.1) 0.5 (0.4, 1.0) 7.5 (3.2, 16.1) 7.3 (3.2, 17.2) 0% 46 29 25 
Center K 9.1 (6.1, 14.6) 7.2 (4.6, 12.1) 1.6 (0.8, 2.5) 4.5 (3.0, 8.1) 3.2 (1.8, 4.6) 0% 16 76 9 
Center L 8.2 (5.5, 14.4) 6.2 (4.6, 8.8) 1.2 (0.5, 3.5) 4.2 (1.6, 7.1) 3.0 (1.8, 4.4) 0% 1 24 75 
          
All centers 10.3 (6.5, 16.7) 7.9 (4.6, 14.1) 0.7 (0.3, 2.4) 4.8 (2.6, 9.2) 3.0 (1.0, 6.3) – – – – 
ICC (p-value) 7.0% (p=0.04) 13.2% (p=0.02) 20.6% (p=0.01) 2.9% (p=0.05) 11.0% (p=0.03) – – – – 
a Five Australian centers were combined and presented as a single center so that there were a meaningful number of participants for analysis.  
b Time from first to last consults with either a nephrologist, a surgeon, and a professional performing a psychosocial evaluation (restricted to donors with all three consults) 
ICC – intraclass correlation coefficient (proportion of the variance in the outcome explained by between-center differences); a p-vale <0.05 was interpreted as significant variability 




6.3.2 Transplant center characteristics associated with longer 
evaluation times 
Associations of transplant center characteristics were only assessed in the prospective 
cohort. We found no association between the total evaluation time and the number of 
living-donor and deceased-donor transplants performed at the center, the number of full-
time equivalent living donor coordinators, the number of 24-hour urine tests usually 
performed at the center, and whether centers routinely performed nephrology, surgery 
and psychosocial consults all within 24 hours of each other (p>0.2 for all). This did not 
change after adjustment for individual-level donor age, sex, relationship to the recipient, 
or whether the donation occurred through paired exchange (Table 10).  
Table 10: Transplant center characteristics associated with donor evaluation times 
in the prospective cohort 
 
Average time for different measures of the donor evaluation in months,  














Time from CT 





#LD Txc,d -0.4 (-2.2, 1.4) -0.3 (-2.6, 2.0) -0.1 (-0.8, 0.6) -0.4 (-0.4, 1.1) -0.0 (-1.7, 1.7) 
#DD Txc,d 0.6 (-0.7, 1.9) 0.9 (-0.7, 2.6) -0.2 (-0.7, 0.3) 0.1 (-0.5, 0.8) 0.4 (-0.8, 1.7) 
FTEc,e 4.0 (-2.7, 10.7) 2.7 (-6.4, 11.8) 1.4 (-1.0, 3.8) 2.2 (-0.1, 4.4) 2.1 (-4.4, 8.7) 
      
#LD Tx/FTEc -0.1 (-0.2, 0.1) -0.03 (-0.2, 0.2) -0.03 (-0.1, 0.03) -0.02 (-0.05, 0.1) -0.01 (-0.1, 0.2) 
# 24h urinesf -1.1 (-4.9, 2.7) -0.1, (-5.0, 4.8) -0.6 (-2.0, 0.8) -1.6 (-2.9, -0.3) -1.2 (-4.7, 2.4) 
Same-day consultsg -2.5 (-8.8, 3.7) -4.7 (-12.3, 2.8) 2.0 (-0.04, 4.1) -1.1 (-3.9, 1.6) -5.2 (-9.9, -0.6) 
a Adjusted for donor age, sex, relationship to intended recipient, and donation through kidney paired donation. Five 
Australian centers were combined due to the number of participants recruited. A positive number means the characteristic 
is associated with a longer evaluation time, expressed in months of additional time. As an example of interpretation, 
transplant centers that differ by 10 transplants performed per year also differ by -0.4 months in the total evaluation time. 
b Time from first to last consults with either a nephrologist, a surgeon, and a professional performing a psychosocial 
evaluation (restricted to donors with all three consults) 
c Obtained from each institution in 2012 (the mid-year and most active year of study recruitment). The number of 
transplants performed serve as indicators of the transplant center volume. Variables were treated as a continuous.  
d per 10 transplants 
e per 0.5 FTE 
f transplant centers were categorized as generally performing zero, one, or two 24-hour urine analyses based on the highest 
proportion in the three rightmost column of Table 9 and treated as a continuous variable (estimate is per 24-hour urine 
test).  
g transplant centers were dichotomized as generally performing same-day consults if the nephrology, surgery, and 
psychosocial evaluation was performed within 2 days for at least 10% of the donors (Centers A, H, and I from Table 9). 
The reference group is “no”.  
CT – computed tomography; LD Tx – living donor kidney transplant; DD Tx – deceased donor kidney transplant FTE – 




6.3.3 Individual donor factors associated with longer evaluation times  
We explored whether individual-level factors were associated with the total evaluation 
time in unadjusted (Table 12) and adjusted (Table 13) analyses. The prospective cohort 
was adjusted for donor age, sex, and relationship to the recipient. The retrospective 
cohort was further adjusted for donor urban/rural status and median neighbourhood-
income quintile. In the prospective cohort we did not have information on whether the 
recipient was receiving dialysis at the start of the donor evaluation. In the retrospective 
cohort, we separated the results by whether or not the recipient was on dialysis at the time 
the donor evaluation started, as this might influence the urgency of donation (if the goal 
was pre-emptive kidney transplantation). For these analyses we also focused on donors 
who received a pre-emptive kidney transplant (N=311), separating out those who started 
dialysis while the donor evaluation was underway, as for the latter many patients take 
some time to acclimatize to dialysis after it is initiated, which may delay the time to 
complete the transplant evaluation and confound associations measured in the present 
study.18  
After adjustment, the evaluation took longer if the donor was older (by 0.7 to 2.0 months 
per 10-years of age). The evaluation time was shorter among rural versus urban donors [-
2.7 (95% CI: -0.3, -5.1)] in the pre-emptive transplant cohort, with the trend of a shorter 
time in the dialysis-dependent cohort [-1.4 (-3.0, 0.2)]. There was a non-linear 
relationship between neighbourhood-household income and the time to complete the 
evaluation, and results varied in the cohorts: in the prospective cohort, the most and least 
affluent quintiles completed the evaluation in the shortest amount of time and the middle 
group took the longest. In the dialysis-dependent cohort, the least affluent group took the 
longest time to complete the evaluation [2.8 (0.8, 4.9) months longer than the most 
affluent], while in the pre-emptive transplant cohort results were qualitatively different. 
Sensitivity analysis in the prospective cohort using a deprivation index as a measure of 
socioeconomic status did not change these results (Table 11). For every mL/min/1.73 m2 
increase in recipient eGFR, the evaluation time was increased an average of 0.8 months 
(p<0.001). For every 30-day delay in recipient referral, the time of donor evaluation 




in the pre-emptive transplant cohort (p<0.001). Other factors included the relationship to 
the intended recipient, the cause of kidney failure, and non-renal recipient co-morbidities, 
which differed qualitatively depending on the cohort of study. The most influential 
contributor was whether the donor participated in paired exchange, which prolonged the 
average time until donation by 6.6 (1.6, 9.7) months. Finally, and of weaker importance, 
was the association between female and non-white donors on longer evaluation times, 
which was only observed in the dialysis-dependent cohort (although point estimates for 
female donors were in a similar direction in all cohorts). 






Combined deprivation index  
(Canada and Australia) 
 N (%) N (%) N (%) beta p-value 
Deprivation      
1 (least deprived) 168 (27%) 21 (45%) 189 (28%) 0 (referent) 0.24 
2 150 (24%) 9 (19%) 159 (24%) -0.9 (-3.6, 1.7)  
3 127 (20%) 9 (19%) 136 (20%) 0.5 (-2.1, 3.1)  
4 98 (16%) 8 (17%) 106 (16%) 1.7 (-3.1, 6.5)  
5 (most deprived) 81 (13%) 0 (0%) 81 (12%) -1.7 (-4.6, 1.3)  
      
Residential Instabilityc      
1 (least deprived) 126 (20%) – – 0 (referent) 0.02 
2 150 (24%) – – -1.2 (-3.8, 1.3)  
3 138 (22%) – – 1.2 (-0.8, 3.2)  
4 117 (19%) – – 2.5 (-1.3, 6.2)  
5 (most deprived) 93 (15%) – – -0.4 (-3.0, 2.3)  
Deprivation quintiles derived at the national level from several socioeconomic variables from the 2006 
national census 
a Canadian Marginalization Index derived from Statistics Canada (Matheson et al1). Material 
deprivation included six variables related to family structure, income, and employment. Residential 
instability included seven variables primarily related to the home. 
b Socio-economic Indexes for Areas (SEIFA) as an index of relative socioeconomic disadvantage2. 
Deprivation index included variables related to family structure, income, education, and various others. 
 
For every 3-month increase in the time between consults, the time to complete the 
evaluation increased by 0.8 (0.5, 1.1) months in the pre-emptive transplant cohort 
(p<0.001), 1.1 (0.2, 2.0) months in the dialysis-dependent cohort (p=0.02), and 2.8 (2.5, 
3.1) months in the prospective cohort (p<0.001). After adjustment, the time between 




1.0)] and the dialysis-dependent cohort [-3.2 (-4.6, -1.8)], but not in the prospective 
cohort [4.2 (-1.5, 9.9)].  
Table 12: Factors associated with total donor evaluation time, unadjusted estimates 
 Prospective cohort 
16 transplant centers in 
Canada and Australia 
Retrospective cohort  
5 transplant centers in 
the province of Ontario, Canada   
Unknown if recipient 
was receiving dialysis at 
start of donor evaluation 
(n=849) 
Recipient receiving 
dialysis at start of the 
donor evaluation 
(N=631) 
Recipient was not 
receiving dialysis at the 
start of the donor 
evaluation, and a pre-
emptive transplant was 
achieved (N=311) 
 beta (95% CI)a p-value beta (95% CI)a p-value beta (95% CI)a p-value 
Demographic factors 
Donor age, per 10 years 1.12 (0.34, 1.89) 0.005 0.33 (-0.17, 0.83) 0.20 2.19 (1.70, 2.68) <0.001 
Recipient age, per 10 
years  
na na 0.66 (0.34, 0.99) <0.001 -0.53 (-1.40, 0.35) 0.24 
       
Female sex       
donor 0.91 (-0.24, 2.07) 0.12 1.33 (0.41, 2.24) 0.005 1.85 (-0.93, 4.64) 0.19 
recipient na na 0.77 (-0.79, 2.32) 0.33 0.94 (-2.13, 4.01) 0.55 
       
Donor smoking status at 
recruitment (within last 
30 days)* 
      
Not smoking 0 (reference) 0.04 na na na na 
Recently quit -1.32 (-2.94,0.31)  
 
   
Still smoking -1.80 (-3.31, -0.29)  
 
   
       
Donor marital status        
e 0 (reference) 0.38 na na na na 
not married -0.97 (-3.14, 1.20)  
 
   
       
Non-white Race       
donor 1.17 (-1.51, 3.85) 0.39 1.82 (0.16, 3.49) 0.03 0.20 (-4.45, 4.85) 0.9 
recipient na na 0.59 (-0.47, 1.66) 0.27 -0.86 (-5.36, 3.63) 0.71 
       
Rural residence       
donors -0.27 (-2.02, 1.48) 0.76 -1.24 (-2.84, 0.36) 0.13 -2.14 (-4.09, -0.18) 0.03 
recipients na na -1.57 (-3.47, 0.32) 0.10 -1.69 (-2.16, -1.22) <0.001 




      
University/college 0 (reference) 0.62 na na na na 
Trades/high school or 
less 
0.44 (-1.32, 2.21) 
 
 
   
       
Donor employment 
status 
      
Full-time 0 (reference) 0.63 na na na na 
other 0.38 (-1.11, 1.88)  
 
   
       
Donor income quintile       
5, highest 0 (reference) 0.17 0 (reference) 0.10 0 (reference) <0.001 
4 1.96 (0.24, 3.67)  0.24 (-1.00, 1.49)  -3.28 (-4.92, -1.64)  
3 2.98 (0.33, 5.63)  0.36 (-0.65, 1.37)  -0.68 (-5.2, 3.83)  
2 1.92 (-0.69, 4.52)  0.12 (-1.35, 1.58)  0.85 (-0.84, 2.54)  




       
Recipient income 
quintile)b 
      
5, highest na na 0 (reference) 0.07 0 (reference) <0.001 
4   0.26 (-1.80, 2.32)  -0.55 (-2.54, 1.44)  
3   1.57 (0.15, 2.98)  -0.95 (-5.63, 3.74)  
2   0.10 (-1.42, 1.62)  1.06 (-3.37, 5.5)  
1, lowest   2.89 (0.04, 5.73)  2.8 (-2.86, 8.47)  
       
Pre-donation clinical characteristics 
Donor eGFRc       
≥90 mL/min/1.73 m2 0 (reference) 0.28 0 (reference) 0.75 0 (reference) <0.001 
80-89 mL/min/1.73 
m2 
-1.52 (-3.81, 0.78) 
 -0.73 (-2.62, 1.16) 
 
4.73 (1.30, 8.16) 
 
<80 mL/min/1.73 m2 0.61 (-0.68, 1.91)  -0.07 (-1.46, 1.33)  2.87 (1.84, 3.90)  
       
Recipient eGFR at 
donor first contact, per 
mL/min/1.73 m2c 
na na na na 0.79 (0.66, 0.93) <0.001 













na na 1.85 (-0.91, 4.61) 0.19 5.16 (1.11, 9.20) 0.01 
Heart failure na na 1.84 (-0.84, 4.51) 0.18 3.25 (-2.39, 8.89) 0.26 
Diabetes na na 0.28 (-0.56, 1.13) 0.51 -3.95 (-5.78, -2.13) <0.001 
Hypertension na na 0.43 (-0.69, 1.54) 0.45 -4.74 (-6.83, -2.65) <0.001 
       
Donor body mass index, 
kg/m2 
      
Underweight (<18.5) -2.79 (-5.58, -0.01)      
Normal (18.5-24.9)  0 (reference) 0.05 na na na na 
Pre-obese (25-29.9) 0.85 (-1.47, 3.17)      
Obese (30-34.9) 0.46 (-0.82, 1.74)      
Very obese (≥ 35) 2.07 (-2.31, 6.45)      
       
Donor blood pressure       
Normal 0 (reference) 0.61 na na na na 
Pre-hypertensive -0.01 (-1.41, 1.40)      
Hypertensive 3.28 (-3.39, 9.94)      
       
Time to recipient 
referral 
na na 
0.39 (0.27, 0.50) <00001 0.82 (0.71, 0.93) <0.001 
       
Other characteristics 
Relationship       
Spouse 0 (reference) 0.04 0 (reference) 0.03 0 (reference) <0.001 
Sibling -2.07 (-5.71, 1.57)  -0.65 (-3.39, 2.09)  0.27 (-2.49, 3.03)  
Parent -1.64 (-6.08, 2.81)  -1.22 (-3.0, 0.56)  1.52 (-3.73, 6.77)  
Child -4.12 (-8.80, 0.56)  1.13 (-0.65, 2.9)  -4.1 (-8.39, 0.18)  
Other relation -4.44 (-8.89, 0.01)  -0.07 (-3.85, 3.71)  -4.2 (-6.02, -2.38)  
Unrelated 0.74 (-4.47, 5.95)  1.35 (0.01, 2.69)  0.31 (-1.99, 2.62)  
       
Participated in kidney 
paired donation 
7.00 (3.75, 10.3) <0.001 na na na na 
       
Surgery type performed       
Laparoscopic 0 (reference) 0.19 na na na na 
Open -1.23 (-3.07, 0.61)      
       
Cause of kidney failure       
GN/autoimmune na na 0 (reference) <0.001 0 (reference) <0.001 
Polycystic   2.75 (-0.48, 5.97)  -0.95 (-4.76, 2.85)  




Other   1.53 (-0.28, 3.34)  0.03 (-4.16, 4.21)  
Unknown 
  1.94 (1.19, 2.69) 
 -1.55 (-11.02, 
7.93) 
 
       
Year of transplant, per 
year 
0.23 (-0.72, 1.17) 0.64 0.08 (-0.11, 0.27) 0.40 0.06 (-0.23, 0.36) 0.67 
       
Distance to transplant 




donor 0.05 (0.01, 0.10) 0.03 0.12 (0.02, 0.23) 0.02 -0.26 (-0.42, -0.11) 0.001 
recipient na na 0.04 (-0.14, 0.21) 0.67 -0.20 (-0.36, -0.05) 0.009 
The total evaluation time was defined as the time from the donor’s evaluation start date until donation. A positive number means 
the factor was associated with a longer donor evaluation time, expressed in months of additional time. The median (25th, 75th) 
total donor evaluation time for the prospective cohort, dialysis-dependent cohort, and pre-emptive transplant cohort was 10.3 
(6.5, 16.7), 10.6 (6.4, 21.6) and 9.5 (7.0, 14.3), respectively.a beta estimates with 95% confidence intervals (CI) obtained from 
linear regression accounting for clustering by transplant center (generalized estimating equations). The beta estimate 
corresponds to the average difference in total evaluation time for a change in category (compared to the reference category) or a 
1-unit increment in a continuous variable (unless otherwise specified) 
b neighbourhood-income quintile derived from the 2006 Canada Census (Canadian donors only) 
c kidney function measured using CKD-EPI equation (mL/min/1.73 m2) from serum creatinine identified at any point in the 
evaluation for donors and within 3 months of the donor’s evaluation start date for recipients. 
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation. 
eGFR – estimated glomerular filtration rate; GN – glomerulonephritis; na – not available 
 
Table 13: Factors associated with total donor evaluation time, adjusted estimates 
 Prospective cohort 
16 transplant centers 
Canada and Australia 
Retrospective cohort  
5 transplant centers 
Ontario, Canada only  
Unknown if recipient 
was receiving dialysis at 
start of donor evaluation 
(n=849) 
Recipient receiving 
dialysis at start of the 
donor evaluation 
(N=631) 
Recipient was not 
receiving dialysis at the 
start of the donor 
evaluation, and a pre-
emptive transplant was 
achieved (N=311) 
Variable beta (95% CI)a,b p-value beta (95% CI)a,c p-value beta (95% CI)a,c p-value 
Demographic factors 
Donor age, per 10 years 0.81 (0.39, 1.57) 0.04 0.67 (0.31, 1.02) <0.001 2.02 (1.72, 2.31) <0.001 
       
Female donor sex 0.72 (-0.54, 1.99) 0.26 1.22 (-0.07, 2.51) 0.06 1.51 (-1.04, 4.06) 0.25 
       
Donor smoking status at 
recruitment (within last 
30 days)* 
      
Not smoking 0 (reference) 0.18 na na na na 
Recently quit -1.31 (-2.89, 0.28)  
 
   
Still smoking -1.20 (-2.82, 0.41)  
 
   
       
Non-white donor race – – 2.07 (0.86. 3.29) <0.001 – – 
       
Rural donor residence – – -1.41 (-3.02, 0.20) 0.09 -2.71 (-5.10, -0.31) 0.03 
       
Socioeconomic factors 
Donor income quintiled       
5, highest 0 (reference) 0.02 0 (reference) 0.05 0 (reference) <0.001 
4 2.17 (0.82, 3.52)  0.41 (-0.95, 1.78)  -2.90 (-4.09, -1.71)  
3 3.07 (0.47, 5.68)  0.65 (-0.11, 1.40)  -0.59 (-5.82, 4.64)  
2 2.64 (0.02, 5.26)  0.29 (-1.43, 2.01)  1.33 (-1.08, 3.75)  
1, lowest 0.88 (-0.42, 2.18)  2.84 (0.75, 4.93)  -1.06 (-5.21, 3.09)  




Pre-donation clinical characteristics 
Donor eGFRf       






3.46 (1.48, 5.45) 
 
<80 mL/min/1.73 m2     1.46 (0.36, 2.56)  
       
Recipient eGFR at 
donor first contact, per 
mL/min/1.73m2f 
na na na na 0.83 (0.71, 0.95) <0.001 












na na 1.56 (-0.75, 3.88) 0.19 3.74 (-0.21, 7.70) 0.06 
Heart failure na na 1.64 (-1.14, 4.41) 0.25 – – 
Diabetes na na – – -4.17 (-6.98, -1.36) 0.004 
Hypertension na na – – -4.53 (-6.08, -2.98) <0.001 
       
Donor body mass index, 
kg/m2 
      
Underweight (<18.5) -3.74 (-7.59, 0.12)      
Normal (18.5-24.9)  0 (reference) 0.10 na na na na 
Pre-obese (25-29.9) 1.10 (-1.42, 3.62)      
Obese (30-34.9) 0.47 (-0.89, 1.83)      
Very obese (≥ 35) 2.05 (-2.67, 6.78)      
       
Time to recipient 
referral 
na na 0.38 (0.29, 0.51) <0.001 0.86 (0.75, 0.97) <0.001 
       
Other characteristics 
Relationship       
Spouse 0 (reference) 0.14 0 (reference) <0.001 0 (reference) <0.001 
Sibling -1.63 (-5.20, 1.94)  -0.06 (-2.84, 2.71)  1.07 (-1.74, 3.88)  
Parent -1.55 (-6.07, 2.97  -0.95 (-2.63, 0.72)  1.06 (-4.34, 6.45)  
Child -2.71 (-7.00, 1.57)  2.17 (0.43, 3.92)  -1.45 (-4.68, 1.77)  
Other relation -3.97 (-8.21, 0.27  0.55 (-3.38, 4.49)  -3.94 (-5.70, -2.18)  
Unrelated 1.06 (-4.02, 6.14)  1.87 (0.51, 3.24)  0.94 (-1.54, 3.43)  
       
Participated in kidney 
paired donation 
6.59 (1.61, 9.74) <0.001 na na na na 
       
Surgery type performed       
Laparoscopic 0 (reference) 0.46 na na na na 
Open -0.84 (-3.06, 1.39)      
       
Cause of kidney failure       
GN/autoimmune na na 0 (reference) <0.001 0 (reference) <0.001 
Polycystic   2.39 (-0.30, 5.07)  -2.45 (-5.79, 0.88)  
Diabetes   0.96 (-1.11, 3.03)  -7.18 (-10.9, -3.50)  
Other   1.58 (-0.27, 3.43)  -1.06 (-5.01, 2.88)  
Unknown   2.16 (1.40, 2.92)  -3.29 (-11.0, 4.42)  
       
Distance to transplant 
program, per 50 km 
0.04 (-0.00, 0.08) 0.07 0.11 (-0.03, 0.25) 0.13 -0.19 (-0.46, 0.08) 0.17 
The total evaluation time was defined as the time from the donor’s evaluation start date until donation. A positive number means 
the factor was associated with a longer donor evaluation time, expressed in months of additional time. 
a beta estimates with 95% confidence intervals (CI) obtained from linear regression accounting for clustering by transplant center 
(generalized estimating equations). The beta estimate corresponds to the average difference in total evaluation time for a change in 
category (compared to the reference category) or a 1-unit increment in a continuous variable (unless otherwise specified). 
b adjusted for donor age, sex, and relationship to the recipient. 
c adjusted for donor age, sex, urban/rural status, median neighbourhood-income quintile, and relationship to the recipient. 




e kidney function measured using CKD-EPI equation (mL/min) from serum creatinine identified at any point in the evaluation for 
donors and within 3 months of the donor’s evaluation start date for recipients. 
* donors were recruited a median (25th, 75th percentile) of 2.3 (1.3, 7.5) weeks prior to donation. 
eGFR – estimated glomerular filtration rate; GN – glomerulonephritis; na – not available; analyses not done due to unadjusted 
p>0.2 (from Table 12) are shown by a dash (–) 
 
6.4 Discussion 
Using data available on living kidney donors from 16 transplant centers, we assessed 
living donor evaluation times using five different potential process indicators that can be 
used to assess the timeliness of a living donor evaluation. 
We found the total time to complete the evaluation was a median 10 months, with 
25% of donors experiencing an evaluation period of 16 months or more. Some of this 
time is appropriate and necessary to complete a quality evaluation. Sometimes there are 
findings that require additional examination for a comprehensive living donor work-
up23,24, but we believe that at least the most common additional tests should not prolong 
the evaluation by 3-9 months.10 Other reasons for a longer evaluation time may be 
appropriate to reduce risks to the donor and recipient (e.g., weight loss, smoking 
cessation, blood pressure control).25,26 However, some transplant programs may require 
these issues to be resolved before the evaluation begins, which may explain why we did 
not find any of our evaluation times to be associated with these factors. Other reasons that 
influence the donor evaluation time such as age, sex, ethnicity and geography may be 
non-modifiable, yet understanding why such factors lead to a longer evaluation may 
influence how the evaluation is organized. For example, transplant programs may 
perform multiple tests on the same day to respect the travel requirements of donors who 
live far away. This may explain the weak association between distance and evaluation 
times and the shorter total evaluation time and time between consults among rural donors 
in the present study.27 Participating in kidney paired donation was the strongest predictor 
of longer evaluation times, which has some implications to the emerging practice of 
including compatible pairs.28–30  
Recipient factors are also important. A delayed recipient referral significantly 




improving patient education about living donor transplantation and increasing appropriate 
and timely transplant recipient referrals from kidney clinics.31,32 A higher recipient eGFR 
increased the donor evaluation time in the subset of pre-emptive transplants, which is 
likely an appropriate pace to the living donor evaluation to extend use of the recipient’s 
native kidneys until the transplant is needed. This was one reason why we presented 
some of our results stratified by whether the intended recipient was on dialysis at the time 
the donor evaluation started and whether the recipient received a pre-emptive 
transplant.18 
There was considerable between-center variability for all measures. Those with 
the shortest time between consults (Centers I, A, and H) frequently performed these 
consultations on the same day (I>A>H; Figure 11 and Table 9). Although these centers 
may not have had the shortest total evaluation and approval times, there was a consistent 
ordering amongst them for both of these metrics (I<A<H). Despite this, these centers had 
the longest time between approval and donation (I>A>H). These results suggest that 
although combining tests on the same day may be a viable and donor-centric process 
improvement strategy, other factors are also important (e.g., the time needed to secure 
operating time after donor approval). How one center is performing compared to another 
must be interpreted cautiously given the centers may differ with respect to donor case-
mix (e.g., proportion of donors donating through kidney paired donation, the proportion 
of donors who are obese), available resources (e.g., equipment and personnel), and the 
protocols they use to evaluate and select living donor candidates (e.g., how much they 
participate in kidney paired donation; their minimum requirements to evaluate a 
candidate). Adjustment for individual patient-level factors did not substantially change 
the point estimates, suggesting that center-level factors may be important drivers of 
evaluation times. A more detailed understanding of how different programs evaluate 
donor candidates is warranted. The living donor evaluation may be expedited under 
special circumstances that were not detailed in the present study, including urgency to 
avoid dialysis or to complete the evaluation before a deadline to enter a next matching 
cycle for kidney paired donation. Transplant centres should organize themselves to have 




There are many negative implications of a prolonged living donor evaluation that 
remain to be reported. First, many donors report negative experiences that may be a 
barrier to living kidney donation.10,11,15,16 Second, a prolonged living donor evaluation 
may increase the likelihood of competing events, including deceased donor kidney 
transplantation or the intended recipient becoming ineligible for transplant due to illness 
or death.7,33,34 Finally, there are costs to the healthcare system related to a longer living 
donor evaluation as recipients continue to accrue costs attributable to kidney disease 
(e.g., dialysis).35 Reducing the donor evaluation time when appropriate is a priority for 
patients, providers, and the healthcare system. 
These two multi-centre studies provide new information not available elsewhere 
by reporting multiple measures of potentially meaningful process outcomes, examining 
factors associated with these outcomes, and demonstrating substantive center-to-center 
variability.11,24,27,33,36,37 Many results are presented by transplant center, and other centers 
can collect and compare similar measures of performance. However, this study has 
several important limitations that should be addressed in future efforts. First, this study 
only included donors and the findings do not reflect the time to determine the candidacy 
of excluded donors, or the time to work-up donor candidates who were approved but 
ultimately did not donate. Second, we lacked information on program-level factors that 
may explain some variability in donor evaluation times (e.g., evaluation of multiple 
donor candidates simultaneously or sequentially38). Such data would be important to 
ascertain whether delays could be attributable to resources (i.e., human resources, wait-
time for testing) or differences in living donor program processes. Third, we lacked some 
data on individual-level factors that may affect the living donor evaluation time (e.g., 
recipient illness that may have temporarily affected their transplant eligibility and their 
donor’s evaluation process; various donor-driven reasons including financial or time 
constraints). Fourth, we used proxy dates to estimate several evaluation times, which may 
reduce the accuracy of some measures. Fifth, some of the center-to-center differences in 
donor evaluation times may be explained by differential data completeness rather than 
true differences. Finally, these results may not generalize to living donor programs in 





This study was prompted by a consensus that an evaluation time of six months is too long 
for many donors.11,16 The transplant community needs to further explore and define the 
reasons why some candidates experience prolonged evaluations and why some transplant 
centers have much longer evaluation times than others. A better understanding of these 
reasons can inform quality improvement initiatives to improve the experiences of 
candidates going through the evaluation process. 
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Chapter 7  
7 The flow of living kidney donor candidates through the 
evaluation process at a single centre 
 
7.1 Introduction 
There are several reasons why a transplant program may wish to assess the flow of living 
kidney donor candidates through its evaluation process. Knowledge of trends in the 
number of active open evaluations and the types of tests performed can be used to inform 
human resource planning and the required volume of specialized tests such as computed 
tomography (CT) angiography or nuclear renography.1 Information on the length of the 
evaluation process for candidates who go on to donate as well as those who are deemed 
ineligible to donate can be shared with candidates at the beginning of the evaluation 
process as part of informed consent.2 To guide quality improvement initiatives, it can be 
valuable to understand the reasons why the evaluation period is longer in some 
candidates than others, and the implications that this may have on the likelihood a 
candidate will complete their evaluation, or the length of time their intended recipient 
continues to receive dialysis (or needs to begin dialysis).3–5 However, there is no accepted 
way to assess the flow of living kidney donor candidates in a donor evaluation program, 
and our detailed search of bibliographic databases in the form of a scoping review only 
identified a limited number of illustrative examples (Chapter 4).6 These studies presented 
a few key metrics that can be used to compare the relative efficiency between programs, 
such as the time to complete the evaluation and the proportion of candidates who 
ultimately donated. However, the lack of consistent definitions of key dates renders many 
comparisons difficult, and lack of granularity of the data impairs interpretation. 
With the paucity of available evidence to date, we conducted this case study of a single 
program in Ontario, Canada, where we provide an example of how a program can review 






7.2.1 Data sources and variables 
We retrospectively reviewed the medical records for all living donor candidates who 
contacted the London Health Sciences Living Donor program in Ontario, Canada 
between January 1, 2013 and December 31, 2016 (herein referred to as “the study 
period”). This included all evaluations which were open and ongoing at the beginning of 
the study period (January 1, 2013), as well as evaluations which began during the 4-year 
study period. Evaluations could be open and ongoing by the end of the study period 
(December 31, 2016). 
We collected data on donor demographics, social habits, and medical factors from their 
medical records, which included clinic notes, diagnostic and lab test results, a preliminary 
screening checklist, living donor coordinator notes, and a self-reported medical-social 
questionnaire (MSQ). The preliminary screening checklist is conducted over the phone or 
email, which ascertains general information about prior cancer history, hypertension, 
diabetes, cardiovascular or cerebrovascular disease, body mass index (BMI), and history 
of renal stones. The MSQ is a detailed (11-page) paper or electronic questionnaire that 
ascertains a detailed account of the candidates’ social, medical, travel, and family history. 
Many programs have some form of MSQ that may be paper-based, electronic, or 
available through some online submission portal.6 
Blood pressure and BMI were ascertained early in the evaluation phase, as these would 
be most predictive of the trajectory of the evaluation. We used the BMI that was self-
reported on the MSQ, and blood pressure readings were done at a clinic or local drug 
store and readings were submitted with the MSQ; these measures would be similarly 
reported for all candidates (donors and non-donors). Blood pressure was estimated from 
an average of up to five measurements. The second digit of the Canadian postal code was 
used as an indicator of rural or urban residence (rural if zero; urban otherwise). Persistent 
hematuria was defined as the presence of blood in the urine in at least 50% of a minimum 
of three random urine sample tests performed on different days (the presence of blood 




Table 14: Classification of urine blood as positive, negative, or inconclusive 
Positive   
trace blood 3-4 RBC 4-6 RBC 
3-5 RBC 5-15 RBC 3+ RBC 
blood (2) 1+ blood 13 RBC 
3-10 RBC mod blood >10/uL RBC 
moderate blood 16-50 RBC 11-20 RBC 
<10 RBC 3 p/ul RBC 20-30 RBCs 
large blood 5-20 RBC 5-30 RBC 
6-10 RBC 3-5 microscopic RBC/HPF blood (2+) 
blood (1+) 0.3 blood 25-50% dysmorphic RBC 
3+ blood >10mg/L blood 10 blood 
6-11 RBC >50 RBC 11-25 RBC 
3 RBC 2+ blood 20-30 RBC 
small blood 16 RBC trace-intact blood 
   
Inconclusive   
1-5 RBC small blood (menses started this day) 
0-5 RBC 2-5 RBC 
<5 RBC large blood - patient on menses 
moderate blood (patient on menses) small blood, rare RBC 
trace blood (patient had menses) occasional RBC 
1-3 RBC   
   
Negative   
1-2 RBC   
trace blood (expected)   
Classification of results as positive, inconclusive, and negative was based on expert opinion. If 50% of 
a candidates’ results were positive then the candidate was said to have persistent hematuria. 
RBC – red blood cell; HPF – high-powered field 
 
Recipient data were obtained from a local transplant database, which included the date an 
intended recipient started dialysis, the date transplant recipient candidates were referred 
for transplant evaluation, and the date transplant candidates were placed on the deceased 
donor wait-list. Information on intended recipients not referred to the program was 
unavailable. Unlike what occurs in some other countries including the United States, in 
Ontario a complete referral package is sent from the nephrologist managing the patient 
with kidney failure to a transplant centre for an assessment of transplant eligibility. This 
referral package includes the results of complete bloodwork, an electrocardiogram, an 
echocardiogram, cardiac perfusion testing (when a patient has cardiac risk factors), 
infectious disease and virology testing, complete cancer screening per Ontario guidelines, 
a chest x-ray, and an abdominal/renal ultrasound. The transplant centre acknowledges 





7.2.2 The evaluation 
The living donor evaluation was segmented into distinct phases. The evaluation began at 
the time the candidate made contact with the program (phoned, emailed, in-person visit). 
In this study, proceeding to the screening phase of the evaluation occurred if the program 
received the MSQ (complete or incomplete). Proceeding to the evaluation phase was 
defined as date the (completed) MSQ was reviewed by the program coordinators and a 
decision rendered about proceeding to the next phase of the evaluation. The evaluation 
phase started with the first laboratory test or consult after the screening phase, and ended 
with a definitive decision on ineligibility, candidate withdrawal, or donation (since the 
date of approval is not documented or defined). 
Candidates were considered lost to follow-up if there was no progress with the evaluation 
for at least three months and there was no indication that their evaluation was placed on 
hold or was terminated because the candidate withdrew or was deemed ineligible. Thus, 
we assumed they were no longer interested in becoming a donor but did not wish to 
communicate this to the program explicitly. There was no system in place to attempt to 
contact these candidates, although gentle reminders were sometimes solicited. 
Reasons for a delayed evaluation were abstracted from the clinical notes whenever 
encountered, although there was no systematic process for categorizing or documenting 
the duration of the delay.  
7.2.3 Statistical methods 
This study is largely descriptive, and results are reported as mean (standard deviation, 
SD) or median (25th, 75th percentile), where appropriate. Comparisons between donors 
and non-donor candidates were conducted using chi-square tests for categorical data and 






A total of 1,069 living donor candidates were active for some portion of the study period. 
Of these, 741 (69%) candidate evaluations were terminated without donation (e.g. 
candidates were deemed ineligible, indicated they wanted to withdraw, or were lost to 
follow-up); 138 (13%) were still undergoing evaluation by the end of the study period 
(although 20 ended up donating by January 2018); 103 (10%) candidates donated during 
the study period; and 87 (8%) candidate evaluations were on hold by the end of the study 
period, although the reason was unknown. 
Mean (SD) candidate age was 46 (14) years, and BMI was 27.0 (5.2) kg/m2. Candidates 
were predominantly women (66%), white (85%), and lived in an urban neighbourhood 
(76%) (Table 15). Most candidates wished to donate to a friend or non-relation (21%), a 
sibling (20%), or a distant relation (19%). Only 8% of candidates intended to donate 
anonymously (non-directed donation), two of whom had to have their kidney removed 
for their own health. During the study period, the program had 2.0 full-time equivalent 
living donor nurse coordinators, 1.0 full-time equivalent administrative assistant, and 2 
nephrologists and 2 surgeons who were available to discuss open cases and see 8-10 new 
living kidney donor candidates in consultation each month. 
Table 15: Donor candidate characteristics (n=1066) 
Characteristic Donor (n=123) Non-donor (n=946) 
Age, years 47.8 (11.1), n=121 45.3 (14.1), n=809 
BMI, kg/m2 26.6 (3.5), n=119 27.0 (5.5), n=475 
SBP, mmHg 121 (9.9), n=115 122 (11.8), n=369 
DBP, mmHg 76 (6.8), n=115 76 (8.4), n=369 
   
Travel distance (km)   
Euclidean distance 91 (42, 168), n=118 94 (23, 165), n=552 
Driving distance 110 (54, 193), n=118 115 (27, 189), n=552 
   
Sex   
Male 39 (32%) 316 (34%) 
Female 84 (68%) 607 (66%) 
   
Race   
White 103 (89%) 383 (84%) 
Arabic 3 (3%) 21 (4%) 
South Asian 3 (3%) 12 (3%) 
East Asian 1 (1%) 13 (3%) 
Black/Indo-Caribbean 3 (3%) 9 (2%) 
Other 3 (3%) 16 (4%) 
   




Urban 90 (76%) 428 (76%) 
Rural 28 (24%) 134 (24%) 
   
Married 105 (85%) 463b 
   
Intended recipient relation   
Friend or non-relation 10 (8%) 194 (22%) 
Sibling 26 (22%) 169 (20%) 
Distant relation 23 (19%) 168 (20%) 
Spouse 27 (22%) 86 (10%) 
Parent 10 (8%) 99 (11%) 
Child 15 (13%) 80 (9%) 
Non-directed (anonymous)c 10 (8%) 67 (8%) 
   
Donor blood type   
O 66 (54%) 288 (47%) 
A 38 (31%) 214 (35%) 
B 14 (12%) 88 (15%) 
AB 3 (3%) 20 (3%) 
   
Recipient blood type   
O 49 (42%) 301 (44%) 
A 44 (38%) 269 (39%) 
B 18 (15%) 89 (13%) 
AB 6 (5%) 25 (4%) 
   
Enrolled in kidney paired donation 19 (23%) 29b 
   
Anti-hypertensive medications 8 (7%) 84 (9%) 
Type II diabetes 0 (0%) 10 (1%) 
   
Smoking at screening   
current 15 (13%) 101 (21%) 
former 35 (29%) 130 (28%) 
never 69 (58%) 239 (51%) 
Results are reported as mean (standard deviation), median (25th percentile, 75th percentile), or N 
(percent), where appropriate 
a defined using second digit of Canadian postal code (rural if 0, urban otherwise) 
b no denominator 
c 1 in each group had to get their kidneys removed for their own health 
 
7.3.1 Healthcare encounters over the study period  
The annual number of new candidates who contacted the program doubled from 167 in 
2013 to 348 in 2016, with a concomitant 45% increase in the number of donations (22 in 
2013 to 32 in 2016) (Figure 12). The average number of candidates coming forward for 
the same recipient increased over time from a median of 2 (1, 7) (maximum 13) [mean 






Figure 12: Number of contacts and donations that occurred between January 1, 
2013 and December 31, 2016 at London Health Sciences Centre (N=935)  
 





The number of specific healthcare encounters also increased during the study period, 
including the number of nephrology consults, psychosocial assessments, CT angiograms, 
and initial crossmatch tests (Figure 14). In contrast, the number of surgery consultations 
remained stable and the number of nuclear renograms decreased. The number of donors 
performing two or more 24-hour urine tests decreased over time: 19/22 (87%) in 2013, 
20/23 (87%) in 2014, 12/26 (46%) in 2015, and 5/32 (16%) in 2016. 
 
Figure 14: Annual number of healthcare encounters by year 
7.3.1.1 Donor candidate attrition for all new contacts during the 
study period 
We followed all candidates through their evaluation process, restricted to those with a 
first contact date during the study period (n=939). After contacting the program, 427 
(45%) candidates did not proceed to the screening phase, 203 (22%) did not proceed to 
the evaluation, and 228 (24%) did not complete the evaluation (Figure 15). By January 
2018, 95/939 (10%) donated. Loss of follow-up with the donor candidate was the most 
common reason for attrition, which usually occurred during screening (e.g. not screened 
out at initial contact, yet did not return the MSQ; Table 16). Based on medical or 




the initial screening period (e.g. at initial contact), 15% were deemed ineligible following 
a more detailed screening (results from the MSQ), and 21% were deemed ineligible 
during the evaluation period. For candidates with an available date of withdrawal or 
decline (n=290, excluding those who were lost to follow-up), the total time of the 
evaluation was a mean 6.2 (SD 6.1) months and a median 4.3 (1.4, 9.1) months. 
 
Figure 15: Flow of living donor candidates through the living donor program at 
London Health Sciences Centre. All candidates first contacted the program between 
January 1, 2013 and December 31, 2016. Candidates were considered active if they 
did not donate, were not declined, were not placed on hold, or were not lost to 
follow-up before December 31, 2016. Loss to follow-up was considered as 3 months 




Receipt of a deceased donor kidney transplant was recorded in the candidate’s medical 
chart to be a reason for donor candidate attrition in 22 cases, 13 of whom had a candidate 
in the evaluation phase. Loss of recipients due to death or ineligibility occurred in only 
six instances, four of whom had a donor who had passed the screening phase (Table 16). 
Table 16: Reasons for donor candidate attrition at different time-points in the 
evaluation 












No donor follow-up 290 (68%) 24 (12%) 10 (4%) 0 (0%) 
Active donor in period 55 (13%) 27 (13%) 47 (21%) 1 (25%) 
Donor deemed medically unsuitable 30 (7%) 31 (15%) 49 (21%) 0 (0%) 
Will work up other donors first 4 (1%) 25 (12%) 21 (9%) 0 (0%) 
Recipient not ready/not assessed 2 (0%) 21 (10%) 6 (3%) 2 (50%) 
Unknown reason 5 (1%) 10 (5%) 14 (6%) 0 (0%) 
Donor changing lifestyle (i.e., smoking 
cessation, weight loss) 
1 (0%) 21 (10%) 5 (2%) 0 (0%) 
Donor no longer wants to continue with 
donation 
11 (3%) 7 (3%) 7 (3%) 1 (25%) 
Other reasons 4 (1%) 9 (4%) 10 (4%) 0 (0%) 
Recipient received a deceased donor 
transplant 
5 (1%) 4 (2%) 13 (6%) 0 (0%) 
Recipient transplanted by other living donor 3 (1%) 4 (2%) 9 (4%) 0 (0%) 
Incompatible (cross-matching) – not 
interested in kidney paired donation 
0 (0%) 1 (0%) 13 (6%) 0 (0%) 
Donor impaired by support, stressors, and 
responsibilities 
2 (0%) 6 (3%) 5 (2%) 0 (0%) 
Incompatible (ABO) – not interested in 
alternatives 
4 (1%) 6 (3%) 2 (1%) 0 (0%) 
Recipient to wait for deceased donor kidney 
with pancreas or liver 
2 (0%) 2 (1%) 5 (2%) 0 (0%) 
Recipient declined donor or transplant 3 (1%) 2 (1%) 2 (1%) 0 (0%) 
Donor is to be worked up at another program 1 (0%) 3 (1%) 1 (0%) 0 (0%) 
Recipient died or no longer eligible for 
transplant 
1 (0%) 1 (0%) 4 (2%) 0 (0%) 
Incidental finding during evaluation 0 (0%) 0 (0%) 4 (2%) 0 (0%) 
Donor is an international non-directed 
anonymous donor (not accepted by our 
program) 
3 (1%) 0 (0%) 0 (0%) 0 (0%) 
Recipient too healthy for a transplant 1 (0%) 1 (0%) 1 (0%) 0 (0%) 






7.3.1.2 Reasons for a delayed evaluation 
The most frequently encountered reasons for a delayed donor evaluation occurred early in 
the process (Table 17). The most common reason was a delay in the referral of the 
intended recipient to the transplant centre (11% of candidates), as there was limited 
interest in evaluating some living donor candidates in too much detail until their intended 
recipient was referred to the transplant centre. The second most common reason was the 
requirement for the candidate to lose some weight (8% of candidates) or other candidates 
were prioritized when at least one other candidate contacted the program for the same 
intended recipient (4% of candidates). 
Table 17: Reasons for a delayed evaluation process 




Recipient was not assessed yet early 99 (10.5%) 
Candidate needed to lose weight early 74 (7.9%) 
Incidental finding during the evaluation middle-late 37 (3.9%) 
Other donors prioritized throughout 35 (3.7%) 
Other reason throughout 31 (3.3%) 
Smoking cessation early 30 (3.2%) 
Personal reasons throughout 23 (2.4%) 
Donor started the evaluation in another program early 21 (2.2%) 
Language barrier throughout 21 (2.2%) 
Donor coming from another country throughout 19 (2.0%) 
Recipient was not ready to proceed middle-late 17 (1.8%) 
Donor had to get blood pressure under control early 14 (1.5%) 
Donor intends to donate at another program early 13 (1.4%) 
Recipient’s health had to improve throughout 6 (0.6%) 
Operating room time difficult to get late 6 (0.6%) 
Recipient kidney’s still function so transplant surgery can 
be delayed  
early 
2 (0.2%) 
Donor needed time to think or discuss with recipient early 2 (0.2%) 
   
 
7.3.1.3 Recipient dialysis status 
Data were available from the transplant database for 860 (92%) intended recipients. 
Among these, 359 (42%) were on dialysis before their donor candidate started their 
evaluation, 316 (37%) were never on dialysis, and 185 (21%) started dialysis after this 




months of their candidates’ evaluation start date) (Figure 16). Among donors, 20% of 
their intended recipient started dialysis before donation (29% for non-donors). Omitting 
the 92-day buffer to complete the evaluation (a time sufficient to complete the 
evaluation) increased this estimate to 35% for donors (37% for non-donors). The 
proportion of living donor transplants that were pre-emptive increased over time: 18% 
(4/22) in 2013, 27% in 2014 (6/22), 38% in 2015 (9/24), and 34% (11/32) in 2016. Of the 
36 recipients who started dialysis after the evaluation was underway for at least three 
months, this occurred a mean 356 (SD 197) days after the first contact date [median 351 
(243, 419) days].  
 




Recipients were referred to the transplant centre a median 9 (-108, 104) days (n=667) 
after their donor candidate first contacted the program, and were activated on the 
deceased donor wait list a median 175 (63, 306) [mean 127 (SD 572)] days (n=532) after 
their donor candidate first contacted the program. 
7.3.2 The evaluation process 
Among donors who donated during the study period who had a first contact date 
available (97/103, 94%), the time from first contact until donation was a mean 13.7 (15.7) 
months, median 9.2 (6.1, 14.0) months. The total evaluation time decreased over the 
study period from a median 12.8 (7.5, 14.9) in 2013 to 7.1 (4.8, 12.4) in 2016 
(Spearman’s rho=-0.24, p=0.02) (Figure 17). 
 
Figure 17: Average time from first contact until donation (n=97) 
7.3.2.1 Timeliness of the evaluation 
The candidate contacted the transplant program usually by phone (65%) or email 




the program received the completed questionnaire a median 8 (3, 18) days later (Figure 
18). The overall process from first contact until the MSQ was reviewed with the 
candidate took a median 40 (22, 90) days.  
 





Since delays in this step may be predominantly donor-driven, we express the time to 
complete various components of the evaluation using the date the MSQ was received as 
the point of reference (Figure 19). The renal ultrasound, chest x-ray and 
electrocardiogram were completed a median 40 days after this time-point, the initial 
crossmatch, psychosocial evaluation, and nephrology consult after a median of 50-57 
days, and the CT, nuclear renogram, and surgical consult after a median of 82-89 days. 
Donors completed these tests on a median 5 of different dates (range 2-9 days, mean 4.7 
days, SD 1.4 days).  
 
 
Figure 19: Time from receipt of the medical-social questionnaire (MSQ) until 
various tests in the living donor evaluation were completed 
The initial cross-match was conducted a median 118 (63, 203) days after first contact 
(n=186), and the final cross-match was conducted a median 95 (56, 133) days afterwards. 
The first recipient serum that was used for cross-match testing was obtained from the 
recipient a median 19 (-43, 102) days after first contact. Since at least two samples 




have been conducted 2 months after this date, a median of 48 (0, 115) days earlier than 
actually performed. 
For candidates with a nephrology, urology, and psychosocial assessment, the time 
between consults was a mean 54 (74) days and a median 27 (4, 69) days (n=127) and was 
similar for donors (median 27 days) and non-donor candidates (median 28 days). 
7.3.2.2 Laboratory, imaging, and consultations 
There were no differences in select serum biochemical parameters between donors and 
non-donor candidates on their first blood test (Table 18). In contrast, donors had 
significantly less urinary albumin (2.6 g/L versus 6.2 g/L) and a lower random urinary 
albumin-to-creatinine ratio (0.16 mg/mmol versus 0.80 mg/mmol) than non-donors on 
their first urine test. Donors were less likely to have persistent hematuria (8/71, 11%) 
than non-donors (21/62, 34%) among those tested, but were more likely to continue with 
the evaluation and have a urine cytology exam (microscopic analysis of urine for 
evidence of malignancy), cystoscopy, or renal biopsy (Table 18).  
There was no difference in 24-hour creatinine clearance (117 versus 114 mL/min/1.73m2) 
or GFR measured by nuclear renogram (107 versus 92 mL/min/1.73 m2) between donors 
and non-donors. The nuclear renogram was performed a median 0 (-35, 4) days from the 
time of the CT scan (if negative, renogram preceded the CT angiography). The time from 
CT until donation was a mean 127 (149) days [median 75 (36, 180) days] (n=74). 
Other tests were required on an individual-level basis, including ambulatory blood 
pressure monitoring (n=54), echocardiography (n=20), stress tests (n=19), and 24-hour 
urine analysis for kidney stones (n=13). Consultation with other healthcare professionals 
were required on an individual basis, including dietitians (n=20), obstetricians or 
gynecologists (n=11), transplant infectious disease (n=11), cardiologists (n=9), 
hepatologists (n=5), gastroenterologists (n=5), and respirologists with or without a 












Lab finding (blood tests)    
Number of blood tests*    
1 2 (3%) 115 (59%) <0.0001 
2 30 (40%) 60 (31%)  
3 19 (25%) 12 (6%)  
4 9 (12%) 5 (2%)  
5 11 (15%) 1 (1%)  
6 4 (5%) 2 (1%)  
    
total protein (g/L) 71.0 (4.2) 71.5 (4.0) 0.47 
albumin (g/L) 44.2 (3.1) 44.1 (2.7) 0.91 
creatinine (μmol/L) 68.9 (11.3) 72.3 (13.9) 0.03 
estimated GFR (mL/min/1.73 m2)a 97.0 (13.8) 94.0 (16.9) 0.12 
    
random glucose (mmol/L) 5.2 (0.7) 5.3 (1.3) 0.39 
fasting glucose (mmol/L) 5.1 (0.5) 5.0 (0.7) 0.27 
2-hour glucose (mmol/L) 5.1 (1.3) 5.8 (1.9) 0.32 
hemo a1c (%) 5.4 (0.4) 5.4 (0.4) 0.38 
    
cholesterol (mmol/L) 5.0 (0.9) 5.0 (1.0) 0.77 
triglyceride (mmol/L) 1.4 (0.9) 1.3 (0.8) 0.54 
HDL (mmol/L) 1.5 (0.5) 1.6 (0.5) 0.43 
LDL (mmol/L) 2.8 (0.8) 2.8 (0.8) 0.96 
    
Lab finding (urine tests)    
Number of urine tests*    
1 0 (0%) 74 (40%) <.0001 
2 4 (5%) 47 (26%)  
3 16 (21%) 31 (17%)  
4 16 (21%) 14 (8%)  
5 13 (18%) 9 (5%)  
6 15 (20%) 5 (3%)  
7+ 11 (15%) 3 (2%)  
    
albumin (mg/L) 2.6 (4.7) 6.2 (12.4) 0.001 
creatinine (mmol/L) 9.9 (7.6) 9.3 (6.6) 0.56 
random albumin/creatine ratio (mg/mmol) 0.16 (0.26) 0.80 (2.46) 0.0007 
    
Number with persistent hematuriab* 8 (11%) 21 (34%) 0.002 
Number with urine cytology* 10 (13%) 17 (2%) <.0001 
Number with cystoscopy* 10 (13%) 10 (1%) <.0001 
Number with renal biopsy* 10 (13%) 4 (1%) <.0001 
    
Lab finding (24 hour urine tests)    
Number of 24h urine tests*    
0 2 (3%) 601 (82%) <.0001 
1 37 (49%) 78 (11%)  
2 28 (37%) 42 (6%)  
3+ 8 (11%) 7 (1%)  
first measured creatinine clearance 
(mL/min/1.73 m2) 
117 (33.4) 114 (55.1) 0.59 
    
Other investigations    
Number with renal ultrasound* 75 (100%) 129 (18%) <.0001 




Number with a nephrology consult* 75 (100%) 90 (12%) <.0001 
Number with a psychosocial consult* 73 (97%) 91(13%) <.0001 
Number with a urology consult* 67 (89%) 61 (8%) <.0001 
    
Lab finding (nuclear renogram)    
Number with nuclear GFR exam* 41 (55%) 51 (7%) <.0001 
Measured GFR (mL/min/1.73 m2) 107 (50.2) 92.4 (23.1) 0.14 
Left split renal function % (left) 51.7 (3.5)% 49.3 (3.7)% 0.004 
    
Self-reported psychosocial historyc    
Ever been treated, diagnosed with, or been 
prescribed medication for a mental, psychiatric, 
or emotional disorder 
   
no 64 (88%) 324 (80%) 0.13 
yes 9 (12%) 80 (20%)  
    
In the past 5 years, have you ever been 
prescribed anti-depressants, anti-anxiety or 
other similar medications by a physician? 
   
no 63 (86%) 308 (75%) 0.04 
yes 10 (14%) 100 (24%)  
    
a estimated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula 
b defined as at least 50% of urine samples positive for blood, restricted to those with at least 3 random 
urine tests (see Table 14 for details) 
c self-reported on medical-social questionnaire 
F p-value calculated using Fisher’s exact test 
W p-value calculated using non-parametric Wilcoxon rank sums test 
*restricted to donors (n=75) and non-donors (n=728) with a completed evaluation (e.g. donation date and 
evaluation end-date within study period)  
GFR – glomerular filtration rate 
 
7.3.3 Living donor candidate expectations 
Many donor candidates answered the MSQ question “Within what time frame are you 
hoping to complete this process (i.e., when will be the best time for you to donate if you 
are found suitable?)”. Many candidates were keen to donate as soon as possible (n=158, 
39%) while others did not express any urgency and were available whenever needed 
(n=246, 61%). Forty-four percent of candidates expressed that the ideal time to donate 
was as early as 1 month from the time the MSQ was completed, whereas 38% required at 
least 4 months and 18% preferred to donate anytime after 6 months. The ideal time to 
donate was less than 4 months by 41% of candidates, while 47% preferred a time >6 
months from the date the MSQ was completed. There were no differences in expectations 





In the present study, we conducted a detailed chart audit to understand the flow of living 
donor candidates through our program. Although labor-intensive, the results are 
informative, enabling us to identify the most frequent reasons causing delay that are 
actionable or warrant further study.  
One study reported a median (25th-75th percentile) time until approval of 4 (1-24) months, 
a median time from approval until donation of 3 (0-9) months, and a median time until 
rejection of 3 (0-48) months.7 Another study reported a mean (standard deviation) time 
until donation of 9.3 (6.5) months.8 One study reported a median time until donation of 
5.9 (3.7-10.6) months from the time of referral (although the referral date was not clearly 
defined).9 One study reported a time from screening bloodwork until donation of 4.3 
months, down from 7.4 months following quality improvement efforts of implementing a 
clinical pathway.10 Finally, one multi-centred study reported multiple metrics for 
evaluation times across multiple centres in Canada and Australia, demonstrating 
substantial variability across programs and estimating a median time until donation of 
10.3 (6.5-16.7) months.5 
We reported a median time until donation of 9.2 months, consistent with previous 
reports5, but also identified a small reduction in the total time until donation over time. 
The number of living donor transplants increased over time, which may be explained 
either by the rise in the number of candidates coming forward for the same recipient, a 
reduction in the evaluation time, or both.11 We expect further efficiencies in the 
evaluation process to result in a greater number of living donor transplants performed, 
which is of itself an important performance indicator. Comparable to other studies, the 
number of times the intended recipient started dialysis, died or became ineligible for 
transplant, or received a deceased donor transplant before their donor candidate 
completed their evaluation occurred often enough to warrant concern, and quality 
improvement efforts should attempt to reduce these occurrences whenever possible.3,4,6  
There are many areas for efficiency improvements. One potential solution is to provide 




States.6 Most living donor programs only evaluate one candidate at a time, but it is 
unclear whether review of the completed MSQ is considered part of this evaluation. 
Review of the MSQ is labor-intensive, requiring at least one hour of living donor 
coordinator time (based on expert opinion). Although as many as 24 candidates came 
forward for one recipient in 2016, we do not expect all of them to complete the MSQ 
since many candidates do not follow up with the program after initial contact. Providing 
the MSQ online with the ability to complete it entirely electronically may ease the 
screening process and facilitate prioritization of candidates using pre-scored instruments 
and flags to enable coordinators to focus on key issues.  
For donor candidates whose evaluation was delayed because their intended recipient was 
not assessed, their evaluation resumed 73% of the time (e.g. this was not a cause for 
termination of the candidate’s evaluation). Nine percent of donors’ evaluations were 
delayed for this reason – had the candidate’s evaluation begun immediately, we would 
have expected some earlier living donor kidney transplants that may in turn improve 
outcomes (particularly if the recipient is on or approaching dialysis).3 In addition to 
earlier recipient referrals, decisions should be made whether to begin (and when to pause) 
the donor candidate evaluation for candidates whose intended recipient was not yet 
evaluated. Other reasons for delay include the need for the candidate to lose weight, 
which is necessary for the safety of the donor and is largely non-modifiable.12,13 Our 
program offers (but does not mandate) consultation with a dietitian in cases of obesity or 
elevated cardiovascular risk factors. Although BMI cut-points may vary between 
programs6, the evaluation is often begun if it is clear that the candidate is making strides 
towards weight loss and the intended recipient has been approved for transplant. Finally, 
another reason for delay was the prioritization of other donor candidates. In some cases, it 
may be more cost-effective to evaluate multiple candidates simultaneously: in our 
population, only 2 donors’ evaluations had a documented delay because other candidates 
were prioritized. Future research is needed to examine this scenario. Future efforts are 
needed to quantify periods of patient-driven and system-driven delay. 
Strategies to improve the efficiency of the living donor evaluation process have been 




others) is to enable a 1-day evaluation for willing candidates. Several transplant centres 
already have such a strategy in place.6,11 A step-wise evaluation is certainly cost-saving to 
the evaluation program, but from a broader perspective, the opportunity cost is high if the 
recipient starts dialysis or continues to accrue costs related to dialysis while waiting for 
their donor.3 Following the screening phase, all candidates are required to complete 
random blood and urine tests. However, there is no consensus whether the requisitions 
for these tests should be provided at the same time as the MSQ or after the MSQ is 
reviewed by the living donor coordinators. Non-donors had significantly less favourable 
urine test results than donors, suggesting a greater emphasis for conducting this test as 
early as possible (perhaps during the initial screening phase). Following screening, all 
candidates could be scheduled for 1-day testing (Figure 20). Some time is then needed to 
establish candidacy, order additional tests on a second visit if needed, and schedule the 
operating room. In this scenario, the candidate is required to visit the transplant centre 
once or twice. Currently, candidates interacted with the healthcare system a median 5 
times before the preoperative assessment (not including visits with a general practitioner 
or other ad hoc tests or consults). Scheduling the operating room as early as possible may 
help reduce the time until donation, which may be particularly important since the time 
from CT angiography (one of the last tests) until donation was the longest segment of the 
evaluation.5,15 This may be due to a number of factors, including donor and recipient 
readiness in addition to scheduling challenges. If successful, a 1-day evaluation should 






Figure 20: Proposed clinical pathway for a 1-day evaluation of living donor 
candidates 
One of the limitations of this study is the underreporting of reasons for delay. At our 
centre, reporting reasons for delay became more routine over time as measures of 
evaluation time were increasingly requested. Another limitation is the lack of data on the 
date the donor candidate was approved. This is a critical date, as this separates delay due 
to the donor evaluation itself from other factors related to scheduling the transplant. 
These reasons are important for quality improvement efforts to streamline the evaluation 
process and reduce possible inefficiencies. A further limitation of this work is the 
unavailability of data regarding the donor candidate experience with the evaluation 
process. 
In conclusion, the living donor evaluation process remains a challenging and resource-
intensive process. A “one-stop shop” testing strategy is one solution to improve the 
efficiency of this process and improve recipient outcomes and the donor experience, 
while potentially reducing costs to the healthcare system. Synoptic reporting of key 
elements will enable future quality improvement efforts, and future work should focus on 
developing these methods. 
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Chapter 8  
8 Initiating maintenance dialysis prior to living kidney 
donor transplantation when a donor candidate 
evaluation is well underway‡‡ 
 
8.1 Introduction 
A pre-emptive kidney transplant avoids the risks of initiating dialysis and results in better 
outcomes and patient experiences compared to other treatment options available to 
patients with kidney failure.1,2 Deceased donor pre-emptive kidney transplants are rare, as 
most patients wait on a list for several years before an offer for a deceased donor kidney 
becomes available.3 For this reason, pre-emptive kidney transplants are typically 
achieved from a living donor.  
There are many challenges to receiving a pre-emptive living donor kidney transplant. 
First, the intended recipient needs to be referred to a transplant program, thoroughly 
evaluated, and approved to receive a kidney transplant. Second, the transplant should be 
timed such that the intended recipient’s native kidneys have not failed to the extent of 
initiating dialysis urgently, but not too early so that the recipient can make use of any 
remaining native kidney function.4 Third, a living donor has to be identified.5 Finally, the 
living kidney donor candidate needs to be thoroughly evaluated and approved for kidney 
donation. For this last consideration, there is a growing appreciation that the living donor 
evaluation process for many motivated donor candidates is lengthy, difficult to navigate, 
and challenging.6–8 The 2017 KDIGO ‘Clinical Practice Guideline on the Evaluation and 
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Care of Living Kidney Donors’ recommends that transplant programs should conduct as 
efficient a donor evaluation as possible, meeting the needs of donor candidates, intended 
recipients and transplant programs.9 Using data from a multi-centre study, the median 
estimated donor evaluation time (time from first contact to nephrectomy) was 10.3 
months (Chapter 6). In some cases a prolonged donor evaluation process may prevent a 
pre-emptive transplant.  
In this study, we focused on a cohort of patients with kidney failure, all who received a 
living donor kidney transplant. We studied persons not receiving dialysis when their 
donor candidate’s evaluation was well underway and determined how often maintenance 
dialysis was initiated before receipt of the living kidney donor transplant. We assessed 
the cost of dialysis treatments, and whether dialysis was started urgently in a hospital 
setting. Finally, we explored whether some unmodifiable and modifiable factors were 
associated with dialysis initiation prior to transplant.  
8.2 Methods 
8.2.1 Design and setting 
We conducted a retrospective analysis of living donor kidney transplants using linked 
databases for the entire province of Ontario, Canada. Ontario has a current population of 
13.7 million people and residents receive access to publicly insured hospital and 
physician services. In 2016 there were approximately 10,000 patients receiving dialysis, 
and 20,000 patients followed in clinics for advanced chronic kidney disease; living 
kidney donor transplants took place in five transplant centres. This study was approved 
by the research ethics board at Sunnybrook Health Sciences Centre, Toronto, Canada. 
Datasets were linked using unique encoded identifiers and analyzed at the Institute for 
Clinical Evaluative Sciences (ICES). The study was conducted according to a pre-





8.2.2 Variables and data sources 
We ascertained demographic characteristics, clinical factors, and outcomes using several 
linked databases. Information on all living kidney donors and recipients in Ontario were 
obtained from Trillium Gift of Life Network10, chart abstraction, and the Canadian Organ 
Replacement Register databases, and included race, blood type, and donor-recipient 
relationship. Additional donor information included the donor’s estimated glomerular 
filtration rate (eGFR) prior to donation. Additional recipient information included 
primary cause of kidney failure, prior transplant history, and serum creatinine, 
hemoglobin, and albumin at the time of dialysis initiation. Recipient referral dates were 
available for recipients transplanted after 2010. Demographic variables were obtained 
from the Registered Persons Database (age, sex, postal codes to calculate the Euclidean 
distance to the transplant centre and to obtain neighbourhood income quintiles from the 
2006 Canada Census). The Canadian Institute for Health Information Discharge Abstract 
Database (CIHI-DAD) and the Ontario Health Insurance Plan (OHIP) datasets were used 
to determine if and when dialysis was initiated (and whether it was started in the hospital 
or outpatient setting), as well as to identify various non-renal comorbidities among 
recipients (Appendix H).11 The ICES Physician Database and OHIP were used to 
determine the start date of the living donors’ evaluation (Appendix I and Appendix J). 
Linked laboratory databases were used to obtain the most recent recipient serum 
creatinine at the time their donor initiated their evaluation (±3 months) and at the time of 
referral (±3 months) in a subset of patients. This database, the Ontario Laboratory 
Information System, includes inpatient and outpatient test values from hospital and 
commercial laboratories, together accounting for 91% of Ontario’s lab results by 2016. 
eGFR was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration) equation (in mL/min per 1.73 m2).12 Dialysis costs were estimated for 
recipients who started dialysis after March 2006 (which was the first available date in our 
data sources when dialysis costs could be reliably ascertained). Costs were tabulated from 
the public payers’ perspective using OHIP billing codes (Appendix H) plus resource 
intensity weights times the cost per weighted case to calculate the cost per case (i.e., 





The selection of living donor kidney transplants for this study is presented in Figure 21. 
This study was restricted to patients who received a living kidney donor transplant, where 
the transplants occurred between April 1, 2004 and March 31, 2014. In this study, we 
focused on the subset of living donor transplants where the recipient was a first-time 
kidney transplant recipient and was not on dialysis when the evaluation process of the 
candidate who ultimately donated to them was well underway. Living donors were 
required to be Ontario residents for at least two years prior to donation to ensure that 
information on the donor evaluation process was complete and available in our data. We 
excluded donors who were missing a donation date, a nephrology consult, or a surgery 
consult (Figure 21), as these donors were likely from outside of Ontario or may have 
participated in a national kidney paired donation program. We also excluded donors with 
unreasonable patterns of procedures (i.e., nephrectomy codes before donation date) and 
those with a late-stage procedure captured as the first procedure (i.e., a living donor 





Figure 21: Overview of inclusion/exclusion criteria for living kidney donors in this 
study.  
a Living kidney donors were identified through Trillium Gift of Life Network. All 
living donors have a unique identification number that allows linkage across 
datasets.  
b These exclusions are not mutually exclusive so do not sum to 358; nephrology 
consults within two weeks of donation and surgical consults within two days of 
donation were not considered true consults (part of the pre-admission process). 






In this study a pre-emptive transplant was defined as the absence of dialysis billing codes 
for the recipient prior to their transplant. We considered a pre-emptive transplant 
potentially possible if the recipient did not receive dialysis within 92 days following the 
donors’ evaluation start date. For these recipients, if dialysis was initiated prior to 
transplant it was considered a “potential unrealized pre-emptive transplant”. Our opinion 
is that 92 days (three months) is a reasonable buffer time to complete the evaluation 
(which would be the case if the donor was motivated and eligible to donate). In 
sensitivity analysis, we extended this period to four and six months; the United Kingdom 
2020 strategy suggests all potential donors should be offered to complete the donor 
assessment within 4.5 months of referral (where appropriate).14 With the data available to 
us we could not reliably assess how many unrealized pre-emptive kidney transplants were 
preventable [i.e., there were modifiable reasons (inappropriate waiting) that could be 
addressed to realize the pre-emptive kidney transplant]. For this reason we deliberately 
use the wording “potential” unrealized pre-emptive kidney transplant in this paper.  
We defined the total evaluation time as the time when the donor started the evaluation 
(the earliest documented evaluation testing) until the nephrectomy. We defined the total 
approval time as the time from the donor evaluation start until the last specialist consult 
preceding nephrectomy. The procedures that defined the start of the evaluation and the 
consults that defined the approval date are presented in Appendix E. We defined the time 
for consults as the time from the first to the last nephrology, psychosocial, or surgical 
evaluation; this was restricted to donors who had all three consults and was limited to the 
most recent of the three consults. These three consults are a standard part of the donor 
candidate evaluation in all Ontario transplant programs. All times were expressed in 
months. 
8.2.5 Statistical methods 
Descriptive statistics included the mean (standard deviation, SD), median (25th, 75th 




We used a recommended approach to report risk ratios for the association between 
characteristics and dialysis initiation (i.e., a potential unrealized pre-emptive kidney 
transplant; yes/no) [estimates derived from modified Poisson regression models (proc 
genmod using a log link, a Poisson distribution, and a repeated statement (for 
individuals) for robust standard error estimation)].15 To assess whether the results 
differed across the five Ontario transplant programs that performed living donor 
nephrectomies during the study period, we calculated the intraclass correlation coefficient 
using mixed models treating the transplant program as the clustering variable (as a 
measure of the proportion of the variance of the outcome accounted for by differences in 
transplant program).  
To comply with privacy regulations for minimizing the chance of patient identification, 
five or fewer participants are reported as <6. For similar reasons the names of the 
transplant programs and the number of transplants per program were also suppressed. We 
used Statistical Analysis Software Enterprise Guide version 6.1 (2013 by SAS Institute 
Inc., Cary, NC, USA) for all analyses. 
8.3 Results  
8.3.1 Patient population 
A total of 478 living kidney donor transplants were included in the primary analysis 
(Figure 21). Donors were a mean 46 (SD 11) years of age at the time of donation, most 
were white (79%), female (63%), lived in an urban area (87%), had higher 
neighbourhood income (24% were in the highest income quintile versus 13% in the 
lowest), and lived a median of 33 (16, 74) kilometers from the transplant centre where 
they donated (Table 19). The pre-donation eGFR was >80 mL/min per 1.73 m2 in 79% of 
donors. Recipients were similar to donors with respect to age at transplant [mean 44 (SD 
14) years], percent living in urban areas (87%), and neighbourhood income (24% in the 




Most transplants occurred between spouses (28%), siblings (24%), or unrelated donor-
recipient pairs (17%) (Table 19). The proportion of living donor transplants performed in 
Ontario ranged from 6% to 31% across the five transplant programs. 






Age at transplant (years), mean (SD) 46.3 (10.9) 44.0 (14.2) 
   
Sex   
Female 301 (63%) 177 (37%) 
Male 177 (37%) 301 (63%) 
   
Race**   
White 197 (79%) 171 (81%) 
Other 53 (21%) 39 (19%) 
   
Incomea    
5 (highest) 116 (24%) 116 (24%) 
4 125 (26%) 126 (26%) 
3 96 (20%) 95 (20%)* 
2 78 (16%) 80 (17%) 
1 (lowest) 63 (13%) 61 (13%) 
   
Rural residenceb   
Urban 415 (87%) 418 (87%)* 
Rural  63 (13%) 60 (13%) 
   
Blood type   
O 155 (60%) 160 (40%) 
A 77 (30%) 167 (42%) 
B <6 51 (13%) 
AB <6 22 (5%) 
   
Distance to transplant hospital   
<20 km 148 (31%) 124 (25%)* 
20-39 km 115 (24%) 132 (28%) 
40-89 km 118 (25%) 104 (22%) 
>89 km 97 (20%) 118 (25%) 
  median (IQR) 33 (16-74) 29 (15-67) 
  mean (SD) 82 (142) 77 (145) 
   
Donor eGFR at donationc,**   
>89 mL/min/1.73 m2 281 (61%) – 
80-89 mL/min/1.73 m2 80 (18%) – 
<80 mL/min/1.73 m2 96 (21%) – 
  mean (SD) 96.5 (14.1) – 
   
Recipient eGFR at beginning of  
donor evaluationc,d,** 
  
>19 mL/min/1.73 m2 – 30 (21%) 
15-19 mL/min/1.73 m2 – 33 (23%) 
10-14 mL/min/1.73 m2 – 57 (39%) 
<10 mL/min/1.73 m2 – 24 (17%) 
mean (SD) – 16.2 (8.4) 
   






mean (SD)  – 178 (430) 
median (25th, 75th percentile)  – 22 (-66, 322) 
n (%) – 136 (28%) 
   
Recipient eGFR at time of recipient 
referralc,d,** 
  
>19 mL/min/1.73 m2 – 18 (18%) 
15-19 mL/min/1.73 m2 – 24 (25%) 
10-14 mL/min/1.73 m2 – 37 (38%) 
<10 mL/min/1.73 m2 – 19 (19%) 
mean (SD) – 14.3 (5.2) 
   
Recipient comorbidity   
Cardiovascular disease – 186 (39%) 
IHD/CAD – 36 (8%) 
Heart failure – 17 (4%) 
Cancer – 104 (22%) 
   
Diabetes – 63 (13%) 
Hypertension – 384 (80%) 
Anemia – 29 (6%) 
Anxiety/depression – 51 (11%) 
   
Relationship to recipient   
Sibling 115 (24%) – 
Unrelated 79 (17%) – 
Spousal 134 (28%) – 
Parent 60 (13%) – 
Child 59 (12%) – 
Other relation 31 (6%) – 
   
Cause of kidney failure**   
Glomerulonephritis/autoimmune – 84 (26%) 
Other – 78 (24%) 
Polycystic – 75 (23%) 
Diabetes – 47 (14%) 
Unknown etiology – 42 (13%) 
   
Year of transplant   
2004-2007 – 155 (33%) 
2008-2010 – 145 (30%) 
2011-2014 – 178 (37%) 
a categorized into fifths of median neighbourhood income from the 2006 
Canada Census 
b defined as a municipality with <10,000 persons 
c eGFR (estimated glomerular filtration rate) was calculated using CKD-EPI 
equation, in mL/min/1.73 m2.  
d recipient creatinine was measured ± 3 months of the evaluation start date or 
the recipient referral date 
e codified for privacy 
<6 – suppressed due to privacy (either <6 or another cell is <6 for the same 
variable) 
*missing status assigned as ‘urban’, income quintile 3, or travel distance <20km 
** highly missing variable 
SD – standard deviation; IQR (interquartile range – 25th, 75th percentile); 





8.3.2 Potential unrealized pre-emptive kidney transplant 
A total of 478 persons (all who ultimately received a living kidney donor transplant) were 
not on dialysis when the donor candidate (who ultimately donated to them) was being 
evaluated for at least 3 months. Recipient eGFR at the start of their donors’ evaluation 
was a mean (SD) of 16.2 (8.4) mL/min per 1.73 m2, and in those with available data the 
recipient eGFR at recipient referral was 14.3 (5.3) mL/min per 1.73 m2. For pairs with 
available data, the recipient referral predated the date the donor candidate first contacted 
the transplant program 55/136 (40%) of the time (a mean (SD) of -5.2 (4.8) months). 
Donor candidate first contact predated the recipient referral 80/136 (59%) of the time (a 
mean (SD) of 13.5 (13.9) months). The transplant programs in Ontario typically put the 
donor candidate evaluation on hold until the intended recipient is referred for transplant 
evaluation (Chapter 7).  
A total of 167 of 478 recipients (35%) initiated dialysis prior to receipt of their transplant, 
which we consider potential unrealized pre-emptive kidney transplant. In sensitivity 
analyses, requiring the donor candidate to be evaluated for at least 4 or 6 months when 
their recipient (who was not on dialysis) entered the cohort, meant 144/451 (32%) and 
111/412 (27%) of recipients, respectively, initiated dialysis before transplant. 
The mean (SD) eGFR at the time of dialysis initiation was 8.5 (7.2) mL/min per 1.73 m2, 
serum albumin was 35.2 (7.0) g/L, and serum hemoglobin was 105 (42) g/L. A total of 44 
of the 167 recipients (26%) started dialysis as an inpatient in the hospital setting. 
Recipients who started dialysis during their donors’ evaluation did so a median 9.7 (5.4, 
18.7) months after their donor started the evaluation, were transplanted a median 8.8 (3.6, 
16.9) months after starting dialysis, and accrued a mean of $48,717 (SD $55,249) in 
dialysis costs, totaling $8.1 million for the cohort of 167 recipients (2017 Canadian 
dollars). For recipients with available data, the transplant program received the referral 
for recipient evaluation a mean of 68 (SD 913) days [median 363 (198, 448) days] before 




8.3.3 Characteristics associated with a potential unrealized pre-
emptive kidney transplant 
Associations between various characteristics and a potential unrealized pre-emptive 
transplant in an exploratory analysis are presented in Table 20. The recipient was more 
likely to start dialysis if their donor was female [RR 1.30 (0.99-1.70)], if either the donor 
or recipient was from a lower-income neighbourhood [respectively, RR 1.68 (1.16-2.43) 
and RR 1.96 (1.35-2.85) for the lowest quintile versus the highest], and if the donor was 
non-white [RR 1.53 (1.02-2.30)]. Recipient non-renal comorbidity was also a significant 
predictor of starting dialysis, particularly the presence of cardiovascular disease [RR 1.31 
(1.03, 1.66)] and diabetes [RR 1.37 (1.03, 1.83)]. Non-significant associations were 
observed for anemia [RR 1.45 (0.98, 2.14)], ischemic heart disease or coronary artery 
disease [RR 1.35 (0.94, 1.95)], and anxiety or depression [RR 1.33 (0.95, 1.88)]. For 
recipients with available data, dialysis prior to transplant was more likely if there was a 
longer delay between the donor’s evaluation start date and the date the transplant 
program subsequently received the referral to begin the intended recipient’s evaluation 
[RR 1.03 (1.02-1.04) per 30-day delay]. Furthermore, a lower recipient eGFR at referral 
was associated with an increased likelihood of starting dialysis [RR 0.93 (0.86-1.00)], 
while no such association was observed for recipient eGFR at the donor’s evaluation start 
date. There were significant differences across transplant programs (p=0.01), where one 
program was 29% less likely to have a potential unrealized pre-emptive transplant while 
another program was 47% more likely to do so when compared to a reference. However, 
between-centre variability only accounted for 2.8% of the total variability in potential 
unrealized pre-emptive transplant rates (p=0.16). After adjusting for donor sex, donor 
income, and clustering by transplant program, the strength of these associations changed 






Table 20: Characteristics associated with an unrealized potential pre-emptive 
transplant 
Variable 






RR (95% CI)a p-value RR (95% CI) p-value 
Age at donation (years)c 46.0 (11.0) 46.8 (10.7) 1.04 (0.93-1.17) 0.44 – – 
Age at transplant (years)c 44.3 (13.7) 43.5 (15.1) 0.98 (0.90-1.06) 0.59 – – 
       
Sex (donor)       
Male 125 (40%) 52 (31%) 1.0 (ref) 0.06 1.0 (ref) 0.06 
Female 186 (60%) 115 (69%) 1.30 (0.99-1.70)  1.29 (0.99-1.69)  
       
Sex (recipient)       
Male 196 (63%) 105 (63%) 1.0 (ref) 0.97 – – 
Female 115 (37%) 62 (37%) 1.00 (0.78-1.29)    
       
Race (donor)       
White 146 (82%) 51 (71%) 1.0 (ref) 0.04 1.0 (ref) 0.02 
Other 32 (18%) 21 (29%) 1.53 (1.02-2.30)  1.58 (1.06-2.36)  
       
Race (recipient)       
White 123 (83%) 48 (77%) 1.0 (ref) 0.32 – – 
Other 25 (17%) 14 (23%) 1.28 (0.79-2.07)    
       
Income quintile (donor)d       
5 (highest) 81 (26%) 35 (21%) 1.0 (ref) 0.002 1.0 (ref) 0.002 
4 95 (31%) 30 (18%) 0.80 (0.52-1.21)  0.79 (0.52-1.20)  
3 59 (19%) 37 (22%) 1.28 (0.88-1.86)  1.27 (0.87-1.84)  
2 45 (14%) 33 (20%) 1.40 (0.96-2.05)  1.41 (0.97-2.06)  
1 (lowest) 31 (10%) 32 (19%) 1.68 (1.16-2.43)  1.65 (1.15-2.39)  
       
Income quintile (recipient)d       
5 (highest) 84 (27%) 32 (19%) 1.0 (ref) 0.007 N/A – 
4 89 (29%) 37 (23%) 1.06 (0.71-1.59)    
3 60 (20%) 30 (18%) 1.21 (0.80-1.83)    
2 47 (15%) 33 (20%) 1.50 (1.01-2.22)    
1 (lowest) 28 (9%) 33 (20%) 1.96 (1.35-2.85)    
       
Residence (donor)       
Urban 268 (86%) 147 (88%) 1.0 (ref) 0.58 – – 
Rural 43 (14%) 20 (12%) 0.90 (0.61-1.32)    
       
Residence (recipient)       
Urban 266 (86%) 147 (89%) 1.0 (ref) 0.41 – – 
Rural 42 (14%) 18 (11%) 0.84 (0.56-1.27)    
       
eGFR of donor at time of 
donatione 
      
>89 mL/min/1.73 m2 187 (62%) 94 (60%) 1.0 (ref) 0.51 – – 
80-90 mL/min/1.73 m2 48 (16%) 32 (20%) 1.20 (0.87-1.64)    
<80 mL/min/1.73 m2 65 (22%) 31 (20%) 0.97 (0.69-1.35)    
       
eGFR of recipient when…f       
donor evaluation started 16.1 (7.7) 16.4 (10.3) 1.00 (0.97-1.04) 0.84 – – 
recipient referred 15.1 (4.7) 12.6 (6.0) 0.93 (0.87-1.00) 0.06 0.93 (0.86-1.00) 0.05 
       
Recipient comorbidity       
Cardiovascular disease 111 (36%) 75 (45%) 1.28 (1.00-1.63) 0.05 1.31 (1.03-1.66) 0.03 
IHD/CAD 19 (6%) 17 (10%) 1.39 (0.96-2.01) 0.08 1.35 (0.94-1.95) 0.10 
Heart failure sup sup 0.84 (0.40-1.77) 0.64 – – 
Cancer 72 (23%) 32 (19%) 0.85 (0.62-1.17) 0.33 – – 
       
Diabetes 34 (11%) 29 (17%) 1.38 (1.03-1.87) 0.03 1.37 (1.03-1.83) 0.03 
Hypertension 252 (81%) 132 (79%) 0.92 (0.69-1.24) 0.60 – – 
Anemia 15 (5%) 14 (8%) 1.42 (0.95-2.11) 0.09 1.45 (0.98-2.14) 0.06 
Anxiety/depression 29 (9%) 22 (13%) 1.27 (0.90-1.79) 0.17 1.33 (0.95-1.88) 0.10 




Time from donor evaluation 
start until recipient referralg 
-6 (-95, 67) 321 (40, 
875) 
1.03 (1.02-1.04) <.0001 1.02 (1.02-1.04) <.0001 
       
Transplant centreh       
1 – – 0.93 (0.67-1.31)    
2 – – 1.0 (ref) 0.01 N/A – 
3 – – 0.71 (0.46-1.10)    
4 – – 1.47 (1.09-1.99)    
5 – – 1.13 (0.66-1.93)    
       
Relationship       
Spouse 87 (28%) 47 (28%) 1.0 (ref) 0.60 – – 
Sibling 81 (26%) 34 (20%) 0.84 (0.59-1.21)    
Parent 38 (12%) 22 (13%) 1.05 (0.70-1.57)    
Child 33 (11%) 26 (16%) 1.26 (0.87-1.82)    
Other relation 21 (7%) 10 (6%) 0.92 (0.53-1.61)    
Unrelated 51 (16%) 28 (17%) 1.01 (0.69-1.47)    
       
Cause of kidney failure       
GN/autoimmune 45 (26%) 39 (25%) 1.0 (ref) 0.18 1.0 (ref) 0.21 
Polycystic 41 (24%) 34 (22%) 0.98 (0.70-1.37)  0.97 (0.70-1.35)  
Diabetes 18 (10%) 29 (19%) 1.33 (0.96-1.83)  1.30 (0.96-1.77)  
Other 41 (24%) 38 (24%) 1.04 (0.75-1.43)  1.01 (0.73-1.39)  
Unknown etiology 27 (16%) 15 (10%) 0.77 (0.48-1.23)  0.78 (0.49-1.24)  
       
Year of transplant       
2004-2007 101 (32%) 54 (32%) 1.0 (ref) 0.54 – – 
2008-2010 99 (32%) 46 (28%) 0.91 (0.66-1.26)    
2011-2014 111 (36%) 67 (40%) 1.08 (0.81-1.44)    
       
Distance to transplant 
centre (donor) 
      
<20 km 93 (30%) 55 (33%) 1.0 (ref) 0.87 – – 
20-39 km 78 (25%) 37 (22%) 0.87 (0.62-1.21)    
40-89 km 77 (25%) 41 (25%) 0.94 (0.68-1.29)    
90+ km 63 (20%) 34 (20%) 0.94 (0.67-1.33)    
       
Distance to transplant 
centre (recipient) 
      
<20 km 83 (27%) 39 (23%) 1.0 (ref) 0.65 – – 
20-39 km 89 (29%) 43 (26%) 1.02 (0.71-1.46)    
40-89 km 64 (20%) 40 (24%) 1.20 (0.84-1.72)    
90+ km 74 (24%) 44 (27%) 1.17 (0.82-1.65)    
a RR (risk ratio) estimated using modified Poisson regression (Poisson distribution, log link, robust standard error 
estimation). A risk ratio greater than 1.0 refers to a higher risk of starting dialysis (a potential pre-emptive transplant lost). 
b adjusted for donor sex and donor income quintile, and clustering by transplant centre 
c risk ratio refers to 10-year increment  
d categorized into fifths of median neighbourhood income from the 2006 Canada Census 
e calculated using CKD-EPI equation (mL/min/1.73 m2). Clinical cut-points used  
f calculated using CKD-EPI equation (mL/min/1.73 m2), creatinine was measured at the time the donors’ evaluation started 
(±3 months) or at the time of recipient referral (±3 months). The RR corresponds to a 1 mL/min/1.73 m2 increment in 
eGFR. Results were similar if categorized as 20+, 15-19, 10-14, and <10 mL/min/1.73 m2 (p=0.45 for eGFR at donor 
evaluation start; p=0.06 for eGFR at recipient referral). 
g calculated as the time from the donor evaluation start date until the recipient referral date. Negative values mean the 
recipient was referred to the transplant centre before the donor evaluation started. Risk ratio reflects a 30-day increment. 
h transplant centre codified for privacy 
CI – confidence interval; N/A – not applicable (for recipient income quintile this is due to collinearity with donor income 






8.3.4 Time to complete the living donor evaluation 
The median total donor evaluation time among donors whose recipients were 
transplanted pre-emptively was 10.6 (6.4, 21.6) months [mean 15.3 (12.0) months]. For 
those who started dialysis during the evaluation, the median was twice as long: 22.4 
(13.1, 38.7) months [mean 25.4 (14.0) months] (p<0.0001) (Figure 22). Similar results 
were observed for the time until approval: respectively, median 9.13 (5.9, 20.2) months 
[mean 14.3 (12.0) months] versus median 20.9 (11.7, 37.8) months [mean 24.2 (14.0) 
months] (p<0.0001). In contrast, we did not observe a relationship with a prolonged time 
to complete the major consultations with a higher likelihood of potential unrealized pre-
emptive transplant: median 6.01 (1.77, 17.7) months [mean 11.0 (11.9) months] for pre-
emptive transplants, median 6.47 (2.50, 15.8) months [mean 11.2 (11.4) months] for an 
unrealized potential pre-emptive transplant (p=0.87). 
 
Figure 22: Boxplots showing the distribution of donor evaluation times. The time to 
complete the evaluation was defined as the period from evaluation start until 
nephrectomy. Boxes represents interquartile ranges (25th to 75th percentile). 




Horizontal lines represent the upper fence (75th percentile plus 1.5× interquartile 
range) and lower fence (25th percentile minus 1.5× interquartile range). Plus 
symbols indicate points that fall outside the fence. 
8.4 Discussion 
To our knowledge no prior study has described recipient outcomes in the context of the 
time to evaluate a living kidney donor candidate. To address this, we studied a group of 
people across five transplant programs in Ontario, Canada for the period 2004 to 2014, all 
who received living donor kidney transplants. We found that a third of persons not 
receiving dialysis when their donor’s evaluation was well underway initiated dialysis 
prior to receiving their living donor kidney transplant. This dialysis cost was $8.1 million 
and 44/167 (26%) recipients initiated their dialysis urgently in hospital. 
A recently published guideline in the United Kingdom has recommended that 50% of all 
eligible recipients are transplanted preemptively, and that all donors are able to complete 
their work-up in 18 weeks should they choose to do so.14 We agree with this and believe 
that, for a healthy, motivated donor whose intended recipient has been cleared for 
transplant, 4 months is sufficient to complete a thorough evaluation while providing 
sufficient time for donor reflection. The time to complete the necessary nephrology, 
surgery and psychosocial consultations therefore should not be measured on the order of 
months and presents an opportunity for improvement. We are aware that some centers 
(including ours) have transitioned towards scheduling these consults on the same day or 
within 2 consecutive days of each other, particularly for donor candidates who live far 
from the transplant center. There is some evidence to suggest that centers that conduct 
same-day consults may have a faster time until approval (Chapter 6). There appeared to 
be a fair amount of consistency on how Ontario transplant programs evaluate living 
kidney donor candidates, which was evident when setting standards for the Canadian 
national kidney paired donation program.16 However, operational decisions are made by 
individual living donor programs, and there is currently no recommendation on the 
timeliness of the evaluation.9 Thus, we do expect variability in pre-emptive 
transplantation rates across transplant programs, much like variability in recipient referral 




evaluation protocols at each program, and determining how protocols affect the 
timeliness of the evaluation should be a focus of future work. 
We believe these novel observations should be the focus of quality improvement 
efforts.18 In the current study, we did not address the degree to which these dialysis starts 
could have been prevented, nor did we have information on reasons for the length of the 
evaluation for the donor or the intended recipient. Some of the delay in the donor 
candidate evaluation process may be due to the unpredictable nature of kidney failure. 
For example, it is possible the recipient’s health suddenly deteriorated, placing the living 
donors’ evaluation on hold until the recipient was well enough after receiving dialysis to 
receive a kidney transplant. This may avoid unnecessary donor work-up in case the 
recipient is no longer eligible for transplantation or avoid expiration of some donor’s test 
results until the recipient is eligible again. Conversely, deterioration of the recipient’s 
health may result in an expedited living donor evaluation to transplant the intended 
recipient before their health deteriorates further (i.e., before dialysis initiation, before 
potential transplant ineligibility). Although the donor and recipient evaluations are mostly 
independent, there is some communication that attempts to optimize coordination, 
outcomes, resource utilization, and donor burden. Other reasons for delay may result 
when more time is needed to complete a thorough evaluation, including initial test results 
that required further investigation, clearance of the donor related to any pre-existing 
comorbidity, or the requirement that some donor candidates change their lifestyle (e.g., 
lose weight or reduce their smoking).19,20 Delays due to these reasons are appropriate and 
may be necessary to uphold the quality of the evaluation and the safety of donor 
candidate approval. However, in this study the living donor evaluation was underway for 
almost 10 months before 50% of the recipients in this group started dialysis, a sufficient 
amount of time to complete an evaluation even in the presence of some delay. Moreover, 
delays may stem from the donor or the intended recipient as they come to terms with 
living donor kidney transplantation.21,22 Determining what factors are modifiable will be 
critical to be able to modify them and reduce the proportion of recipients starting dialysis. 
This study also has other important limitations that should be addressed in future studies. 




estimates of the total evaluation time (which includes all the time until nephrectomy) 
aligns with our clinical experience and is consistent with prior reports23, the validity of 
this estimate needs to be substantiated using more accurate (and agreed-upon) start dates. 
The date the living donor first contacted the transplant program was unavailable, but is 
now being actively collected by Ontario transplant programs. The date of approval is 
important because many factors can influence the time until donation even after the donor 
has been approved to donate. Also, because evaluation practices in Ontario may differ 
from those used in other regions, the time until approval may allow additional 
comparisons to be made, and multiple metrics may be more informative than single 
metrics in isolation. Second, only patients who received a living kidney donor transplant 
were included in this study. It remains to be established whether improvements in the 
time to evaluate donor candidates can prevent lost opportunity for living donor 
transplants (e.g., due to competing events like intended recipient illness, death, or 
deceased donor kidney transplantation)24,25 or influences candidates who drop out during 
the evaluation process.18 Donor candidates who did not donate are not currently 
identifiable from administrative datasets alone. Further, many data on recipient referral 
dates were missing and we did not have information on when the intended recipient was 
approved for transplantation. Finally, among recipients who had no relation to their 
donors, we were unable to untangle the effects of non-directed anonymous donation 
versus kidney paired donation.26,27 
In our exploratory analysis, several characteristics were associated with a greater 
likelihood of not realizing a potential pre-emptive living donor kidney transplant. Donors 
who were female, non-white and lived in a low-income neighborhood were all less likely 
to donate pre-emptively. These characteristics are all difficult or impossible to modify, 
but understanding the mechanism may suggest areas where potential modifications may 
be possible. We did find dialysis prior to transplant was more likely if the recipient was 
referred with a lower eGFR and if there was a longer delay between the donor’s 
evaluation start date and the date the transplant program subsequently received the 
referral to begin the intended recipient’s evaluation. These suggest earlier recipient 
referrals may prevent some recipients from starting dialysis. In Ontario, there is a 




organized by their nephrologist prior to submitting a referral package to a transplant 
program for evaluation.28 Often, donor candidates contact transplant programs while this 
pre-transplant-referral testing for their recipient is underway, but the transplant programs 
usually do not advance the donor candidate evaluation until they receive a referral 
package for the intended recipient (as is the general approach in Ontario). From one 
perspective, it may not be worth while spending resources evaluating donors before their 
intended recipient is referred because many of these recipients may not be eligible for 
transplant or may never be referred, thereby wasting time and resources that could be 
spent on other donor evaluations. On the other hand, the potential implications of a late 
referral could at least partly be offset by a donor evaluation that is either quicker or starts 
before the recipient is referred. If the recipient is never referred or is not a transplant 
candidate, then this may result in some donor candidates pursuing non-directed donation 
instead. There is clearly a trade-off here that should be studied, as this is a potentially 
modifiable area for quality improvement. In this study we only reported data from five 
transplant programs in Ontario; our impression is these programs are similar to others 
throughout Canada, but we do not have data to corroborate this. We believe that this 
metric (the proportion of potential pre-emptive transplants that were unrealized) should 
be measured and reported by all programs nationally and internationally to facilitate 
comparisons and quality improvement efforts. 
In conclusion, by linking donor evaluation times with recipient outcomes, this study 
raises the possibility of some modifiable adverse impact of a prolonged living donor 
evaluation process. These effects might not only be restricted to recipient health 
outcomes, but also may extend to the living donor’s experience and to healthcare costs 
attributable to starting and/or maintaining dialysis until transplantation.29,30 These 
findings inform future research and quality improvement activities that aim to help 
patients with kidney failure improve their chances of realizing a pre-emptive kidney 
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Chapter 9  




For eligible patients with end-stage kidney disease, living donor kidney transplantation 
improves patient survival and quality of life and reduces healthcare costs compared to 
maintenance dialysis.1–3 However, completing a living kidney donor evaluation according 
to current standards takes time and effort.4 For many donor candidates and their intended 
recipients, the time to complete this evaluation is currently too long, which may have 
several unintended consequences for patients and the healthcare system. We have 
illustrated these consequences in Figure 23 for different types of recipients, where the 
black horizontal bars represent current living kidney donor candidate evaluation times 
from start (subscript s) to finish (donation; subscript f). First, the potential recipient may 
no longer be able to receive a transplant due to illness or death (Figure 23, patient af).
5–9 
Second, the recipient may remain on dialysis longer than otherwise necessary, which may 
result in adverse outcomes following transplantation, reduced quality of life, ongoing risk 
of complications related to dialysis, and higher healthcare costs (Figure 23, patient 
bf).
10,11 Third, the recipient may initiate dialysis before their donor is approved, 
potentially jeopardizing the benefits of pre-emptive transplantation, reducing quality of 
life, and increasing healthcare costs (Figure 23, patient cf).
12 Finally, the recipient may 
receive a kidney from a deceased donor, an organ that could have gone to another 
recipient in need if the living donor transplant had been realized.6,13 A poorly timed or 
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prolonged living kidney donor evaluation can contribute to any of these adverse 
outcomes. 
 
Figure 23: Potential effects of a more efficient living kidney donor evaluation 
process. Possible effects of a more efficient living donor evaluation (a’-d’) for different types of 
potential recipients (a-d). Subscript s indicates the start of the living kidney donor candidate 
evaluation and subscript f indicates when the evaluation is finished. Recipient “a” is receiving 
maintenance dialysis when the living donor candidate evaluation begins and dies during the 
evaluation without receiving a transplant. Recipient “b” is receiving maintenance dialysis when the 
donor candidate evaluation begins and receives a living donor transplant. Recipient “c” is not 
receiving maintenance dialysis and has a low estimated glomerular filtration rate when the donor 
candidate evaluation begins, starts maintenance dialysis during the evaluation, and receives a living 
donor transplant. Recipient “d” is not receiving maintenance dialysis and has a low estimated 
glomerular filtration rate when the living donor candidate begins and receives a living donor 
transplant at a time when they could have lived longer with their native kidneys prior to initiating 
maintenance dialysis. For each of the potential recipients (a to d) the period from subscript “s” to 
subscript “f” represents a current donor candidate evaluation time (black horizontal bars); the 
period from subscript “s prime (s’)” to “f prime (f’)” represents a new shorter evaluative time (red 
horizontal bars). A more efficient living donor evaluation is completed in a shorter time and is better 
timed to promote optimal recipient outcomes (i.e., avoid dialysis or minimize the time spent on 
dialysis). Transplants occurring at time-point af’ instead of af may prevent some deaths; transplants 
occurring at time-point bf’ compared with bf will reduce the time the recipient spends on dialysis; 
transplants occurring at time-point cf’ instead of cf may prevent some people from starting dialysis 
altogether; evaluation df’ instead of df will reduce the amount of time the recipient lives with his/her 




by necessity. Individual recipients may progress differently and may die or receive dialysis (e.g. at a 
time of developing acute kidney injury) at any time throughout the recipient’s kidney disease 
progression. 
The 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline on 
the Evaluation and Care of Living Kidney Donors recommends that transplant programs 
“conduct as efficient a donor evaluation as possible, meeting the needs of donor 
candidates, intended recipients and transplant programs.”4 However, this 
recommendation remains ungraded because of insufficient evidence. In reality, the 
definition of an “efficient” evaluation is subject to interpretation. We believe that an 
efficient evaluation process is one that is completed in an appropriate time-frame (which 
may depend on the donor and recipient candidates’ needs), achieves the best possible 
outcomes for donors and recipients, and prudently uses healthcare resources.  
In this study, we explored the potential effects of an earlier living donor evaluation 
completion and donation date on recipient outcomes and healthcare costs attributable to 
potentially preventable dialysis. We used current observed outcomes from Ontario, 
Canada as the ‘base case’ scenario, and examined several “what if” scenarios for 
comparison had the living donor transplant occurred earlier. 
 
9.2 Methods 
9.2.1 Setting and databases 
Ontario is Canada’s largest province with a population of 13.6 million people; it has a 
single-payer universal publicly funded healthcare system where healthcare encounters, 
procedures and diagnoses are recorded for all Ontario citizens in large healthcare 
databases. We used information held at the Institute for Clinical Evaluative Sciences 
(ICES), which allowed linkage across multiple datasets in Ontario, Canada using a 
unique identifier. All living kidney donors in Ontario were identified through a database 
maintained by the provincial transplant agency Trillium Gift of Life Network.14 Using 




estimated the date the donor candidate started the evaluation using a healthcare test 
generally performed early in the living donor evaluation (described previously).12 The 
physician claim database (OHIP) and the hospital-based Canadian Institute for Health 
Information (CIHI) Same-Day Surgery and Discharge Abstract databases were used to 
identify the date the recipient initiated dialysis.12 The study was approved by the research 
ethics board at Sunnybrook Health Sciences Centre, Toronto, Canada.  
9.2.2 Patient populations 
All living donors in this study were Ontario residents for at least 2 years before donation, 
started the living donor evaluation on April 1, 2006 or later, and ultimately donated 
before April 1, 2014. They were divided into three mutually exclusive cohorts based on 
the following information at the time when the living donor evaluation started: 1) donors 
whose recipients were on dialysis (patient bs in Figure 23); 2) recipients who theoretically 
could have been transplanted pre-emptively (were free from dialysis for at least 3 months 
after the donor started their evaluation) but started dialysis before transplant (patient cs in 
Figure 23); and 3) recipients who were transplanted pre-emptively (patient ds in Figure 
23).12,15 Classifying the cohort in this way enabled the outcomes to be evaluated 
separately for each cohort (outcomes described below).  
We did not have data on donor candidates who did not ultimately donate to their intended 
recipient using administrative databases at ICES. Instead, we conducted detailed medical 
chart review for all living donor candidates who contacted the living donor program at 
the London Health Sciences Centre in London, Ontario between 2013 and 2016 (medical 
records were more complete during this time; Chapter 7). Donor candidate evaluation 
start date was defined as the date a detailed medical-social questionnaire completed by 
the candidate was reviewed by the program. If this date was unavailable, the date the 
candidate first contacted the program was used. The date the evaluation ended was the 
date the intended recipient died (patient as in Figure 23), was deemed no longer eligible 
for transplant, or received a deceased donor kidney transplant. To be included, the living 
donor candidate must have had at least 3 months of active evaluation (with any lab tests 




approval was obtained from Lawson Health Research Institute in London, Ontario 
(Appendix K).  
9.2.3 Outcomes 
This study was undertaken from the perspective of the Ontario government, which 
operates under a single-payer universal public healthcare system. Outcome data were 
based on four domains: time, pre-emptive transplantation, healthcare costs, and available 
additional kidneys for transplantation (summarized in Table 21 and described below). We 
defined the total evaluation time as the time the donor first started the evaluation until 
donation. We estimated the proportion of potential pre-emptive transplants lost as the 
proportion of recipients who were not on dialysis when the donor evaluation was 
underway for at least three months (the denominator) but started dialysis before 
transplant (the numerator). We estimated the total recipient dialysis costs for recipients 
from the time the donor started the evaluation until donation (costs described below). The 
number of potential transplants lost was calculated as the number of times the intended 
recipient died, became ineligible for transplant, or received a deceased donor kidney 
transplant despite having at least one living donor candidate whose evaluation was 
underway for at least three months. Since the number of potential transplants lost was 
obtained from the medical records of a subset of all donors in Ontario, we extrapolated 
these estimates to the entire Ontario population during the study period. Outcomes were 
presented using the mean (standard deviation, SD), median (25th, 75th percentile), and 
proportion (95% confidence interval), where appropriate.  
Table 21: Definition of Outcomes 
Term Applied to Definition 
Domain: Time 
Total evaluation time base case the time the donor first started the evaluation until 
donation 
total time recovered scenario-specific the difference in the total evaluation time between 
the scenario and the base case for all donors 
total time lost scenario-specific the difference in the total evaluation time between 
the scenario and the base case for donors whose 
recipients were transplanted pre-emptively in the 
base case 




the scenario and the base case for donors whose 
recipients were already on dialysis when their living 
donor started the evaluation 
Domain: Pre-emptive transplants 
Potential pre-emptive 
transplants 
base case recipients who were not on dialysis when the donor 
first started the evaluation for at least three months 
proportion of potential 
pre-emptive transplants 
lost 
scenario-specific the proportion of potential pre-emptive transplants 
that did not occur (the recipient started dialysis 
before transplant) 
number of recipients 
saved from starting 
dialysis 
scenario-specific the difference in the number of potential pre-emptive 
transplants and the number of potential pre-emptive 
transplants lost 
Domain: Healthcare costs 
Total recipient dialysis 
costs 
base case the sum of all recipient dialysis-related costs to the 
healthcare system 
total recipient dialysis 
costs saved 
scenario-specific the difference in the total recipient dialysis costs 
between the scenario and the base case 
Domain: Number of transplants 
Number of living donor 
transplants lost 
base case the number of recipients who died or were no longer 
eligible to receive a transplant or who received a 
deceased donor kidney transplant despite having a 
living donor whose evaluation was underway for at 
least three months 
number of living donor 
transplants gained 
scenario-specific the difference in the number of transplants lost 
We devised 13 hypothetical scenarios (described below) where the transplant date would 
occur at an earlier date than the actual transplant date. Using Figure 23 to illustrate, a 
recipient who was actually transplanted at time-point bf could instead have received a 
transplant at time-point bf’. Using this new transplant date, we recalculated the outcomes 
and compared them to the base case. We calculated the total time recovered as the 
difference in the total evaluation time [(bf+cf+df)-(bf’+cf’+df’); the length of dark 
horizontal bars minus the length of light horizontal bars in Figure 23]. The total time lost 
was calculated as a subset of the total time recovered, restricted only to donors who 
donated pre-emptively (df-df’ in Figure 23). This represents a lost period of survival only 
with native kidney function prior to initiating dialysis due to an earlier transplant. We 
calculated the dialysis time saved as a subset of the total time recovered, restricted only to 
donors who were already on dialysis when the evaluation started (bf-bf’ in Figure 23). We 




number of pre-emptive transplant failures (patients whose evaluation times corresponded 
to category cf-cf’ in Figure 23). We estimated the total recipient dialysis costs saved as 
the differences in accrued dialysis costs over the period [(bf+cf)-(bf’+cf’)] in Figure 23. 
Finally, we estimated the number of transplants gained as the difference in the number of 
transplants lost due to intended recipient death, loss of transplant eligibility, or receipt of 
a deceased donor kidney transplant. For donor candidates who did not donate, we 
assumed their evaluation would have been completed and they would have donated in a 
time corresponding to each scenario’s median total evaluation time.  
9.2.4 Scenarios 
In scenarios 1-5, the time between consecutive healthcare visits related to the living 
donor evaluation process were changed, which is shown pictorially in Figure 24. This 
was done using a longitudinal dataset with each healthcare visit for each donor on a 
separate row, sorted by date.12 We used the 25th and 50th percentile of the distribution for 
all time-between-test transitions for Scenarios 1 and 2, respectively. For example, if the 
median (25th, 75th percentile) time to transition from a nephrology consult to a surgical 
consult was 23 (3, 66) days, then for all donors who had this specific chronological 
transition, we replaced their actual observed time with 25th and 50th percentile values 
(e.g., 3 days for scenario 1 and 23 days for scenario 2) and re-calculated the new 
(hypothetical) transplant date (Figure 24A). The distribution of some of these transition 










We replaced the time between tests with a zero if two tests were to be modeled to occur 
on the same day (scenarios 3-5; Figure 24B). For example, if a psychosocial evaluation 
was modeled to occur on the same day as a nephrology consult, then the actual transition 
time for all donors who had these two visits in succession would be changed to zero 
(regardless of the order of tests). This occurred in 189+65=254 instances (Appendix L). If 
a test was completely removed (nuclear renogram in scenario 6), we replaced the time 
between this test and any other test (regardless of the order of tests) with a zero 
(Appendix L).  
In scenarios 7-10, we shifted the transplant date to occur 1-, 2-, 3-, and 6-months earlier 
(Figure 24C). The resulting transplant dates reflect any combination of a quicker 
evaluation and/or an evaluation that simply started earlier. In a sensitivity analysis, the 3-
month reduction in evaluation time was sampled from a gamma distribution (mean 3, SD 
1) instead of being applied as a fixed value. 
In Scenarios 11-13, we determined the hypothetical transplant date resulting from a 
proportionate reduction in the total time to complete the evaluation (10%, 25%, and 50% 
faster), setting a minimum evaluation time of three months (Figure 24D). In sensitivity 
analysis, the 25% reduction in evaluation time was sampled from a probability 
distribution [beta (mean 0.25, SD 0.02)] instead of being applied as a fixed value. 
9.2.5 Costs 
The ICES case-costing macro was used to tabulate recipient dialysis costs starting from 
April 1, 2006, which included various facility costs associated with dialysis treatment 
(i.e., dialysate, vascular access, nursing time) from the National Ambulatory Care 
Reporting System (NACRS).16 The macro uses resource intensity weights multiplied by 
the cost per weighted case to derive the cost per case for all healthcare in a hospital 
setting.16 We combined these estimates with physician claim codes and dialysis facility 
costs to obtain a final estimate of recipient dialysis costs.12 Costs were estimated from the 
perspective of the provincial government and presented in $CAD 2016. We did not assess 




all patients who receive a transplant (rather it is the timing of that transplant that affects 
the costs related to dialysis waiting for the transplant to occur).  
 
9.3 Results 
9.3.1 Patient population 
We used data on 877 living donors who began their evaluation after March 2006: 497 
(57%) of recipients were already on dialysis when the living donor started the evaluation 
(cohort bs in Figure 23), 360 (41%) were potential pre-emptive transplants (cohorts cs+ds 
in Figure 23). We excluded 20 (2%) living donors who could not be classified (i.e., valid 
linkage to recipient was not available). A total of 19 potential transplants lost were 
identified from chart review over a 3-year period (6 corresponded to cohort as in Figure 
23; 13 received a deceased donor kidney transplant). 
9.3.2 The base case 
The total time to complete the donor candidate evaluation was a median of 10.5 (6.93, 
17.7) months [mean 14.2 (10.6) months], 122/360 (34%) recipients were potential pre-
emptive transplants lost, and recipient dialysis costs were a median of $17,162 ($33, 
$66,054) per recipient [mean $44,065 (SD $61,990)] (Table 2). The 122 recipients who 
were potential pre-emptive transplants lost started dialysis a median 7.8 (5.0, 15.4) 
months [mean 11.9 (9.9); minimum 3.0 months] after their donor started the evaluation 
(Figure 25A) and were transplanted a median 8.7 (4.0, 16.3) months [mean 11.6 (10.1) 
months; minimum 5 days] after dialysis started (Figure 25B). Thirty percent (36/122) 
recipients started dialysis urgently in hospital. The total evaluation time for the 20 donor 
candidates who did not donate (one recipient had two candidates being evaluated) was a 
mean 4.8 (SD 7.9) and a median 8.0 (4.4, 11.3) months. Extrapolated to the whole 
province over the 8-year study period, 172 potential transplants were lost because the 
intended recipient died before receiving the transplant or lost transplant eligibility, and 





Figure 25: Time until dialysis since the donor started the evaluation (A); and time 
until transplant after dialysis started among recipients who could have been 
transplanted preemptively (B) 
9.3.3 Scenarios 
The mean time recovered, mean time lost, mean dialysis time saved, mean dialysis costs 
saved, and mean costs saved per month saved are presented in Table 22 for each scenario 




and number of living donor transplants gained are presented in Table 23 for each scenario 
compared to the base case.  
The most effective scenario (from our list) in terms of absolute gains (differences in 
outcomes) resulted when the transition times between all tests took on the value of the 
25th percentile. This resulted in a median total evaluation time of 2.2 months (a very 
optimistic scenario). More realistic scenarios reduced the total evaluation time by half 
(scenarios 2, 10, and 13). These scenarios saved a mean $22,000-$26,000 in recipient 
dialysis costs per recipient, prevented a minimum of 45 recipients from potentially 
starting dialysis altogether during the study period (>5 per year), could have given at least 
86 intended recipients a transplant they otherwise did not receive (>11 per year), and 
introduced an additional 286 (>35 per year) kidneys to the organ donation pool.  
The most effective scenarios in terms of relative gains (cost savings per month saved) 
resulted when the evaluation time was shortened towards the end of the evaluation time – 
the time during which more intended recipients are on dialysis. The mean intended 
recipient dialysis costs saved per month recovered was highest if the transplant occurred 
one month sooner ($4,116 per month recovered). This was associated with 0.27 (SD 
0.45) months of native kidney time foregone, 0.58 (SD 0.50) months of dialysis time 
averted, seven recipients potentially avoiding dialysis altogether, and savings of $4,116 
(SD $4,642) in dialysis costs per recipient. This could have given at least 58 intended 
recipients a transplant they otherwise did not receive (7.2 per year), and introduced an 
additional 172 kidneys to the organ donation pool (21.4 per year). This was followed by 
only slightly reduced marginal gains if the transplant occurred two months earlier 
($4,011/month recovered) and three months earlier ($4,018/month recovered). A 10% 
reduction in the time to complete the evaluation was more effective than performing the 
transplant one month earlier since a greater absolute reduction took place for longer 
evaluation times (those that are more likely to accrue more costs). A 10% reduction in the 
time to complete the evaluation saved $5,689 (SD $8,636) in recipient dialysis costs, but 
was more wasteful than performing the transplant one month earlier in terms of 
performing a transplant when a patient’s native kidney function was sufficient not to 




Table 22: Evaluation time, dialysis time, and cost savings by scenario 
 
 
Total time (months) (n=877) 



























 Corresponding cohort in Figure 23 b,c,d d b b,c,d b,c,d b,c,d b,c,d 
– Observed transition times (base case) – – – 10.5 (6.93-17.7) – $17,162 ($332-$66,054) – 
1.  Reduce/increase all transition times to the first 
quartile (best-case scenario) 
11.6 (9.71) 3.18 (7.56) 5.31 (7.08) 2.17 (1.54-3.24) $37,092 ($54,764) $1,079 ($0-$10,719) $3,587 ($4,152) 
2.  Reduce/increase all transition times to the median 
transition-specific transition time 
7.84 (8.58) 2.24 (6.05) 3.35 (5.62) 5.13 (3.70-7.77) $25,951 ($44,031) $3,818 ($0-$29,163) $3,420 ($4,319) 
3.  Psychosocial and nephrology consults done on the 
same day  
0.09 (0.85) 0.02 (0.23) 0.03 (0.24) 10.5 (6.93-17.7) $241 ($2,266) $17,038 ($262-$66,054) $2,922 ($3,823) 
4.  Psychosocial, nephrology, and surgical consults 
done on the same day 
0.65 (1.65) 0.16 (0.74) 0.34 (1.08) 9.95 (6.14-17.2) $2,534 ($8,739) $15,307 ($0-$61,846) $3,580 ($4,688) 
5.  Reduce time to see a cardiologist to zero (if 
occurred after a nephrology consult) 
0.06 (0.66) 0.03 (0.45) 0.03 (0.45) 10.5 (6.93-17.7) $144 ($1,790) $17,170 ($271-$65,571) $3,063 ($4,314) 
6.  Remove nuclear renograms from the evaluation 
process 
0.55 (1.21) 0.12 (0.4) 0.29 (0.70) 10.2 (6.93-17.0) $2,121 ($6,813) $16,501 ($0-$61,846) $3,451 ($4,389) 
7.  Overall reduction by 1 month 1.02 (0) 0.27 (0.45) 0.58 (0.50) 9.49 (5.91-16.7) $4,116 ($4,642) $14,299 ($0-$58,890) $4,116 ($4,642) 
8.  Overall reduction by 2 months 2.00 (0) 0.54 (0.89) 1.14 (0.99) 8.51 (4.93-15.7) $8,021 ($9,093) $10,837 ($0-$50,764) $4,011 ($4,547) 
9.  Overall reduction by 3 months 3.02 (0) 0.81 (1.34) 1.71 (1.50) 7.49 (3.91-14.7) $12,055 ($13,594) $7,490 ($0-$43,310) $4,018 ($4,531) 
 9a. Average reduction by 3 months4 2.92 (1.94) 0.81 (1.66) 1.66 (2.05) 7.80 (4.06, 15.0) $9,533 (14,094) $10,609 ($0, $45,836) $3,594 (4,209) 
10.  Overall reduction by 6 months 6.01 (0) 1.62 (2.67) 3.41 (2.98) 4.50 (0.92-11.7) $22,266 ($25,036) $1,214 ($0-$22,006) $3,711 ($4,173) 
11.  Reduction by 10% 1.41 (1.09) 0.38 (0.89) 0.67 (0.84) 9.46 (6.21-15.9) $5,689 ($8,636) $14,421 ($0-$56,364) $3,954 ($4,657) 
12.  Reduction by 25% 3.52 (2.69) 0.96 (2.21) 1.66 (2.09) 7.89 (5.19-13.2) $13,617 ($20,377) $8,648 ($0-$44,389) $3,833 ($4,485) 
 12a. Average reduction by 25%4 3.62 (3.94) 1.00 (2.76) 1.69 (2.57) 7.71 (5.05, 12.9) $12,835 ($21,768) $8,379 ($0-$43,201) $3,795 ($4,430) 
13.  Reduction by 50% 6.97 (5.43) 1.90 (4.40) 3.26 (4.17) 5.26 (3.45-8.84) $24,823 ($35,424) $4,313 ($0-$28,546) $3,680 ($4,568) 
CI – confidence interval; NS – not stated to comply with privacy regulations that limit reporting a small number of observations; IQR – interquartile range (25th-75th percentile); time was measured in 
months, and costs presented in 2016 $CAD 
1 restricted to recipients who were not on dialysis within 3 months of when the donor began the evaluation 
2 restricted to recipients with valid identification number and complete costing data during the evaluation period 
3 restricted to those who were already on dialysis 
4 Reduction was modeled by randomly drawing from a distribution to allow for random variability. The 3 months reduction was sampled from a gamma distribution parametrized with a mean of 3 
months and a standard deviation of 1 month; the 25% reduction was modeled using a beta distribution with a mean 0.25 and standard deviation 0.02. The number of living donor transplants gained was 








transplants lost (n=360)1 
Number of living donor 
transplants gained (N=19)2 
Description of scenario 
Number 
saved 









 Corresponding cohort in Figure 23 c c a a,b,c,d 
– Observed transition times (base case) – 33.9% (29.0-38.8%) – – 
1.  Reduce/increase all transition times to the first quartile (best-case scenario) 111 3.1% (1.3-4.8%) 172 372 
2.  Reduce/increase all transition times to the median transition-specific transition 
time 
75 13.1% (9.6-16.5%) 86 286 
3.  Psychosocial and nephrology consults done on the same day  <6 NS 58 115 
4.  Psychosocial, nephrology, and surgical consults done on the same day 8 31.7% (26.9-36.5%) 58 143 
5.  Reduce time to see a cardiologist to zero (if occurred after a nephrology consult) 0 33.9% (29.0-38.8%) 58 115 
6.  Remove nuclear renograms from the evaluation process <6 NS 58 115 
7.  Overall reduction by 1 month 7 31.9% (27.1-36.8%) 58 172 
8.  Overall reduction by 2 months 15 29.7% (25.0-34.4%) 58 200 
9.  Overall reduction by 3 months 21 28.1% (23.4-32.7%) 86 258 
 9a. Average reduction by 3 months3 21 28.1% (23.4-32.7%) – – 
10.  Overall reduction by 6 months 46 21.1% (16.9-25.3%) 115 286 
11.  Reduction by 10% 12 30.6% (25.8-35.3%) 58 172 
12.  Reduction by 25% 29 25.8% (21.3-30.4%) 86 200 
 12a. Average reduction by 25%3 30 25.6% (21.0-30.1%) – – 
13.  Reduction by 50% 62 16.7% (12.8-20.5%) 86 286 
CI – confidence interval; NS – not stated to comply with privacy regulations that limit reporting a small number of observations; IQR – interquartile range (25th-75th 
percentile); time was measured in months, and costs presented in 2016 $CAD 
1 restricted to recipients who were not on dialysis within 3 months of when the donor began the evaluation 
2 between April 2004 and March 2014, LHSC performed 7% of the province’s transplants. If X transplants were lost between 2013 and 2016 (4 years), then we expect 
X*8/4 transplants were lost over the 8-year study period. This was divided by 0.07 (7%) to extrapolate the total number of transplants lost over the study period in the 
entire province.  
3 Reduction was modeled by randomly drawing from a distribution to allow for random variability. The 3 months reduction was sampled from a gamma distribution 
parametrized with a mean of 3 months and a standard deviation of 1 month; the 25% reduction was modeled using a beta distribution with a mean 0.25 and standard 





In this study, we project that a transplant occurring on average six weeks earlier (i.e., a 
10% faster evaluation time) would result in average cost savings of $5,689 dialysis costs 
per recipient. Such an improvement would reduce the current median living kidney donor 
evaluation time from 10.5 to 9.5 months – a duration still believed by many to be too 
long.17 For the approximately 220 living donor kidney transplants that occur every year in 
Ontario, shortening the evaluation time by 10% translates to an annual cost savings of at 
least $1.3M due to averted dialysis costs. In addition, up to 29 intended recipients each 
year [(58+172)/8] could have received a transplant they otherwise did not receive (a 
29/220=13% increase), adding an average of $40,000 in cost savings each year over the 
lifetime of the transplant.18 By starting the evaluation earlier, we would expect even 
greater gains. For instance, if a transplant occurred on average only three months sooner, 
we would expect at least $2.7M in cost savings in Ontario every year. Furthermore, 
avoiding or shortening dialysis time for recipients is expected to improve recipient health 
outcomes. Thus, there is much to be gained from improving the efficiency of the living 
kidney donor candidate evaluation process in beyond prompting earlier recipient 
referrals, both of which have been recognized as significant barriers to optimal living 
donor kidney transplantation.3,12,15,19,20 
Where possible, pre-emptive kidney transplantation is the best treatment option for many 
patients with failing kidneys. Over the last decade, the proportion of kidney transplants 
that were pre-emptive increased to about one-third of all living donor transplants in the 
United States.21,22 Despite this, pre-emptive transplantation only accounts for 3% of the 
initial renal replacement treatment modality for all new cases of end-stage kidney disease 
in Canada, an estimate that has remained stable over the last decade (Chapter 1).23 
Inefficiencies in pre-transplant living kidney donor evaluation processes (prolonged 
evaluation times, late recipient referrals) can result in wasted opportunities for pre-
emptive transplantation, which may result in worse survival post-transplant and higher 
costs and complications due to dialysis initiation.12,24,25 Evidence also suggests that 
dialysis onset further delays the living donor evaluation.15 For patients with kidney 




of illness or death.26,27 Moreover, patients live with a poorer quality of life.28 Thus, an 
earlier transplant is better for patients, healthcare providers, and the healthcare system.  
There are many barriers to living donor kidney transplantation. Inefficient living donor 
candidate and intended recipient evaluations should not be among them. These are often 
healthcare systems-level barriers that require healthcare systems-level solutions. For 
example, transplant education at dialysis centres or interdisciplinary chronic kidney 
disease clinics is not standardized and healthcare professionals are often uninformed on 
the benefits of living donor transplantation.29–31 Although transplantation may not be the 
appropriate treatment option for all patients, all transplant-eligible patients should be 
provided the opportunity for high-quality ongoing education, and the nature of this 
education should be documented. Another issue is the possible incentive that some for-
profit dialysis facilities may enjoy by continuing to treat patients with dialysis.32–35 
Although this situation is absent in a Canadian setting where there is universal healthcare, 
there are additional complexities that may exist even after a transplant referral occurs.36,37 
Finally, the wait time to see a nephrologist in Canada can range from 2-8 months.38–40 
This wait time may be longer for living donor candidates, who are essentially seeking an 
elective procedure (not urgent). 
Although we used real data in our models and our conclusions are tenable, efforts to 
reduce the duration of living donor candidate evaluations may not translate to an earlier 
transplant for all recipients for a variety of reasons. The pace of the living donor 
evaluation may be titrated to correspond to the status of the intended recipient (i.e., the 
intended recipient must lose weight or clear an infection before being approved as a 
transplant candidate; the recipient’s kidney function is sufficiently high to delay the 
donor candidate evaluation). Moreover, many donor candidates schedule a donation date 
to coincide with a time of the year when their responsibilities (i.e., workload, childcare) 
can be managed by others. Some donors may also appreciate the time to contemplate 
their decision and may not want a quicker evaluation for personal or health-related 
reasons. However, a quicker evaluation should nevertheless be an option for those who 
want one. Future efforts should focus on defining and capturing key dates in the 




recipient candidates, determining what factors are modifiable, and implementing changes 
at the health system level. 
Given the nature of this study, we had to make several assumptions that may limit the 
accuracy of the estimates. First, the date the donor started the evaluation was obtained by 
proxy using healthcare services utilized over a 4-year time-frame before donation.12 
Second, the time between tests was used to model some scenarios, but the presence of a 
temporally intervening healthcare procedure would have prevented the scenario from 
being modeled accurately, thereby underestimating the effects of Scenarios 3-5. Third, 
only persons who participated in a living kidney donor transplant surgery were available 
in most of our databases. Until recently, most programs in Ontario did not systematically 
capture and report data on living donor candidates (i.e., those who do not donate). Thus, 
our provincial data sources did not capture donor candidate records for intended 
recipients who died prior to ever receiving their transplant or who became ill and 
ineligible to receive a transplant (patient as in Figure 23), or who received a deceased 
donor transplant after the living donors’ evaluation started. To supplement our study data, 
we conducted a detailed medical chart review for all donor candidates who contacted one 
living donor transplant program in Ontario. Although we used medical chart review on all 
donor candidates at this centre to extrapolate the findings to the entire province, the 
number of events were small. We also assumed these estimates were generalizable, did 
not change over the study period, and that all candidates would have donated. Finally, the 
cost savings and improvement in outcomes presented in this report are likely 
underestimates because reductions in morbidity attributable to chronic kidney disease and 
dialysis are difficult to estimate (i.e., infection, hyperparathyroidism, anemia, 
hospitalizations, procedural related complications).  
In conclusion, a more efficient living kidney donor evaluation process is expected to 
result in better recipient outcomes, more living donor transplants, and substantial cost 
savings to the healthcare system.3,41 A small reduction in the waiting time to receive a 
transplant can have a large impact on the number of pre-emptive transplants gained and 
total recipient dialysis costs saved. This vitally important healthcare process will benefit 
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Chapter 10  
10 Health care costs for the evaluation, surgery, and 
follow-up care of living kidney donors*** 
 
10.1 Introduction 
Patients with kidney failure live longer with a better quality of life after kidney 
transplantation when compared to maintenance dialysis.1,2 Recipient outcomes are further 
improved when the transplant comes from a living rather than deceased donor.3–5 As 
shown in modeling studies, an increase in the rate of living donor kidney transplantation 
is an effective strategy to ameliorate the burden of kidney disease, and remains cost-
effective even if donors are paid.6–17 Additional health care resources, however, are 
needed to evaluate, perform donor nephrectomy, and follow living kidney donors after 
donation.18,19  
From a health system payer perspective, an accurate estimate of the costs of living kidney 
donation is important for several reasons. First, a better understanding of the true health 
care costs of donation would improve estimates regarding incremental costs and benefits 
of living donor kidney transplantation. Second, as countries across the globe seek to 
better address the demand for transplantable kidneys, a thorough understanding of 
donation-related health care costs will help project the anticipated expenses that could 
occur with initiatives aimed at increasing rates of living kidney donation. Third, detailed 
cost estimates would better inform the funding allocated to hospitals or clinics which 
provide the service. Finally, a better understanding of current costs may serve as an 
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important baseline measure for future efforts to improve the efficiency and cost of the 
donor candidate evaluation.  
Many prior studies only considered the surgical costs of donation and did not 
fully account for the additional costs of the evaluation and follow-up care of living 
kidney donors.9,16 Studies that did include donor evaluation costs used pre-specified 
donor evaluation protocols of minimum required testing.6,7,15 This method of costing 
underestimates the cost of donation because donors may require repeat tests, additional 
tests due to incidental findings, and tests that are not standard to donor evaluation 
protocols but are needed because of the donor’s personal medical history.  
To contribute to the literature, we conducted this detailed costing study in a 
universal health care system where most health care resource use and costs are incurred 
by a single payer. We investigated donor costs in three time-periods: the pre-donation 
evaluation period (beginning of the donor evaluation until donation), the perioperative 
period [the nephrectomy and the perioperative period (30 days post-donation)] and the 
follow-up period (after the perioperative period until one year following donation).  
 
10.2 Methods 
10.2.1 Design, population and setting 
This was a retrospective analysis of living kidney donors who donated at one of Ontario’s 
five transplant centres between April 1, 2004 and March 31, 2014.20,21 Ontario residents 
have access to universal health insurance coverage through a public payer system, which 
includes all aspects of pre- and post-donation care. All living donors in this study were 
required to be Ontario residents for at least two years prior to donation. As per donor 
evaluation criteria, all donors had at least one nephrology consult and one surgery consult 




10.2.2 Costing periods 
The cost of living kidney donation was estimated separately for three time periods, 
corresponding to three phases of the donation process: 1) the evaluation period (from the 
date the donor started the evaluation until the day before donation), which captures costs 
associated with the living donor assessment; 2) the perioperative period (from the day of 
nephrectomy to 30 days post-donation), which captures costs related to the donor surgery, 
hospitalizations, and any possible perioperative complications (including early 
readmissions); and 3) the one-year follow-up period (from day 31 post-donation until 1-
year post-donation), which includes costs related to longer-term or ongoing 
complications and any routine plus as-needed follow-up care.  
10.2.3 Data collection and costing sources  
All costs were measured from the perspective of the Canadian payer. Donors were 
identified from the Trillium Gift of Life Network (TGLN) database through the Institute 
for Clinical Evaluative Sciences (ICES).20 Several health administrative datasets at ICES 
were used to link the data using unique encoded identifiers. These databases included the 
Ontario Health Insurance Plan (OHIP), which captures all primary care and specialist 
physician billings, Canadian Institute for Health Information (CIHI) Same-Day Surgery 
and Discharge Abstract Database (hospitalizations); National Ambulatory Care Reporting 
System (emergency visits); Ontario Drug Benefits (prescription drug costs for citizens 65 
years of age and older or receiving social assistance); National Rehabilitation Services; 
Complex and Continuing Care; and Long-Term Care. The ICES-derived costing method 
was used to obtain all costs from the various linked databases for a specified time-period 
(inpatient and outpatient costs for the time periods described above). In addition to 
individual billing, this costing method uses resource intensity weights multiplied by the 
cost per weighted case to derive the cost per case.22  
10.2.4 Cost estimation 
We derived the frequency of each health care procedure received and calculated the cost 
of each procedure using the physician claims database codes deemed relevant to the 




restricted this to the evaluation period only as we could not pre-specify relevant health 
care use during the perioperative and follow-up periods). To estimate the total cost of 
donation, all costs (instead of pre-specified procedures) from the above databases were 
summed over each costing period. By including all costs accrued by the living donor, 
there is risk that some costs may have accrued for reasons unrelated to the evaluation 
(i.e., consulting the general physician for a non-specific viral illness). To account for this 
potential over-estimation of costs, a baseline non-donation-related health care cost was 
estimated using a cohort of matched healthy non-donor controls (i.e., individuals with 
similar indicators of baseline health as the donors; described in the Matching section 
below). To estimate the cost of donation with the baseline cost (the cost of the controls) 
removed, we developed a series of regression models (described in Statistical Methods 
below). 
10.2.5 Matching 
All Ontario residents were considered possible controls if they were alive, <80 years of 
age as of April 1, 2006, were not missing sex, and had no prior history of living kidney 
donation themselves. The eligible 17,092,895 control candidates were assigned a random 
date (a fake “donation date”) to match the distribution of donation dates observed in the 
donors. Controls who were >79 years or died before their assigned donation date were 
excluded (ineligible to donate), resulting in 16,640,699 potential controls. Since donors 
are a highly selected healthy subset of the population, controls with any diagnostic, 
procedural, or intervention codes which suggested ill health or a contraindication to 
donation were excluded. These included codes related to dialysis, cancer, cardiovascular 
disease, human immunodeficiency virus, nephrectomy, renal biopsy, pulmonary disease, 
liver disease, systemic lupus erythematosus, rheumatoid arthritis, genitourinary disease, 
or alcoholism (full list of codes in Appendix M).  
Potential controls were excluded if they were not Ontario residents for at least 2 
years prior to their donation date or gave birth between 2 months prior and 6 months after 
the donation date (similar exclusions were previously applied to the donors). A total of 
6,151,385 potential controls and 1,214 donors were available for matching (not missing 




date (±2 years), sex, rural/urban status, and neighbourhood-level income quintile. Four 
controls were matched to each donor.  
10.2.6 Statistical methods 
To estimate the cost of living donation, we used a series of multivariable regression 
models applied to the matched cohort and conducted various statistical tests to assess the 
fit of each model (described below). This approach is recommended for cost data because 
of its positive and skewed distribution.23,24 Covariates included an indicator for 
donor/control status, age at the donation date, sex, urban/rural status, the year of donation 
(2003-2007, 2008-2010, and 2011-2014), neighbourhood-level income quintile, and the 
total evaluation time in months. The effect of a variable on costs was reported using the 
marginal effects post-estimation procedure in STATA, which uses the method of recycled 
predictions to provide estimates of mean cost. We were interested in the marginal effect 
of the dichotomous variable donor/control status, which represents the additional cost 
associated with living kidney donors (compared to controls). The marginal effect of any 
other covariate is interpreted as the incremental cost associated with a change in one unit 
of that covariate, holding the other factors constant. To assess whether the cost for donors 
was different from controls across levels of a covariate, we introduced an interaction term 
with the donor indicator in a separate model. A significant interaction term (pint<0.05) 
means that the cost of the donor is significantly different from controls across levels of 
the covariate included in the interaction. In the case where the predictor is only present in 
donors (i.e., recipient’s dialysis status21,25, transplant centre), then the analysis is 
automatically restricted to donors only and the marginal effect is reported (pint is not 
available). 
We tested and compared the fit of ordinary least squares (OLS) regression on 
untransformed costs, log-transformed costs, and square-root-transformed costs. Non-
linear models included the exponential conditional means model and Poisson regression 
with maximum likelihood estimation. We fit a variety of generalized linear models 
(GLMs) using a combination of link functions (identity, square-root, log) and 
distributional families (Gaussian, gamma, inverse Gaussian, and Poisson). We also 




heteroskedastic versions, extended estimating equations, and two-component finite 
mixture models using gamma distributions.24 If more than one GLM had similar indices 
of fit, we performed a Park test to choose the best fit model. We also explored various 
statistical indices of badness of fit, including the Pregibon link test, a modified Hosmer-
Lemeshow test, and the Pearson’s correlation p-value.23,24 For each of these tests, a 
higher p-value is more desirable. We also considered statistics such as R2, root mean 
square error (RMSE), and mean absolute percentage error (MAPE), where a lower value 
is desired. To guard against potential over-fitting, we assessed statistics following cross-
validation, including RMSE and MAPE (lower is better), mean prediction error (MPE; 
zero is desirable), and the p-value for the Copas test (a test for over-fitting; higher is 
desirable).23,24 Ultimately, GLMs were selected for each analysis: log-normal for the 
evaluation period, square-root-Poisson for the perioperative period, log-gamma for the 
follow-up period, and square-root-gamma for the entire duration period. Robust standard 
errors were calculated in all models to accommodate clustering by transplant centre 
where the donation occurred. 
We reported mean (standard deviation, SD), median (25th, 75th percentile), and the 
mean difference (95% confidence interval, CI) from marginal effects, where appropriate. 
All costs are reported in 2017 Canadian dollars. 
10.2.7 Sensitivity analysis 
As of April 1, 2006, the ICES-derived costing method improved to accommodate primary 
care physician payments under capitation following primary care reform to the costing 
data, in addition to dialysis facility visit costs and cancer clinic visit costs.22 We 
conducted sensitivity analysis in the subset of our cohort with an evaluation start date of 
April 1, 2006 or later using the updated costing method to accommodate these costs. 
Sensitivity analyses were also performed on the model chosen to estimate the donor costs 
since more than one model may fit the data for some analyses.  
10.2.8 Software and privacy 
We used Statistical Analysis Software SAS v9.4 or SAS Enterprise Guide 6.1 (2013 SAS 




Procedures and consultations for 5 or fewer donors are not reported to comply with 
privacy requirements for minimizing the chance of patient identification. The study was 
approved by the research ethics board at Sunnybrook Health Sciences Centre, Toronto, 
Canada.  
10.3 Results 
We identified 1,256 living kidney donors who completed the evaluation and donated in 
Ontario during the study period (Figure 26). Donors had a median of 28 (20, 39) health 
care procedures (tests and consults) during the evaluation phase, performed during a 
median 16 (11, 24) separate visits (which meant the procedures/tests were performed on 
different dates). Donors were a mean 45 (SD 11) years of age, were mostly female (63%), 
white (78%), lived in urban areas (87%), and lived in higher-income neighbourhoods 
(23% in the highest quintile versus 15% in the lowest).  
 
Figure 26: Donor selection and matching flow chart. *Using the Ontario Health 
Insurance Plan (OHIP) database, the health care utilization patterns for these 
donors were described for the evaluation period (n=1256), perioperative period 
(n=1240), and follow-up period (n=1223). **fake nephrectomy date was assigned to 





10.3.1 Health care utilization patterns 
Appendix N presents the list of procedures considered relevant to living kidney donation 
and the frequency of use during the evaluation (1256/1256, 100%), donation (1240/1256, 
99%), and follow-up (1223/1256, 97%) periods. The most costly health care procedure 
during the evaluation was consultation with a nephrologist, with a mean 1.91 
consultations per donor at a mean cost of $135 per consultation, accounting for 15% of 
the total evaluation cost (Appendix O and Appendix P). The second most costly test was 
computed tomography, which were performed a mean 1.08 times per donor, representing 
10% of the total evaluation at mean a cost of $170 per exam. This was followed by 
nuclear medicine glomerular filtration rate test (9.0%), consultation with a surgeon or 
urologist (8.1%) and bloodwork (7.9%).  
10.3.2 Cost of the living donor transplantation process 
A total of 1099/1214 (91%) donors were successfully matched to 4396 controls (4 
controls per donor; Figure 26). The matched donors were similar to the unmatched 
donors with respect to age (p=0.47), sex (p=0.27), urban status (p=0.82), and 
neighbourhood income quintile (p=0.13) (Table 24). The mean total health care costs 
during the evaluation period for donors and their matched controls were $4,522 (SD 
$1,073) and $881 (SD $3,061), respectively. The mean adjusted total cost attributable to 
the donor evaluation process was $3,596 (95% CI $3,350-$3,842) (Table 25). Similarly, 
the mean cost attributable to the perioperative period was $11,694 (95% CI $11,415-
$11,973) and the mean cost attributable to follow-up in the first year after donation was 
$1,011 (95% CI $793-$1,230). The incremental cost of living donor-related care to the 
payer across all observation periods was $16,290 (95% CI $15,814-$16,767) (Table 25; 
Figure 27A-D). Using pre-specified health care procedures, the cost of the living donor 






Table 24: Living donor characteristics (n=1099) 
 Donors (N=1099) 
Age at donation 45.1 (11.1) 
  
Sex  
Women 694 (63%) 
Men 405 (37%) 
  
Race  
White 480 (78%) 
Non-white 135 (22%) 
  
Income quintilea  
5, highest income 238 (22%) 
4 275 (25%) 
3 231 (21%) 
2 182 (16%) 
1, lowest income 173 (16%) 
  
Urbanization  
Urban 959 (87%) 
Rural  140 (13%) 
  
Era  
2004-2007 286 (26%) 
2008-2010 399 (36%) 
2011-2014 414 (38%) 





Figure 27: Distribution of health care costs for A) the pre-donation evaluation 
period (start of evaluation until the day before donation); B) perioperative period 
(day of donation until 30-days post-donation); C) one year of follow-up period (after 
perioperative period until 1-year post-donation); and D) the entire period from 
evaluation start until 1-year post-donation. Controls were matched to donors and 








Table 25: Cost of living kidney donation (n=4396 controls and 1099 donors) 
 Mean (SD) 
Median  
(25th, 75th percentile) 
Mean difference  
(95% CI) 
Pre-donation evaluation costs      
Control $881 ($3,061) $149 ($0, $634) – 
Donor $4,270 ($3,846) $3,115 ($2,305, $4,843) – 
t-test – – $3,641 ($3,701-$3,898) 
GLM-MEa,b – – $3,596 ($3,350-$3,842) 
Perioperative costs       
Control $62 ($374) $0 ($0, $0) – 
Donor $11,757 ($4,869) $11,427 ($10,542, $12,224 – 
t-test – – $11,695 ($11,407-$11,984) 
GLM-ME a,c – – $11,694 ($11,415-$11,973) 
One-year follow-up costs       
Control $753 ($2,421) $139 ($0, $577) – 
Donor $1,686 ($4,057) $977 ($562, $1,683) – 
t-test – – $933 ($682-$1,183) 
GLM-ME a,d – – $1,011 ($793-$1,230) 
Total costs        
Control $1,696 ($4,541) $470 ($25, $1,550 – 
Donor $17,966 ($8,401) $16,116 ($14,539, $19,026) – 
t-test – – $16,268 ($15,754-$16,784) 
GLM-ME a,e – – $16,290 ($15,814-$16,767) 
GLM-ME – generalized linear model, marginal effects of donor status; SD – standard deviation; CI – 
confidence interval. 
Costs are presented in 2017 Canadian dollars. 
Donors and their matched controls started the evaluation after March 31, 2003 
a adjusted for age, sex, urban/rural status, income quintile, year of transplant, and total evaluation time 
(in months), p<0.0001 for all mean differences in the table. 
b log-normal 
c square-root Poisson 
d log-gamma 









10.3.3 Predictors of costs  
Over the total donation period, health care costs were higher for women [$534 ($179, 
$890) higher than men], older persons [$316 ($172, $460) per 10-year increase in age], 
and over a longer pre-donation evaluation period [e.g. a longer window for health care 
utilization; $52 ($46, $58) per month] (Table 26). Health care costs were lower in more 
recent years [-$718 (-$1,217, -$218) in 2011-2014 compared with 2004-2007]. Health 
care costs did not differ by the person’s neighbourhood income quintile (p=0.66) or urban 
versus rural residence (p=0.77). There was no significant difference in costs due to an 
interaction between the donor/control indicator and sex, age, or duration of the evaluation 
(pint>0.1 for all). There was a significant interaction with era: in 2011-2014 the 
incremental cost of donation was $810 ($44, $1,577) higher than before 2008. 
In the subset of donors (n=1,099), health care costs were higher if the recipient 
started dialysis during the donor’s evaluation [$886 ($19, $1,752) compared with pre-
emptive transplants], but this did not affect health care costs during the perioperative 
(p=0.82) or follow-up (p=0.68) periods (Table 26). There was a non-significant trend in 
different costs across transplant centres for the evaluation and follow-up periods (p=0.07 
and p=0.09, respectively) (Table 26). Costs were significantly different across transplant 
centres during the perioperative period, ranging from -$1,318 (-$1,971, -$664) to $599 (-




Table 26: Predictors of cost by donation period 
 Evaluation perioda Perioperative periodb Follow-up periodc All periodsd 
 Incremental coste,f pe,f pintf,g Incremental coste,f pe,f pintf,g Incremental coste,f pe,f pintf,g Incremental coste,f pe,f pintf,g 
Female (vs. male) sex $208 ($44, $372) 0.01 0.47 $39 (-$22, $100) 0.21 0.57 $220 ($81, $360) 0.002 0.38 $534 ($179, $890) 0.003 0.67 
             
Age, per 10-years $77 (-$7, $160) 0.07 0.67 $55 ($30, $80) <.0001 0.86 $196 ($123, $269) <.0001 0.91 $316 ($172, $460) <.0001 0.82 
             
Evaluation time per 
month $52 ($46, $58) <.0001 0.14 $1 (-$1, $4) 0.4 0.11 -$3 (-$9, $2) 0.24 0.45 $65 ($49, $81) <.0001 0.21 
             
Urban (vs. rural) 
residence -$185 (-$467, $97) 0.20 0.36 -$77 (-$239, $85) 0.35 0.87 $152 (-$37, $341) 0.12 0.31 -$76 (-$576, $425) 0.77 0.98 
             
Income quintile             
5, highest 0 (reference) 0.95 0.35 0 (reference) 0.51 0.16 0 (reference) 0.23 0.85 0 (reference) 0.66 0.67 
4 $26 (-$200, $251)   -$13 (-$106, $79)   $95 (-$86, $276)   $22 (-$419, $463)   
3 $24 (-$221, $269)   -$20 (-$130, $90)   $124 (-$70, $318)   $233 (-$314, $779)   
2 -$64 (-$310, $182)   -$55 (-$155, $44)   $25 (-$173, $222)   -$215 (-$714, $284)   
1, lowest $19 (-$264, $301)   -$61 (-$144, $23)   $272 ($6, $538)   $231 (-$350, $811)   
             
Era             
2004-2007 0 (reference) 0.60 0.01 0 (reference) 0.02 0.42 0 (reference) 0.005 0.02 0 (reference) 0.0003 0.15 
2008-2010 $89 (-$133, $311)   $3 (-$75, $81)   $78 (-$116, $271)   $74 (-$469, $620)   
2011-2014 $106 (-$103, $316)   -$81 (-$150, -$12)   -$179 (-$353, -$4)   -$718 (-$1,217, -$218)   
             
Recipient dialysis 
statush          
   
pre-emptive 0 (reference) 0.06 N/A 0 (reference) 0.82 N/A 0 (reference) 0.68 N/A 0 (reference) 0.19 N/A 
dialysis-dependent $269 (-$233, $772)   -$224 (-$1,192, $743)   -$151 (-$521, $220)   -$44 (-$1,203, $1,115)   
started dialysis $886 ($19, $1,752)   -$67 (-$825, $691)   $7 (-$454, $468)   $1,373 (-$175, $2,921)   
             
Transplant centre             
1 0 (reference) 0.07 N/A 0 (reference) <.0001 N/A 0 (reference) 0.09 N/A 0 (reference) 0.004 N/A 
2 $63 (-$613, $738)   -$631 (-$938, -$324)   -$13 (-$432, $406)   -$559 (-$1,408, $290)   
3 $390 (-$519, $1,300)   -$2,242 (-$2,746, -$1,739)   -$107 (-$685, $470)   -$1,997 (-$3,223, -$771)   
4 -$561 (-$1,147, $25)   $599 (-$502, $1,701)   -$325 (-$846, $197)   -$406 (-$1,899, $1,087)   
5 $236 (-$713, $1,185)   -$1,318 (-$1,971, -$664)   -$676 (-$1,143, -$209)   -$1,747 (-$2,878, -$616)   
a-d generalized linear model using a log link and normal distribution for the evaluation period (from the evaluation start until the day before donation); a square-root link and a Poisson distribution for the perioperative 
period (from the date of donation until 30 days post-donation); a log link and gamma distribution for the follow-up period (from day 31 post-donation until day 365 post-donation); and a square-root link and gamma 
distribution for the all periods (from the evaluation start until day 365 post-donation) 
e incremental costs and p-values were obtained from a marginal effects analysis 
f adjusted for donor/control indicator donor sex, age, time to complete the evaluation, urban/rural status, neighbourhood income quintile, and era of donation 
g p-value from an interaction term with the donor/control indicator (pint) 
h pre-emptive – recipients were not on dialysis before transplant; dialysis-dependent – recipients were on dialysis prior to (or within 3 months of) the time their donor starting their evaluation; started dialysis – 
recipient started dialysis at least 3 months after their donor’s evaluation started. 




10.3.4 Estimated cost of the evaluation process for candidates 
who did not donate 
We estimated the cost of the evaluation assuming the donors were donor candidates who 
only completed a portion of their evaluation. The donor candidate evaluation cost was 
$1,633 ($1,452, $1,813) if the candidates completed 50% of the evaluation and $2,699 
($2,463, $2,936) if they completed 90% of the entire evaluation (Table 27). There was a 
nearly linear relationship between the proportion of the evaluation completed and the cost 
of the donor evaluation (Figure 28). 
Table 27: Cost of living donor evaluation donors by proportion of evaluation 
completed (n=1099) 




Cost of evaluationa 
0% 0 months $0 
10% 1.0 (0.66, 1.84) $337 ($285, $388) 
25% 2.7 (1.77, 4.76) $865 ($773, $963) 
50% 5.5 (3.61, 9.59) $1,633 ($1,452, $1,813) 
75% 8.2 (5.45, 14.4) $2,320 ($2,102, $2,537) 
90% 9.9 (6.54, 17.4) $2,699 ($2,463, $2,936) 
100% 11.0 (7.36, 19.4) $3,596 ($3,350, $3,842) 
a costs reported in 2017 Canadian dollars using the marginal effects post-
estimation procedure following generalized linear regression with a log-link and 





Figure 28: Cost of the living donor evaluation assuming the donors completed only a 
portion of their completed evaluation (n=1099). Costs are presented in 2017 
Canadian dollars. 
10.3.5 Sensitivity analysis 
When we restricted the analysis to donations after April 1, 2006 to accommodate the cost 
of capitation, the total cost of health care for living donors was very similar [mean 
$16,666 (95% CI $15,799, $16,867)]. The cost of the evaluation, perioperative, and 
follow-up periods were also similar: $3,565 ($3,319, $3,810), $11,741 ($11,409, 
$12,073), and $989 ($747, $1,232), respectively.  
In sensitivity analyses which altered the regression model selected, models that fit the 
data as well or only slightly worse than the base case did not change the marginal effect 
estimates for perioperative and follow-up donor costs, but the evaluation costs ranged 
from a mean $3,414 ($3,229, $3,599) with the square-root gamma model to $4,239 
($3,852, $4,626) with the log-gamma model. 
10.4 Discussion 
In this study from Ontario Canada, we found that the average cost to the health care 
system attributable to a living kidney donor was $16,290. Most of these costs were 




evaluation period ($3,596). The cost of the evaluation for potential donors who 
completed 25% of their evaluation was $865. 
After adjusting for the donor/control indicator, higher health care consumption was 
observed during the evaluation period for women, older individuals, and those with a 
longer evaluation period. These observations were expected and consistent with the 
literature.26 We did not find any evidence that the cost of donation was different 
concerning these factors (non-significant interaction terms). However, we found that the 
evaluation costs were significantly higher for donors if their intended recipient started 
dialysis partway through their evaluation. This may be due to incidental donor candidate 
findings that require further work-up (e.g. characterizing ovarian or hepatic lesions 
identified by renal ultrasound). In turn, a prolonged evaluation caused by the recipient 
initiating dialysis may result in some tests being repeated, which is additional to 
background health care consumption. While we did not observe any differences across 
transplant programs for the cost of the evaluation, there was significant variability in the 
cost of the perioperative period. As this is the most costly period of donation, 
understanding the reasons for these differences and any effects on outcomes may identify 
opportunities for cost-savings.  
To the best of our knowledge, only one study attempted to describe the costs of the 
evaluation, donation, and follow-up periods separately for a small sample of living donor 
kidney transplants (n=130).8 The cost of donor candidates (those who did not donate) 
were included in three studies.8,10,27 However, the cost of a partial donor assessment may 
vary from centre-to-centre depending on their procedures for living donor work-up: 
transplant programs that perform multiple tests on the same day28 or those that evaluate 
multiple candidates simultaneously may incur higher evaluation costs since donor 
candidates who did not donate will have a greater number of tests performed. We 
reported the cost of partial evaluations, assuming non-donors would be scheduled to 
receive the same evaluation process as donors. Individual programs can interpret these 




Previous studies have estimated the total cost of living donation-related care as $23,937 
in Alberta Canada, $15,462 in France, and $15,850 in Spain (cf. $16,290 in this study, all 
in 2017 $CAD).7,8,11 The donor evaluation period accounted for a significant proportion 
of the total cost of living donation: 11% in the Alberta study, 12% in the Spanish study, 
and 22% in this study (the periods differed in the French study). The estimated health 
care costs in the current study are lower than the Alberta study8, particularly those related 
to the perioperative period ($11,644 vs. $18,482). Our study captured the health care 
utilization for donors more comprehensively, so it is unclear why the donation costs are 
much higher in Alberta. Although we did not include the cost of partial evaluations, the 
cost of the pre-donation phase was similar.  
Having a non-donor control group and adjusting for covariates is a novel approach to 
estimate the incremental costs associated with living donation. This methodology (where 
all costs are included) guards against both underestimation (does not omit relevant costs 
since all costs are captured) and overestimation (does not include irrelevant costs since on 
average these are removed by the controls), and also provides a measure of precision. 
However, there are some limitations that should be acknowledged. First, the 
reimbursement costs for out-of-pocket expenses borne by the donors were not available.29 
These costs are often remunerated by government-funded organizations and should be 
included if a governmental perspective is desired.30 Second, in this study we only 
considered persons who became donors. The health care utilization of donor candidates 
who did not donate should be described in future work. Several candidates may be 
evaluated to realize one kidney transplant, and some evaluations may not result in the 
identification of a suitable donor. Summating all these candidate evaluation costs may be 
important for some purposes. Third, the cost of running a living donor program was not 
measured. This includes the cost of personnel (e.g., living donor nurse coordinator, social 
work support, administrative assistant), equipment, and overhead. Fourth, we only looked 
at one-year follow-up costs. Some costs related to donation may take decades to manifest 
(i.e., possible donation-related kidney disease). Fortunately, the 15-year increase in the 
absolute risk of kidney failure attributable to donation appears to be small.31 Finally, 
these estimates pertain to a universal health care system, where 78% of donors were of 




We found that the cost of living kidney donation in Ontario, Canada is on average 
$16,290 per donor. The perioperative period is the largest component of the costs 
($11,694 per donor) followed by the evaluation ($3,596 per donor) and follow-up periods 
($1,011). While substantial costs of living donor care are related to the nephrectomy 
procedure, comprehensive assessment of costs must include evaluation and follow-up 
care. These estimates are informative for planning future work to support and expand 
living donation and transplantation, and directing efforts to improve the cost efficiency of 
living donor care. 
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11.1 Summary of the literature 
The scoping review of the literature revealed a limited number of studies that reported on 
the efficiency of living donor evaluations. We also did not find reporting of efficiency 
metrics on the websites of living donor programs across Canada, the United States, the 
United Kingdom, or Australia. The total time to complete the evaluation was infrequently 
reported and measured using different time-points, some of which were only loosely 
defined (Table 4). In addition, the number of intended recipients who may have missed 
an opportunity for a living donor transplant (pre-emptive or otherwise) were sparsely 
reported (Table 3). Only more recently has evidence emerged suggesting that a faster 
evaluation process results in more living donor kidney transplants and more pre-emptive 
transplants.1 Our results further support these claims. Following the consensus conference 
on living donor transplantation, Moore et al provided several recommendations to 
improve the efficiency of the living donor evaluation.2 The authors discussed the role of 
the referring nephrologist in educating potential recipients and donor candidates on living 
kidney donation. Providing such education as early as possible may enable potential 
recipient candidates to pursue transplant evaluation and identify potential donors. This 
may also provide more information for potential living donor candidates to consider 
donation. However, the effect education has on the efficiency of the living donor work-up 
remains unknown (e.g., does a more informed donor candidate complete the evaluation 
quicker?). There is a trial underway to adapt the “Explore Transplant” and “Explore 
Living Donation” programs from the United States for use in Ontario 
(https://etontario.org/about-this-program/).3,4 Moore et al also suggest that various blood 
tests and anthropometric assessments should be conducted before visiting the transplant 
centre, particularly for candidates who live far away.2 In Chapter 3, we recognized that 
this process design deserves merit (regardless of distance), and while many programs 
already ask candidates to complete preliminary blood and urine tests at a local lab before 
visiting the transplant centre, there is little evidence about when this request should be 




outset or only after they pass the preliminary screening phase? Finally, the authors 
recommended using community nephrologists, particularly for candidates who live far 
from the transplant centre.2 Community nephrologists do not have the same experience 
with living donation as transplant nephrologists, which may produce variability in the 
selection and evaluation of living donor candidates (Appendix A).5–9 Without evidence of 
the efficacy of placing more responsibility on community nephrologists in the work-up of 
living donor candidates, we cannot endorse this as efficiency-improving recommendation 
at this time, yet acknowledge this as a potential source of quality improvement. This 
specific area requires further investigation, as the use of community nephrologists may 
reduce wait times and travel burden for some candidates. 
11.2 Summary of contributions to the field 
Given the paucity of published data and the enthusiasm of patients surrounding this issue, 
we conducted a series of studies to inform the efficiency of the living donor evaluation.  
First, we estimated the time to complete the evaluation. Using data from multiple sources, 
we established that the time until donation was a median 9-11 months across transplant 
centres. For many donors, this time is often overwhelming and fraught with uncertainty.10 
Although we explored individual-level (donor, recipient, and transplant) and some centre-
level factors associated with longer evaluation times, the strongest predictors of a longer 
time until donation was participation in kidney paired donation. Some process 
improvements may help improve the timeliness of this process (e.g. shipping kidneys 
rather than donors; more frequent matching cycles).11 However, this is also reflective of 
the fact that many recipients in paired donation programs are hard to match (e.g., AB 
blood types, presence of antibodies against antigens prevalent among potential 
donors).11,12 The second most noteworthy factor associated with a longer evaluation time 
was a longer time until recipients were referred to the transplant centre. This suggests that 
dialysis centres and multidisciplinary chronic kidney disease clinics could be more 
proactive at educating and referring potential recipients for transplant evaluation.13,14 This 
is consistent with the observation that recipient readiness (e.g. delayed recipient referrals) 
was one of the most frequently encountered reasons for a delayed living donor evaluation 




result in some candidates abandoning the process, a suspected outcome that remains 
difficult to study.1,15 Thus, measuring the evaluation time allows living donor programs to 
compare their performance with other programs and provides a starting point to guide 
improvement efforts. 
Second, we estimated the potential undesirable consequences that can occur with a 
prolonged evaluation process. We found that the evaluation time was twice as long for 
donors whose recipient started dialysis while their evaluation was underway. Although 
poor recipient health may have prolonged the donor’s evaluation (e.g. recipient may have 
become temporarily ineligible for transplant), we anticipate that a longer evaluation was 
frequently a cause of recipients starting dialysis for several reasons. First, the donor’s 
evaluation is often completed by a different healthcare team than the recipient’s 
healthcare team.16,17 This is intended to ensure the donor healthcare team is focused on 
donor safety without the pressures of promoting recipient health (the donor is being 
harmed for the benefit of the recipient). Second, 50% of the recipients started dialysis at 
least 9 months after their donor started their evaluation, ample time to complete a donor 
assessment (Figure 25). All of these donors donated, meaning that they were all healthy 
enough and motivated enough to complete the evaluation and donate a kidney. It is 
therefore unclear why their evaluation wasn’t completed before their recipient started 
dialysis. We also estimated the number of potential living donor transplants that could 
have occurred if the evaluation was quicker. Under these scenarios, we assumed the 
donor candidate was motivated and would have been deemed eligible to donate and 
therefore provide an upper limit of the number of missed opportunities. Altogether, this 
evidence suggests that a quicker evaluation is possible and would result in more living 
donor transplants, more pre-emptive transplants, less time on dialysis (and therefore 
better recipient outcomes), and reduced healthcare expenditures related to dialysis. These 
conclusions are consistent with the sole report linking efficiency improvements to some 
of these outcomes.1 
Third, we estimated the cost to the healthcare system for a completed living donor 
evaluation as well as for partial evaluations. Accurate costing is needed to help programs 




donor evaluation. For example, if the evaluation process was streamlined and completed 
within 3-4 months, then more evaluations (completed or partial) would be conducted 
during a given fiscal year1, thereby increasing costs. These projections may inform 
capital and capacity planning to ensure resources are available to continue to conduct 
timely evaluations and living donor transplants. These costs are also needed to inform 
decision models on whether donor candidates should be evaluated sequentially or 
simultaneously. 
After summarizing the literature and generating novel results, we are able to explore 
additional avenues to improve the efficiency of living kidney donation (Figure 5). I 
briefly describe these efforts in the subsections below. 
11.2.1 Sequential versus simultaneous evaluations 
As demonstrated in Chapter 7, the number of living donor candidates coming forward for 
evaluation for the same recipient increased over time. As prospective recipients are 
increasingly advertising their need on social media, situations where multiple candidates 
are available will become more common. Living donor programs usually evaluate one 
candidate at a time and prioritize candidates who are considered more likely to donate 
(4.4.1.3). This is done to save resources and avoid unnecessary testing for candidates who 
ultimately would not donate. However, most candidates do not donate, and the evaluation 
time for non-donor candidates was estimated to take a median 3 to 4 months (Chapter 7). 
If the initial candidate does not donate, then the time until a true living donor is found 
will be prolonged by at least this amount. During this additional time, the intended 
recipient may start dialysis, will spend a longer time on dialysis, may lose eligibility for 
transplant due to their illness, or may instead receive a deceased donor kidney transplant 
(Chapter 8 and Chapter 9). Thus, the uncertainty of the outcome of living donor 
candidates (donation or non-donation) combined with a lengthy evaluation process may 
make simultaneous evaluations more cost-effective than sequential evaluations, 





To explore this decision, I constructed a decision tree with a Markov model to follow 
donor candidate-recipient groups from the start of the first donors’ evaluation until the 
intended or actual recipient dies (e.g. a lifetime time horizon). Quality-adjusted life-years 
(QALYs) gained was determined using utilities derived from the literature for chronic 
kidney disease (if not yet on dialysis), dialysis, and transplant. Costs included the cost of 
dialysis over time and the cost of the living donor evaluation (partial for non-donors, 
complete for donors), derived from the literature and the estimates from Chapter 10. The 
time to complete the evaluation for donors and non-donors were derived from estimates 
obtained in Chapter 6 and Chapter 7. We modeled several scenarios, varying the number 
of candidates coming forward from 2-4 and the number of donors (candidates who would 
donate upon completion of their evaluation) varied from 1-4 (versus non-donors, who 
would not donate upon completion of their evaluation). We also considered the scenario 
when the intended recipient was not on dialysis (potentially pre-emptive) when the first 
donor candidates’ evaluation started, using data from Chapter 8 to inform the risk of 
starting dialysis over time. We also conducted probabilistic sensitivity analyses to 
accommodate parameter uncertainty. 
The incremental cost-effectiveness ratio (ICER) was negative for all scenarios, driven by 
higher cost savings and more QALYs gained with simultaneous evaluations. For 
example, when 2 candidates came forward for the same candidate who was on dialysis 
and 1 candidate was a donor, there was a 50% probability that the donor would be 
selected first if they were evaluated sequentially. Simultaneous evaluations resulted in 
greater cost savings over the lifetime of the recipient than did sequential evaluations 
(cost = -$19,520) and also produced more QALYs (QALY = 0.44). By breaking down 
some of the cost and effect components, the donor evaluation was more costly in the 
simultaneous strategy ($5,261 versus $4,192 due to the cost of evaluating the non-donor), 
but this was offset by the reduced dialysis cost ($56,290 versus $69,086) that resulted 
from a quicker evaluation time (0.63 versus 0.78 years). Moreover, this prolonged time 
until donation resulted in a greater proportion of recipients receiving a living donor 
transplant (92.6% vs. 89.1%) under the simultaneous method, which may be attributable 




instead (1.7% versus 2.4%). In the potentially pre-emptive scenarios, the added cost of 
dialysis in the sequential strategy may be exacerbated by the longer evaluation phase 
when the non-donor is evaluated first, resulting in more intended recipients starting 
dialysis before the donor evaluation was completed. The ICER was most sensitive to the 
donor and non-donor evaluation times, the cost of dialysis, and the cost savings 
associated with living donor transplantation. If the recipient was potentially preemptive at 
the outset of the evaluations, the ICER was also sensitive to the probability of starting 
dialysis. Regardless of the number of candidates coming forward, even if all candidates 
were donors, simultaneous evaluations were still cost-effective (under probabilistic 
sensitive analyses only) since the fastest donor was chosen. 
 
11.2.2 Reducing the number of tests I – omit the nuclear 
renogram for split renal function††† 
Several studies were identified by the scoping review (Chapter 4) that assessed replacing 
the split renal function assessment by nuclear renography with split kidney volume by 
computed tomography (CT) imaging (Figure 8). The rationale behind this logic is: 1) 
there is a relationship between kidney size and function; and 2) all donors must complete 
a CT scan to assess the renal vasculature. Since a scoping review is inappropriate to 
summarize the literature on this specific topic, we conducted a systematic review of the 
literature, identifying a total of 18 studies for inclusion after applying exclusions. We 
supplemented these studies with individual-level patient data from living donor 
candidates assessed at London Health Sciences Centre between 2013 and 2016. We 
measured the split renal volume from the actual CT images using the ellipsoid formula 
and abstracted the split renal function from the nuclear renogram reports. 
                                                 
 
†††




The Pearson’s correlation coefficient (r) was the measure of association reported by most 
studies. For studies that did not report r yet presented a scatterplot or Bland-Altman plot, 
we digitized the datapoints from the published figures and generated r using the digitized 
(e.g., individual-level) data. We pooled this measure using Fisher’s z-transformation 
using a random-effects model. For individual-level analyses (e.g., using digitized data), 
we performed linear regression to obtain a more interpretable estimate of the association 
between split renal volume and split renal function. 
After pooling 19 studies (n=1,479), we obtained a pooled correlation of 0.74 (95% 
confidence interval 0.61, 0.82). By linear regression using individual-level data, we 
observed a 0.76 (95% CI 0.71, 0.81) percentage-point increase in split renal function 
(SRF) percent for every 1% increase in split renal volume (SRV) percent. SRV had a 
specificity of 88% for discriminating SRF% at a threshold that could influence the 
decision of which kidney is to be removed (between-kidney difference ≥10%). 
Predonation SRV% and SRF% similarly predicted kidney function 6-12 months 
postdonation: r=0.05 (-0.02, 0.13). 
SRV has the potential to replace SRF for some candidates. However, it is uncertain 
whether it can do so reliably and routinely across different transplant centres. The impact 
on clinical decision-making also needs to be determined in a well-designed prospective 
study. 
 
11.2.3 Reducing the number of tests II – omit the nuclear 
renogram for glomerular filtration rate for some candidates 
The second process redesign involved omitting the nuclear renogram for measured 
glomerular filtration rate (mGFR) assessment among candidates with particular pre-test 
characteristics (Figure 9).19 An algorithm was recently published online and tested in a 
French cohort of donors.20 The rationale behind this algorithm is that a young donor 
candidate with a very high estimated GFR (eGFR) will have a very high probability of a 
mGFR exceeding the cut-point for acceptability, rendering this test superfluous. This 




specified cut-point deemed acceptable to the living donor program (e.g. ≥80 mL/min/1.73 
m2). The pre-test probability is based on age, sex, race and eGFR, factors that are 
predictive of mGFR. Conversely, candidates with a very high pre-test probability of a 
very low mGFR (e.g. <60 mLmin/1.73 m2, which is unacceptable for donation by all 
programs) could be excluded without confirmation by nuclear renography. 
Using data from living donors across Canada and Australia (Chapter 6) and for 
candidates evaluated in London Ontario (Chapter 7), we determined the pre-test 
probability of a mGFR at various cut-points (<60, <70, ≥80, and ≥90 mL/min/1.73 m2). 
To avoid false negatives (e.g. having a mGFR <80 mL/min/1.73 m2 but confirmation by 
mGFR is deemed unnecessary), we selected a pre-test probability cut-point that would 
result in 100% sensitivity. Pre-donation eGFR and mGFR were weakly to moderately 
correlated in the cohort of donors (r=0.38, n=768) and the cohort of donor candidates 
(r=0.58, n=101). If the minimum mGFR threshold was 80 mL/min/1.73 m2, a pre-test 
probability >99.94% was needed; only 7 donors had a pre-test probability above this cut-
point and would therefore not have needed a mGFR. Addition of a second eGFR to 
improve the pre-test probability yielded slightly lower cut-point and could have 
prevented 14-15 candidates from requiring a mGFR test (e.g. 4 exams per year). Using 
the estimates from Appendix P (mean cost of $220 per nuclear medicine exam), this 
translates to up to $880 in direct cost savings each year at London Health Sciences (a 
medium-sized program). 
Because the algorithm is based on categorization of key continuous variables (age and 
eGFR), the pre-test probabilities become ordinal. This results in poor discriminative 
ability and large “jumps” in the probabilities between categories. As a result, extremely 
high threshold probabilities are needed to obtain 100% sensitivity. Thus, the current 
prediction tool falls short of warranting its use in medical decision-making. Interpreting 
our findings with the original study and the French validation study, I do not support the 
widespread use of this online diagnostic tool to dictate the use of nuclear renography 




11.2.4 Time from referral to consultation or imaging 
The time until a specialist is available for consult may differ across transplant centres and 
type of specialist. Also, the time until CT imaging is available may also vary. The time 
from referral until imaging or consultation is a common indicator used to measure quality 
of care in Ontario. We attempted to obtain the time of referral from the transplant 
department and the medical records at London Health Sciences, but data were 
unavailable. These wait times are necessary to identify bottlenecks in the evaluation 
process.21,22 Health Quality Ontario provides an interactive online interface for users to 
look at various wait times across Ontario for surgeries and diagnostic imaging 
(http://www.hqontario.ca/System-Performance). Although kidney donation did not 
feature in these reports (e.g. time from referral until nephrectomy), priority-4 (lowest 
priority) patients who should have had a CT scan within 28 days waited a median 31 
days. The median time ranged from a minimum of 5 days (Oxford Advanced Imaging 
Inc. – Ajax) to a maximum of 188 days (Ottawa Hospital). 
11.3 Strengths and Limitations 
11.3.1 Evaluation start date 
One of the limitations of this research is the absence of a clear definition of the candidate 
evaluation start date used to estimate the total evaluation time. Some experts believe that 
the evaluation start date is the date the medical-social questionnaire (MSQ) is received by 
the program. Some candidates take months to complete and return the MSQ (we reported 
a median time of 40 days in Chapter 7), which may reflect the time required by 
candidates to reflect on their decision to donate, wait for other candidates (e.g. other 
family members) to proceed first, or complete their search for information about 
donation. In contrast, other experts believe that this questionnaire is indeed part of the 
evaluation process and the evaluation begins at the time the candidate first contacts the 
program. As part of the evaluation process, the time from first contact until the MSQ is 
received can therefore be subjected to quality improvement efforts by providing the MSQ 
online, reducing the number of questions, or referring candidates to a reliable and up-to-




To estimate the total evaluation time, we were therefore required to make some 
assumptions since data on the first contact date or MSQ were rarely available. In one 
cohort derived using administrative data, we used an algorithm based on healthcare 
utilization patterns. This algorithm was based on expert opinion independent of the data. 
In the cohort comprised of 16 transplant centres across Canada and Australia, we used the 
earliest tests as a surrogate for the evaluation start date (typically blood or urine tests), 
supplemented with first contact dates obtained for many Ontario donors. Finally, in the 
single-centre cohort of living donor candidates in London, Ontario, we abstracted and 
used the actual date the candidate reached out to the program. Despite these differences, 
the estimated total evaluation time was consistent in all three cohorts. Furthermore, these 
estimates aligned with expert opinion (face validity). Finally, these estimates were 
corroborated using costing data, where the cost of partial evaluations approached zero as 
the evaluation time decreased to zero (Figure 28). Had the evaluation start date been 
estimated to be earlier or later than the true date, we would have expected the y-intercept 
to be negative or positive, respectively (concurrent validity). 
11.3.2 Between-centre comparisons 
The large (>1000) Canadian/Australian cohort of living donors was the most appropriate 
dataset to conduct between-centre comparisons because there were 12 transplant centres 
for comparison (compared with the five programs available from Ontario administrative 
data). Although we found statistically significant differences across transplant centres for 
evaluation times, the proportion of potential pre-emptive transplants lost, and the cost of 
living donor evaluations, we were unable to identify the drivers behind these differences.  
Future research is needed, supported by more complete data on the program’s evaluation 
practices and standardized collection and definition of key time-points. We propose one 
approach common to management operations and economics: a data envelopment 
analyses. This method uses linear programming to identify the technically efficient 
programs by simultaneously combining important inputs (e.g. resources + protocols + 
evaluation time) and outputs (e.g. number of transplants + number of pre-emptive 
transplants + number of candidates completing the evaluation).23,24 Efforts are in place to 




identify the relatively inefficient programs and identify the inputs that should be targeted 
for improvement. For example, Program A may produce the same outputs as Program B, 
but may do so with fewer resources. In this case, Program A is more technically efficient 
than Program B because it uses fewer resources to produce the same amount of outputs. 
Program B can improve by either reducing its resources (e.g. personnel) while 
maintaining the same level of production, or increase its level of production (e.g. more 
transplants) while maintaining the same inputs. 
11.3.3 Generalizability 
The evaluation times estimated in this research may not be generalizable to other 
transplant programs (e.g. programs that perform a 1-day evaluation; programs in the 
United States where the CT scan is readily available and can be performed much earlier 
in the evaluation, according to expert opinion). The estimates also may not be consistent 
over time within the same program, as we anticipate all programs across Canada will 
modify their practices to become more efficient (as a result of this research plus ongoing 
engagement and collaboration).25  
The potential cost savings of an earlier living donor transplant may also differ in other 
regions because the distribution of dialysis modalities [e.g. proportion of the population 
treated with peritoneal dialysis (less costly) versus in-centre hemodialysis (most costly)] 
differs.18,26,27 This may also differ for countries where dialysis costs are not completely 
covered by the primary payer: in multiple countries, patients pay some portion of dialysis 
costs through an insurer or out-of pocket.28,29 
11.4 Future directions 
Throughout this thesis, I have argued that key quality indicators and definition of key 
terms are needed to improve the efficiency of the living donor evaluation process. To 
address this gap, we have launched a national Delphi study to identify and define key 
process and outcome indicators that should be measured, monitored, and used to compare 
performance between centres for accountability and quality improvement. 25,30–32 This is 




participation in consensus-type methodology promotes buy-in across the country, and 
data collection cannot be centralized. 
The total time to complete the evaluation is a rather simple and crude metric: it serves as 
a broad indicator of a programs’ efficiency but offers little information on bottlenecks. 
Furthermore, because the definition of an efficient evaluation is so broad, multiple quality 
indicators are needed. For example, Program A may have a prolonged evaluation (longer 
time until approval), but once approved, the donor surgery can be scheduled quickly 
(Figure 29). In contrast, Program B has a quicker evaluation (faster time until approval), 
but has difficultly scheduling the operating theater. The total evaluation time does not 
distinguish these two programs and offers no suggests for quality improvement. 
 
Figure 29: Comparison of two different hypothetical living donor programs with 
identical total evaluation times (defined as the time from evaluation start to 
donation) 
Several process indicators have been suggested and we estimated these where possible, 
including the total time until donation, the time until approval, the time from approval 
until donation, the time from CT angiography until donation, and the time between 
consults. Most of the dates needed to measure process indicators are readily available and 
easily defined (e.g. date of CT). Others were not routinely captured until only recently 
(e.g. the donor candidate first contact date began to be recorded as of January 1, 2016 
across Ontario). Others remain poorly defined (e.g. date of approval) and consensus is 




Outcome indicators (including those in Table 21) also require clear definitions to promote 
generalizability. One such definition is a “potential” preemptive transplant (e.g. could the 
donor candidate have completed their evaluation and donated before their intended 
recipient started dialysis?). 
11.4.1 Implementing a 1-day evaluation 
We believe that the future of living kidney donor evaluation processes in Canada should 
follow the 1-day evaluation in use by other programs. If a 1-day evaluation was 
implemented for all candidates, some of these metrics would become obsolete, yet others 
may weigh more heavily (e.g. time from CT until donation) or new metrics would be 
needed (e.g. time from 1-day evaluation until approval).  
After screening the websites of living donor programs, several programs were identified 
that routinely conduct 1-day assessments, suggesting that this is a feasible process 
improvement strategy that may improve patient outcomes. One program (Belfast, 
Northern Ireland) provided a detailed schedule online.1 We also contacted four programs 
from the United States for additional information, receiving a response from two: 
University of California, Davis and the University of Iowa. Information about these two 
programs were generously provided by the living donor coordinators. 
11.4.1.1 Belfast 
The day begins at 8am with a meeting with the living donor coordinators, blood tests and 
urine tests after a 12-hour (overnight) fast (http://www.donatelife.co.uk/?page_id=306). 
The candidate is then given breakfast and at 9am completes the renal ultrasound and is 
given an injection of a contrast agent for nuclear renographic assessment of split kidney 
function. At 9:30, an injection of another agent is given for total kidney function. 
Between 10am and noon, the nuclear testing for both split function and total kidney 
function are completed, along with a chest x-ray and an electrocardiogram. A 
nephrologist reviews the results in the afternoon and meets with the candidate. A CT scan 
may be performed, but is subject to cancellation if the nephrologist deems the candidate 
is ineligible based on results of tests completed earlier in the day. There appears to be 




of the hospital, meeting with the coordinators and performing blood draws on the 
eleventh floor, nuclear medicine in the cancer centre, and meeting the nephrologist in the 
dialysis unit in another building). No mention is made about their requirements to 
conduct routine psychosocial evaluations. The total evaluation time was reported to be 2-
3 months.1 
11.4.1.2 University of Iowa Organ Transplant Center:  
During the course of the day, the candidate visits the living donor coordinator, social 
worker, psychologist, and surgeon, and conducts a CT scan, chest x-ray, and 
electrocardiogram. The candidate also visits with the independent living donor advocate 
(who happens to be a primary care physician). The advocates perform the medical 
examination, history and educate the potential donor about risk factors and issues related 
to donation, including the ability to back out and issues surrounding confidentiality.33 The 
advocate assumes the role of the nephrologist. As with the Belfast program, the CT scan 
is subject to cancellation. The time from first contact until the 1-day evaluation was 
stated to be 4-6 weeks, and the time until donation varies after the 1-day assessment. 
11.4.1.3 UC Davis Transplant Center:  
The day begins at 7:30am with labs (blood and urine tests). The clinical research center 
registered nurse starts an intravenous line and injects the iohexol dose for nuclear 
renography. At 8:00am, the candidate completes an educational session with the living 
donor coordinators and at 9:00am meets with the nephrologist for a history and physical 
exam. At 10:00am, the candidate meets with the social worker and independent living 
donor advocate. This is followed by a nutritional evaluation and a 1-hour break for lunch. 
In the afternoon, a CT scan is scheduled (can also be canceled if needed) and the 
candidate completes “drop in” tests including chest x-ray and electrocardiogram. The 
morning is completed in the clinic and the afternoon is completed in the hospital. The 
total time from first contact until donation was stated to be approximately 3 months, but 




11.4.1.4 Challenges to a 1-day evaluation 
Some candidates may require additional testing (e.g. stress echo) that is not part of the 1-
day evaluation. In such cases, some tests may be scheduled on a second day and the 1-
day evaluation may be shortened to reduce the burden on the candidate (this is the case at 
UC Davis Transplant Centre for candidates aged 50 years or older).  
Although we anticipate the cost of evaluating non-donor candidates to increase costs to 
the living donor program, such data were unavailable. If a 1-day evaluation does lead to 
more living donor transplants, then while these costs are likely to be recuperated from 
other departments (e.g. dialysis centres), the segmentation of operating costs and funding 
models may hinder such quality improvement projects. Thus, the funding model needs to 
be appropriately addressed to enable more living donor evaluations (e.g. for capital 
planning).  
The wait time for specialists or specialized testing has to be addressed. Conducting more 
tests on candidates who ultimately do not donate represents not only a significant 
financial cost, but also prevents other patients from receiving these consultations or 
diagnostic exams. Thus, more work is needed to ensure healthcare resources are used 
efficiently (e.g. capacity planning). 
Another consideration is the availability of the operating room. If the evaluation process 
was more efficient, we would anticipate more living donor transplants per year. The 
operating room must be able to accommodate this capacity. 
11.4.2 Other quality improvement designs 
There are likely other solutions to improve the efficiency of the living donor work-up, 
including partnering with local pharmacies to lease 24-hour ambulatory blood pressure 
machines free of charge to donor candidates, or running outpatient clinics on weekends. 
The final round of the aforementioned Delphi survey to is aimed to identify and prioritize 




11.5 Resource constraints 
Unlike manufacturing processes, the flow of patients through a healthcare system is 
subject to individual heterogeneity (e.g. unlike cars on an assembly line, each patient is 
unique). Despite this challenge, multiple avenues for process improvement have been 
discussed in the context of our findings and those from the literature. From the 
experience of a single transplant centre (London Health Sciences Centre; Chapter 7), 
there was a rise in the number of living donor transplants, more pre-emptive transplants, 
and more living donor candidates contacting the program (e.g. more evaluations started). 
However, this was not associated with a longer time to complete the evaluation (e.g. due 
to resource constraints). In contrast, this was associated with a shorter time until 
donation. This suggests existing capacity and resource availability, which was somehow 
utilized to improve the efficiency of the evaluation. Without adding resources to the 
system (e.g. more human resources, additional CT scanners), there is an upper limit of 
efficiency that will preclude additional efficiency gains. Moreover, harm can be created 
in other areas because one more CT scan for a living donor may come at the expense of 
one less scan available for another patient. Although this was not in the scope of this 
thesis, future work will inform these issues. If additional resources are warranted, this 
will increase the overhead costs of running a living donor program. Thus, consideration 
of resource constraints in a specific setting is critical to eliminate system constraints and 
ensure the long-term success of a more efficient living donor evaluation process. 
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Appendix A: Variability on living donor eligibility criteria: summary of surveys of 
multiple living donor programs 
 
Age: There has been an upward shift in the age range for donor acceptability across 
programs. Up to 58-59% of centres surveyed in the United States and Europe reported no 
upper age limit.1–3 However, most living donor programs have a lower age limit for donor 
acceptance. Some programs have a cut-off of 25 years of age, while others are willing to 
accept minors under special circumstances.  
Hypertension: Hypertension is a strong risk factor for kidney disease and cardiovascular 
disease, and donor candidates with uncontrolled hypertension are typically excluded. If 
hypertension is controlled (i.e., within normal limits while taking antihypertensive 
medication(s)), then some centres may accept this donor, particularly if the candidate is 
older. Variability exists regarding the number of anti-hypertensive medications permitted 
(ranging from zero to three), the highest acceptable blood-pressure (ranging from 120/80 
to 140/90), and the use of a 24-hour ambulatory blood pressure monitor to rule out white-
coat hypertension (hypertension in a doctor’s office).  
Diabetes: Diabetes is one of the more common absolute contraindications to kidney 
donation (72% across Europe and 64% across the United States2,3), as this is one of the 
leading causes of kidney disease. The presence of pre-donation risk factors (i.e., high 
blood glucose, family history of diabetes, donors of South Asian or Afro-Caribbean 
extraction) often mandates a fasting glucose measurement or an oral glucose tolerance 
test. The maximum glucose concentration used for donor exclusion varies across 
programs, but the upper limit across programs does not exceed 7.0 mmol/L (126 mg/dL).  
Kidney function: kidney function is one of the strongest predictors of kidney disease. 
Kidney function is measured as the rate by which blood is filtered (the glomerular 
filtration rate, GFR) adjusted to body size, in mL/min/1.73 m2. The minimum cut-point 
for donor acceptance generally ranges from 80-100 mL/min/1.73 m2, but lower values 




since GFR declines with age). There is little agreement on the best strategy to evaluate a 
donor candidate’s kidney function. Some programs use measured GFR from urine 
collected over a continuous 24-hour period, estimated GFR (eGFR) using different 
equations, measured GFR using a nuclear renogram, or any combination of these.  
Another indicator of kidney disease is proteinuria (protein in the urine), which may be 
measured using a random urine sample for semi-quantification (i.e., negative, trace, 
small, large) or quantification (g/L) using a dipstick or daily protein elimination using a 
24-hour urine sample (g/day). Acceptance criteria vary across programs, but donors with 
≥100mg/d albumin excretion or microalbuminuria (≥3 mg/mmol albumin-to-creatinine 
ratio) are generally excluded.  
Another indicator of kidney disease is hematuria (blood in the urine), which may be 
measured using a random urine sample for semi-quantification using a dipstick (i.e., 
negative, trace, small, large) and confirmed using a microscopic analysis. Although 
reported only by the American surveys, the definition of hematuria based on the 
microscopic analysis ranges from a minimum of 2-10 red blood cells per high-powered 
microscopic field.2,4 The definition of persistent hematuria may also vary, but presence of 
persistent hematuria generally mandates further testing using a cystocopy or a kidney 
biopsy to rule out underlying kidney disease.5 Urine cytology (looking for cancerous cells 
in the urine) may be performed before cystoscopy or kidney biopsy.6 
Obesity: obesity presents a surgical risk to the donor and also impacts the lifelong risk of 
developing diabetes and kidney disease. The BMI cut-point for acceptance ranges from 
30-40 kg/m2, but information was not provided on methods used by programs to help 
motivated candidates reach the cut-point.3,4  
Cardiac testing: an electrocardiogram and cardiac stress testing is usually reserved for 
candidates with an indication for these tests (i.e., advanced age, cardiovascular risk 
factors). However, some centres perform these tests routinely for all donor candidates.  
Stones: A history of renal stones is a strong risk factor for kidney disease and has 




Although none of the European surveys offered perspective on acceptance criteria, this 
has become less stringent over time in the United States. Many American centres (66%) 
accept donors with a history of a single stone, but other programs may relax this 
restriction based on absence of metabolic risk factors (i.e., hypercalciuria, hyperoxaluria, 
cystinuria, metabolic acidosis, and hyperuricemia).2,4  
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Appendix B: List of Websites 
Country Province or State Centre or agency City Website 
Canada British Columbia St. Paul's Hospital Vancouver http://renal.providencehealthcare.org 
Canada British Columbia Vancouver General Hospital Vancouver http://www.vch.ca 
Canada British Columbia BC Transplant Society * Vancouver http://www.transplant.bc.ca 
Canada Alberta Living Donor Services Program Edmonton http://www.albertahealthservices.ca 
Canada Alberta Southern Alberta Renal Program Calgary http://www.albertahealthservices.ca 
Canada Alberta Northern Alberta Renal Program * Edmonton https://www.kidney.ca 
Canada Saskatchewan Saskatchewan Transplant Program Saskatoon https://www.saskatoonhealthregion.ca 
Canada Manitoba Transplant Manitoba Winnipeg http://www.transplantmanitoba.ca 
Canada Manitoba Health Sciences Centre * Winnipeg http://www.hsc.mb.ca 
Canada Ontario London Health Sciences Centre London http://www.lhsc.on.ca 
Canada Ontario St. Joseph's Health Care System Hamilton https://www.stjoes.ca 
Canada Ontario St. Michael's Hospital Toronto http://www.stmichaelshospital.com 
Canada Ontario Toronto General Hospital Toronto http://www.uhn.ca/MOT 
Canada Ontario The Ottawa Hospital Ottawa http://www.ottawahospital.on.ca 
Canada Quebec Hôpital Ste-Justine Montreal https://www.chusj.org 
Canada Quebec Montreal Children's Hospital * Montreal http://www.thechildren.com 
Canada Quebec Royal Victoria Hospital * Montreal https://muhc.ca 
Canada Quebec C.H. Universitaire de Sherbrooke Sherbrooke http://www.chus.qc.ca 
Canada Quebec Transplant Quebec * agency http://www.transplantquebec.ca 
Canada Nova Scotia/Prince 
Edward Island 
Queen Elizabeth II Health Sciences 
Centre 
Halifax (serves Nova 
Scotia, New Brunswick, 
PEI and Newfoundland 
 https://www.cdha.nshealth.ca 
Canada Nova Scotia/Prince 
Edward Island 
Legacy of Life * agency http://www.legacyoflife.ns.ca 
Canada Nova Scotia/Prince 
Edward Island 
Prince Edward Island Government 
Website * 
agency https://www.princeedwardisland.ca 
Canada New Brunswick Réseau de santé Vitalité Health 
Network 
New Brunswick http://www.vitalitenb.ca 
Canada Newfoundland and 
Labrador 
Western Memorial Regional 
Hospital 
Corner Brook http://westernhealth.nl.ca 
Canada KFOC Kidney Foundation of Canada agency https://www.kidney.ca 
Canada KFOC Canadian Blood Services agency https://blood.ca 
Canada KFOC HealthLink BC agency https://www.healthlinkbc.ca 
USA Alabama UAB Medicine Birmingham https://www.uabmedicine.org 
USA Alaska Providence Anchorage, Eagle 




USA Arizona Phoenix Children's Hospital Phoenix http://www.phoenixchildrens.org 
USA Arizona Banner - University Medical Center 
Phoenix and University Medical 
Center Tucson 
Phoenix + Tucson https://www.bannerhealth.com 
USA California Scripps Center La Jolla https://www.scripps.org 
USA California Loma Linda Medical Center Loma Linda http://medical-center.lomalindahealth.org 
USA California Cedars-Sinai Medical Center Los Angeles https://www.cedars-sinai.edu 
USA California University of California at Los 
Angeles Medical Center 
Los Angeles http://transplants.ucla.edu 
USA California Keck Hospital of USC Los Angeles http://transplant.keckmedicine.org 
USA California St. Vincent Medical Center Los Angeles https://stvincent.verity.org 
USA California St. Joseph Hospital  Orange https://www.sjo.org 
USA California University of California Irvine 
Medical Center 
Orange http://www.ucirvinehealth.org 
USA California Lucile Salter Packard Children's 
Hospital 
Palo Alto http://www.stanfordchildrens.org 
USA California Stanford Health Care Palo Alto https://stanfordhealthcare.org 
USA California Riverside Community Hospital Riverside http://riversidecom 
USA California University of California Davis 
Transplant Center 
Sacramento http://www.ucdmc.ucdavis.edu 
USA California Sharp Memorial Hospital Kidney 
Transplant 
San Diego https://www.sharp.com 
USA California University of California San Diego 
Medical Center 




USA California Rady Children's Hospital and 
Health Center 
San Diego https://www.rchsd.org 
USA California University of California San 
Francisco Medical Center 
San Francisco https://www.ucsfhealth.org 
USA California California Pacific Medical Center San Francisco http://www.cpmc.org 
USA California Living Donation California http://livingdonationcalifornia.org 
USA Colorado University of Colorado Hospital Aurora https://www.uchealth.org 
USA Colorado University of Colorado Anschutz 
Medical Campus 
Aurora http://www.ucdenver.edu 
USA Colorado Children's Hospital Colorado Aurora https://www.childrenscolorado.org 
USA Colorado Centura Porter Adventist 
Hospital 
Denver http://www.porterhospital.org 
USA Colorado Presbyterian/St. Luke's Denver http://pslmc.com 
USA Connecticut Hartford Hospital Transplant 
Center 
Hartford https://hartfordhospital.org 
USA Connecticut Yale New Haven Hospital New Haven https://www.ynhh.org 
USA Delaware Christiana Care Health System Newark https://christianacare.org 
USA Delaware Alfred I duPont Hospital for 
Children 
Wilmington https://www.nemours.org 
USA District of Colombia Georgetown University Medical 
Center 
Washington D.C. https://www.medstargeorg 
USA District of Colombia George Washington University 
Hospital 
Washington D.C. https://www.gwhospital.com 
USA Florida Gulf Coast Medical Center Ft. Myers http://largomedical.com 
USA Florida UF Health Shands Hospital Gainesville https://ufhealth.org 
USA Florida Mayo Clinic Jacksonville Jacksonville http://www.mayoclinic.org 
USA Florida Largo Medical Center Largo http://largomedical.com 
USA Florida Jackson Memorial Hospital 
University of Miami School of 
Medicine 
Miami http://www.jacksonhealth.org 
USA Florida Florida Hospital Medical Center Orlando https://www.fhtransplant.com 
USA Florida Tampa General Hospital Tampa https://www.tgh.org 
USA Florida Cleveland Clinic Florida Weston Weston https://my.clevelandclinic.org 
USA Georgia Emory University Hospital Atlanta https://www.emoryhealthcare.org 
USA Georgia Children's Healthcare of Atlanta 
at Egleston 
Atlanta https://www.choa.org 
USA Georgia Piedmont Hospital Atlanta http://www.piedmont.org 
USA Georgia AU Medical Center Augusta https://www.augustahealth.org 
USA Hawaii The Queen's Medical Center Honolulu http://www.queenstransplantcenter.org 
USA Illinois Rush University Medical Center Chicago https://www.rush.edu 
USA Illinois University of Chicago Medical 
Center 
Chicago http://www.uchospitals.edu 
USA Illinois Ann & Robert H. Lurie Children's 
Hospital of Chicago 
Chicago https://www.luriechildrens.org 
USA Illinois University of Illinois Medical 
Center 
Chicago http://hospital.uillinois.edu 
USA Illinois Northwestern Memorial Hospital Chicago https://www.nm.org 
USA Illinois Loyola University Medical Center Maywood https://www.loyolamedicine.org 
USA Illinois Advocate Christ Medical Center Oak Lawn http://www.advocatehealth.com 
USA Illinois OSF Saint Francis Medical 
Center 
Peoria https://www.osfhealthcare.org 
USA Illinois Memorial Medical Center Springfield https://www.memorialmedical.com 
USA Indiana Lutheran Hospital of Fort Wayne Ft Wayne http://www.lutheranhospital.com 
USA Indiana St. Vincent Hospital and Health 
Care Center 
Indianapolis https://www.stvincent.org 
USA Indiana Indiana University Health  Indianapolis http://iuhealth.org 
USA Iowa Iowa Methodist Medical Center Des Moines http://www.unitypoint.org 
USA Iowa Mercy Medical Center-Des 
Moines 
Des Moines https://www.mercydesmoines.org 
USA Iowa University of Iowa Hospitals and 
Clinics and Iowa City VA Medical 
Center 
Iowa City https://uihc.org 
USA Kansas University of Kansas Hospital Kansas City http://www.kumed.com 
USA Kansas Saint Luke's Health System Kansas City https://www.saintlukeshealthsystem.org 





USA Kentucky Jewish Hospital Louisville http://www.kentuckyonehealth.org 
USA Louisiana Ochsner Foundation Hospital New Orleans https://www.ochsner.org 
USA Louisiana Tulane Medical Center New Orleans http://tulanehealthcare.com 
USA Louisiana Willis-Knighton Medical Center Shreveport http://www.wkhs.com 
USA Maine Maine Medical Center 
Transplant Program 
Portland https://mainehealth.org 
USA Maryland University of Maryland Medical 
System 
Baltimore http://www.umm.edu 
USA Maryland Johns Hopkins Hospital Baltimore https://www.hopkinsmedicine.org 
USA Maryland Walter Reed National Military 
Medical Center at Bethesda 
Bethesda http://www.wrnmmc.capmed.mil 
USA Massachusetts Massachusetts General Hospital Boston http://www.massgeneral.org 
USA Massachusetts Brigham and Women's Hospital Boston http://www.brighamandwomens.org 
USA Massachusetts Boston Children's Hospital Boston http://www.childrenshospital.org 
USA Massachusetts Beth Israel Deaconess Medical 
Center 
Boston http://www.bidmc.org 
USA Massachusetts Boston Medical Center Boston https://www.bmc.org 
USA Massachusetts Tufts Medical Center Boston https://www.tuftsmedicalcenter.org 
USA Massachusetts Lahey Clinic Medical Center Burlington http://www.lahey.org 
USA Massachusetts Baystate Medical Center Springfield https://www.baystatehealth.org 
USA Massachusetts UMass Memorial Medical Center Worcester https://www.umassmemorialhealthcare.org 
USA Michigan University of Michigan Medical 
Center 
Ann Arbor http://www.uofmhealth.org 
USA Michigan Children's Hospital of Michigan Detroit https://www.dmc.org 
USA Michigan Henry Ford Hospital Detroit https://www.henryford.com 
USA Michigan Harper University Hospital 
Detroit Medical Center 
Detroit https://www.dmc.org 
USA Michigan St. John Hospital and Medical 
Center 
Detroit http://www.stjohnprovidence.org 
USA Michigan Helen DeVos Children's Hospital Grand Rapids https://www.spectrumhealth.org 
USA Michigan Mercy Health Saint Mary's Grand Rapids http://www.smhealthcare.org 
USA Michigan William Beaumont Hospital Royal Oak http://www.beaumont.edu 
USA Minnesota University of Minnesota Medical 
Center, Fairview 
Minneapolis https://www.mhealth.org 
USA Minnesota Abbott Northwestern Hospital Minneapolis https://www.allinahealth.org 
USA Minnesota Hennepin County Medical 
Center 
Minneapolis http://www.hcmc.org 
USA Mississippi The University of Mississippi 
Medical Center 
Jackson https://www.ummchealth.com 
USA Missouri Children's Mercy Hospital Kansas City http://www.childrensmercy.org 
USA Missouri St. Luke's Hospital of Kansas 
City 
Kansas City https://www.saintlukeshealthsystem.org 
USA Missouri Research Medical Center Kansas City http://researchmedicalcenter.com 
USA Missouri St. Louis Children's Hospital St. Louis http://www.stlouischildrens.org 
USA Missouri Barnes-Jewish Hospital St. Louis https://www.barnesjewish.org 
USA Missouri SSM Health Saint Louis 
University Hospital 
St. Louis http://www.ssmhealth.com 
USA Nebraska The Nebraska Medical Center Omaha https://secure.nebraskamed.com 
USA Nevada University Medical Center of 
Southern Nevada 
Las Vegas https://www.umcsn.com 
USA New Hampshire Dartmouth-Hitchcock MC (Mary 
Hitchcock Memorial Hospital) 
Lebanon http://www.dartmouth-hitchcock.org 
USA New Jersey Our Lady of Lourdes Medical 
Center 
Camden https://www.lourdesnet.org 
USA New Jersey RWJ Barnabas Health Edison, Rutherford https://www.barnabashealth.org 
USA New Jersey Hackensack University Medical 
Center 
Hackensack http://www.hackensackumc.org 
USA New Jersey Saint Barnabas Medical Center Livingston https://www.barnabashealth.org 
USA New Jersey Robert Wood Johnson New Brunswick http://www.rwjuh.edu 
USA New Mexico UNM School of Medicine Albuquerque http://surgery.unm.edu 
USA New Mexico Presbyterian Hospital Albuquerque https://www.phs.org 
USA New York Albany Medical Center Hospital Albany http://www.amc.edu 
USA New York Erie County Medical Center Buffalo http://www.ecmc.edu 





USA New York Westchester Medical Center Mount Pleasant http://westchestermedicalcenter.com 
USA New York Mount Sinai Medical Center New York City http://www.mountsinai.org 
USA New York New York-Presbyterian 
Hospital/Weill Cornell Medical 
Center 
New York City http://www.nyp.org 
USA New York Montefiore Medical Center New York City http://www.montefiore.org 
USA New York NY Presbyterian 
Hospital/Colombia Univ. Medical 
Center 
New York City http://www.nyp.org 
USA New York New York University Medical 
Center 
New York City http://nyulangone.org 
USA New York State University of New York, 
Downstate Medical Center 
New York City http://www.downstate.edu 
USA New York Strong Memorial Hospital, 
University of Rochester Medical 
Center 
Rochester https://www.urmc.rochester.edu 
USA New York University Hospital of State 
University of New York at Stony 
Brook 
Stony Brook https://www.stonybrookmedicine.edu 
USA New York State University of New York, 
Upstate Medical University 
Syracuse http://www.upstate.edu 
USA North Carolina University North Carolina 
Medical Center 
Chapel Hill http://www.uncmedicalcenter.org 
USA North Carolina Carolinas Medical Center Charlotte http://www.carolinashealthcare.org 
USA North Carolina Duke University Hospital Durham https://www.dukehealth.org 
USA North Carolina Vidant Health Greenville https://www.vidanthealth.com 
USA North Carolina Wake Forest Baptist Medical 
Center 
Winston-Salem http://www.wakehealth.edu 
USA North Dakota Sanford Bismark Medical 
Center, Sanford Medical Center 
Fargo 
Bismark, Fargo http://www.sanfordhealth.org 
USA Ohio University of Cincinnati Medical 
Center 
Cincinnati http://uchealth.com 
USA Ohio The Christ Hospital  Cincinnati https://www.thechristhospital.com 
USA Ohio Children's Hospital Medical 
Center 
Cincinnati https://www.cincinnatichildrens.org 
USA Ohio The Cleveland Clinic Foundation Cleveland https://my.clevelandclinic.org 
USA Ohio University Hospitals of Cleveland Cleveland http://www.uhhospitals.org 
USA Ohio Ohio State University Medical 
Center 
Columbus https://wexnermedical.osu.edu 
USA Ohio University of Toledo Medical 
Center 
Toledo http://uthealth.utoledo.edu 
USA Oklahoma Integris Baptist Medical Center Oklahoma City http://integrisok.com 
USA Oklahoma OU Medical Center Oklahoma City https://www.oumedicine.com 
USA Oklahoma Children's Hospital of Oklahoma Oklahoma City https://www.oumedicine.com 
USA Oklahoma Saint Francis Hospital Tulsa https://www.saintfrancis.com 
USA Oklahoma St John Medical Center Tulsa http://www.stjohnhealthsystem.com 
USA Oregon Legacy Good Samaritan 
Hospital and Medical Center 
Portland http://www.legacyhealth.org 
USA Oregon Oregon Health and Science 
University 
Portland http://www.ohsu.edu 
USA Pennsylvania Lehigh Valley Hospital Allentown https://www.lvhn.org 
USA Pennsylvania Geisinger Medical Center Danville https://www.geisinger.org 
USA Pennsylvania UPMC Hamot Erie http://www.upmc.com 
USA Pennsylvania Pinnacle Health System at 
Harrisburg Hospital 
Harrisburg http://www.pinnaclehealth.org 
USA Pennsylvania Penn State Milton S Hershey 
Medical Center 
Hershey http://hmc.pennstatehealth.org 
USA Pennsylvania Thomas Jefferson University 
Hospital 
Philadelphia http://hospitals.jefferson.edu 
USA Pennsylvania Temple University Hospital Philadelphia http://kidney.templehealth.org 
USA Pennsylvania Hospital of the University of 
Pennsylvania 
Philadelphia https://www.pennmedicine.org 
USA Pennsylvania Albert Einstein Medical Center Philadelphia https://www.einstein.edu 





USA Pennsylvania Hahnemann University Hospital Philadelphia https://www.hahnemannhospital.com 
USA Pennsylvania Allegheny General Hospital Pittsburg https://www.ahn.org 
USA Pennsylvania Children's Hospital of Pittsburgh 
of UPMC 
Pittsburg http://www.chp.edu 
USA Pennsylvania University of Pittsburg Medical 
Center 
Pittsburg http://www.upmc.com 
USA Pennsylvania Crozer-Chester Medical Center Upland http://www.crozerkeystone.org 
USA Pennsylvania The Lankenau Hospital Wynnewood https://www.mainlinehealth.org 
USA Rhode Island Rhode Island Hospital Providence https://www.lifespan.org 
USA South Carolina Medical University of South 
Carolina 
Charleston http://www.muschealth.org 
USA South Dakota Avera McKennan Hospital Sioux Falls http://www.avera.org 
USA Tennessee Erlanger Medical Center Chattanooga http://www.erlanger.org 
USA Tennessee University of Tennessee Medical 
Center at Knoxville 
Knoxville http://www.utmedicalcenter.org 
USA Tennessee Methodist University Hospital Memphis http://www.methodisthealth.org 
USA Tennessee Centennial Medical Center  Nashville http://tristarcentennial.com 
USA Tennessee St. Thomas Hospital Nashville https://www.sthealth.com 
USA Tennessee Vanderbilt University Medical 
Center and Nashville VA Medical 
Center 
Nashville https://www.vanderbilthealth.com 
USA Texas UT Southwestern Medical 
Center/William P. Clements Jr. 
University Hospital 
Dallas http://www.utswmedicine.org 
USA Texas Children's Medical Center of 
Dallas 
Dallas https://www.childrens.com 
USA Texas Medical City Dallas Hospital Dallas http://medicalcityhospital.com 
USA Texas Methodist Dallas Medical Center Dallas http://www.methodisthealthsystem.org 
USA Texas Baylor University Medical Center Dallas http://www.baylorhealth.com 
USA Texas Las Palmas Medical Center El Paso http://laspalmasdelsolhealthcare.com 
USA Texas Medical City Fort Worth Fort Worth http://medicalcityfortworth.com 
USA Texas Baylor All Saints Medical Center Fort Worth http://www.baylorhealth.com 
USA Texas Texas Health Harris Methodist 
Fort Worth Hospital 
Fort Worth https://www.texashealth.org 
USA Texas University of Texas Medical 
Branch at Galveston 
Galveston https://www.utmbhealth.com 
USA Texas Houston Methodist Hospital Houston http://www.houstonmethodist.org 
USA Texas CHI St. Luke's Health Baylor 
College of Medicine Medical 
Center 
Houston http://www.chistlukeshealth.org 
USA Texas Texas Children's Hospital Houston https://www.texaschildrens.org 
USA Texas Memorial Hermann Hospital, 
University of Texas at Houston 
Houston http://www.memorialhermann.org 
USA Texas University Hospital, University of 
Texas Health Science Center 
San Antonio http://www.universitytransplantcenter.com 
USA Texas Methodist Specialty and 
Transplant Hospital 
San Antonio http://sahealth.com 
USA Texas Christus Santa Rosa Hospital 
Medical Center 
San Antonio https://www.christushealth.org 
USA Texas Scott and White Memorial 
Hospital 
Temple http://www.sw.org 
USA Texas East Texas Medical Center Tyler https://www.etmc.org 
USA Utah Intermountain Medical Center Murray https://intermountainhealthcare.org 
USA Utah University of Utah Medical 
Center 
Salt Lake City https://healthcare.utah.edu 
USA Vermont The University of Vermont 
Medical Center 
Burlington https://www.uvmhealth.org 
USA Virginia University of Virginia Health 
Sciences Center 
Charlottesville https://uvahealth.com 
USA Virginia Inova Fairfax Hospital Falls Church  https://www.inova.org 
USA Virginia Sentara Norfolk General 
Hospital 
Norfolk https://www.sentara.com 






USA Virginia Medical College of Virginia 
Hospitals 
Richmond https://www.vcuhealth.org 
USA Virginia Henrico Doctor's Hospital Richmond http://hcavirginia.com 
USA Washington University of Washington 
Medical Center 
Seattle http://www.uwmedicine.org 
USA Washington Seattle Children's Hospital Seattle http://www.seattlechildrens.org 
USA Washington Swedish Medical Center Seattle http://www.swedish.org 
USA Washington Virginia Mason Medical Center Seattle https://www.virginiamason.org 
USA Washington Providence Sacred Heart 
Medical Center & Children's 
Hospital 
Spokane http://washington.providence.org 
USA West Virginia Charleston Area Medical Center Charleston http://www.camc.org 
USA Wisconsin University of Wisconsin Hospital 
and Clinics 
Madison http://www.uwhealth.org 
USA Wisconsin Aurora St. Luke's Medical 
Center 
Milwaukee https://www.aurorahealthcare.org 
USA Wisconsin Froedtert Memorial Lutheran 
Hospital 
Milwaukee http://www.froedtert.com 
USA Wisconsin Children's Hospital of Wisconsin Milwaukee http://www.chw.org 
USA USA National Kidney Foundation agency https://www.kidney.org 
USA USA UNOS/Transplant Living agency https://www.unos.org 
USA USA National Kidney Registry agency http://www.kidneyregistry.org 
USA USA American Transplant Foundation agency http://www.americantransplantfoundation.org 
USA USA Donate Life America agency https://www.donatelife.net 
UK Ireland Belfast City Hospital Belfast http://www.belfasttrust.hscni.net 
UK England Queen Elizabeth Hospital 
Birmingham 
Birmingham https://www.uhb.nhs.uk 
UK England Bristol Southmead Hospital Bristol https://www.nbt.nhs.uk 
UK England Cambridge Addenbrooke's 
Hospital 
Cambridge http://www.cuh.org.uk 
UK Wales Cardiff University Hospital of 
Wales 
Cardiff http://www.cardiffandvaleuhb.wales.nhs.uk 
UK England Coventry University Hospital Coventry http://www.uhcw.nhs.uk 
UK Scotland Edinburgh Royal Infirmary Edinburgh http://www.nhslothian.scot.nhs.uk 
UK Scotland Queen Elizabeth University 
Hospital Glasgow 
Glasgow http://www.nhsggc.org.uk 
UK England Leeds St James's University 
Hospital 
Leeds http://www.leedsth.nhs.uk 
UK England Royal Liverpool University 
Hospital 
Liverpool http://www.rlbuht.nhs.uk 
UK England Guy's Hospital London http://www.guysandstthomas.nhs.uk 
UK England St George's Hospital London https://www.stgeorges.nhs.uk 
UK England The Royal Free Hospital London https://www.royalfree.nhs.uk 
UK England The Royal London Hospital London http://bartshealth.nhs.uk 
UK England West London Renal and 
Transplant Centre 
London https://www.imperial.nhs.uk 
UK England Manchester Royal Infirmary Manchester http://www.cmft.nhs.uk 
UK England Newcastle Freeman Hospital Newcastle http://www.newcastle-hospitals.org.uk 
UK England Nottingham City Hospital Nottingham https://www.nuh.nhs.uk 
UK England Oxford Churchill Hospital Oxford http://www.ouh.nhs.uk 
UK England Plymouth Derriford Hospital Plymouth https://www.plymouthhospitals.nhs.uk 
UK England Sheffield Northern General 
Hospital 
Sheffield http://www.sth.nhs.uk 
UK England Other Leaflets from Sheffield Website http://www.sth.nhs.uk 
UK England Great Ormond Street Hospital London http://www.gosh.nhs.uk 
UK England Evelina London Children's 
Hospital (Guy's) 
London http://www.evelinalondon.nhs.uk 
UK England Leeds Children's Hospital Leeds http://www.leedsth.nhs.uk 
UK England Nottingham Children's Hospuital Nottingham http://www.emeesykidney.nhs.uk 
UK agency Organ Donation (part of NHS 
website) 
  https://www.organdonation.nhs.uk 
UK agency The Renal Association (link to 
PDF) 
  http://www.renal.org 
UK agency Give a Kidney   http://www.giveakidney.org 




UK agency NHS Choices   http://www.nhs.uk 
UK agency Kidney Research UK   https://www.kidneyresearchuk.org 
UK agency Living Kidney Donation   http://livingkidneydonation.co.uk 
UK agency Human Tissue Authority   https://www.hta.gov.uk 
Australia New South Wales John Hunter Hospital Newcastle http://www.hnehealth.nsw.gov.au 
Australia New South Wales Prince of Wales Hospital Sydney http://www.princeofwalesprivatehospital.com.au 
Australia New South Wales Royal North Shore Hospital Sydney http://www.nslhd.health.nsw.gov.au 
Australia New South Wales Statewide Renal Services ? https://www.health.qld.gov.au 
Australia New South Wales Sydney Childrens Hospital Sydney http://www.schn.health.nsw.gov.au 
Australia New South Wales The Childrens Hospital 
Westmead 
Sydney http://www.schn.health.nsw.gov.au 
Australia New South Wales Westmead Hospital Sydney http://www.wslhd.health.nsw.gov.au 
Australia Queensland Queensland Renal Transplant Service https://metrosouth.health.qld.gov.au 
Australia South Australia Central Northern Adelaide Renal http://www.sahealth.sa.gov.au 
Australia Victoria Alfred Hospital Melbourne https://www.alfredhealth.org.au 
Australia Victoria Austin Hospital Melbourne http://www.au 
Australia Victoria Monash Medical (Adults) Melbourne http://www.monashhealth.org 
Australia Victoria Monash Medical (Paediatric) Melbourne https://monashchildrenshospital.org 
Australia Victoria Royal Childrens Hospital  Melbourne http://www.rch.org.au 
Australia Victoria Royal Melbourne Hospital Melbourne https://www.thermh.org.au 
Australia Western Australia Fiona Stanley Hospital Perth http://www.fsh.health.wa.gov.au 
Australia Western Australia Sir Charles Gairdner Hospital Perth http://www.scgh.health.wa.gov.au 
Australia agency Kidney Health Australia http://kidney.org.au 
Australia agency Donate Life Australia http://www.donatelife.gov.au 
Australia agency Transplant Australia https://transplant.org.au 
Australia agency The Department of Health http://www.health.gov.au 
Australia agency Renal Resource Centre (ACI/Kidney Health Australia, PDF) https://www.aci.health.nsw.gov.au 
Australia agency ABC News (article) http://www.abc.net.au 
Australia agency The Conversation (article) http://theconversation.com 
Australia agency Organ Donation and Transplant Foundation of WA http://www.odatwa.org 





Appendix C: List of Participating Centres 
Canadian transplant centres 
Dr. Amit X Garg 
London Health Sciences Centre 
London Ontario, N6A5W9 
 Dr. Christine Dipchand 
Queen Elizabeth II 
Halifax, Nova Scotia, B3H 2Y9 
   
Dr. Liane Feldman 
Royal Victoria Hospital 
Montreal, Quebec, H4A 3J1 
 Dr. Greg Knoll 
Ottawa General Hospital 
Ottawa, Ontario, K1H 8L6 
   
Dr. Darin Treleaven 
St. Joseph’s Hospital 
Hamilton, Ontario, L8N 4A6 
 Dr. Ramesh Prasad 
St. Michael’s Hospital 
Toronto, Ontario, M5B 1W8 
   
Dr. Charmaine Lok 
University Health Network 
Toronto, Ontario, M5G 2C4 
 Drs. Martin Karpinski and Leroy Storsley 
Winnipeg Health Sciences Centre 
Winnipeg, Manitoba, R3A 1R9 
   
Dr. Mauricio Monroy-Cuadros 
Foothills Medical Centre 
Calgary, Alberta, T2N 2T9 
 Dr. Scott Klarenbach 
University of Alberta 
Edmonton, Alberta, T6G 2R3 
   
Dr. Chris Nguan 
Vancouver General Hospital 
Vancouver, British Columbia, V5Z 1M9 
  
   
   
Australian transplant centres (these centres were combined due to sample size) 
Dr. Neil Boudville 
On behalf of 
Monash Medical Centre Clayton, Clayton, Victoria, 3168 
Fremantle Hospital, Fremantle, Western Australia, 6160 
Royal Perth Hospital, Perth, Western Australia, 6000 
Sir Charles Gairdner Hospital, Nedlands, Perth, Westeran Australia, 6009 











Appendix E: List of first and last procedures per donor 
 Number (%) 
Procedure First contact* Approval* 
Intermediate assessment 353 (28%) 90 (7%) 
Biochemistry 175 (14%) – 
Cytology 152 (12%) – 
General consult 138 (11%) – 
Chest x-ray 109 (9%) – 
   
Electrocardiography  96 (8%) – 
Urinalysis  54 (4%) – 
Counselling/psychiatry 50 (4%) 74 (6%) 
Immunohematology  43 (3%) – 
Ultrasound 35 (3%) – 
   
Nuclear medicine 27 (2%) – 
Surgery/urology consult – 913 (73%) 
Nephrology consult – 129 (10%) 
Computed tomography 24 (2%) – 
Cardiac evaluation – 23 (2%) 
   
General surgery consult – 14 (1%) 
Hematology consult – <6 (0%) 
Pathology – <6 (0%) 
Gastroenterology – <6 (0%) 
Neurology – <6 (0%) 
   
Respirology – <6 (0%) 
Endocrinology – 0 (0%) 
Musculoskeletal consult – 0 (0%) 
Rheumatology – 0 (0%) 
   
Echocardiography – – 
Stress test – – 
Plastic surgery – – 
Pulmonary function – – 
*visits not allowed to be a first contact date or approval 











 Title 1 (a) Indicate the study’s design with a commonly used term in 
the title  
Title page 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Background 
Objectives 3 State specific objectives, including any prespecified hypotheses Background 
Methods  
Study design 4 Present key elements of study design early in the paper Methods 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Methods 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Methods 
(b) For matched studies, give matching criteria and number of 
exposed and unexposed 
N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 





8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group 
Methods 
Bias 9 Describe any efforts to address potential sources of bias Methods 
Study size 10 Explain how the study size was arrived at N/A 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
Methods 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Methods 
(b) Describe any methods used to examine subgroups and 
interactions 
Methods 
(c) Explain how missing data were addressed Methods 
(d) If applicable, explain how loss to follow-up was addressed N/A 
(e) Describe any sensitivity analyses N/A 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-





(b) Give reasons for non-participation at each stage N/A 
(c) Consider use of a flow diagram N/A 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Table 8 
(b) Indicate number of participants with missing data for each 
variable of interest 
Table 8, 
Results  
(c) Summarise follow-up time (eg, average and total amount) Table 8, 
Results 




Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
Table 9- 
Table 13 




(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Table 11 
Discussion  
Key results 18 Summarise key results with reference to study objectives Discussion 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 






Appendix G: STROBE Checklist of items that should be included in reports of 
cohort studies 
 Item  Recommendation Section 
 Title 1 (a) Indicate the study’s design with a commonly used term in 
the title  
Title page 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Background 
Objectives 3 State specific objectives, including any prespecified hypotheses Background 
Methods  
Study design 4 Present key elements of study design early in the paper Methods 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Methods 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Methods 
(b) For matched studies, give matching criteria and number of 
exposed and unexposed 
N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 







8  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group 
Methods 
Bias 9 Describe any efforts to address potential sources of bias N/A 
Study size 10 Explain how the study size was arrived at N/A 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
Methods 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
Methods 
(b) Describe any methods used to examine subgroups and 
interactions 
Methods 
(c) Explain how missing data were addressed Methods 
(d) If applicable, explain how loss to follow-up was addressed N/A 
(e) Describe any sensitivity analyses N/A 
Results  
Participants 13 (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-








(c) Consider use of a flow diagram Figure 1 
Descriptive data 14 (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
Table 1 
(b) Indicate number of participants with missing data for each 
variable of interest 
Table 1 
(c) Summarise follow-up time (eg, average and total amount) Figure 2, 
Tables 2-3 




Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
Tables 2-3, 
Appendix 6 




(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 




Key results 18 Summarise key results with reference to study objectives Discussion 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion  
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 
Discussion 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 







Appendix H: List of OHIP and CIHI codes for dialysis status and comorbidity 




OHIP Feecodes "R849" "G323" "G336" "G325" "G326" "G860" "G862" 
"G863" "G865" "G866" "R825" "R826" "R827" "R833" 
"R840" "R851" "G330" "G331" "G332" "G861" "G864" 
"R852" "G082" "G083" "G085" "G090" "G091" "G092" 
"G093" "G094" "G095" "G096" "G294" "G295" "G333" 
"H540" "H740" 
CIHI ICD-9 "V451" "V560" "V568" "36104" 
ICD-10 "T824" "Y602" "Y612" "Y622" "Y841" "Z49" "Z992" 
"N180" "E1022" "E1023" "E1122" "E1123" "E1322" 
"E1323" "E1422" "E1423" 
procedure codes "5127" "5195" "6698" 
intervention 
codes 
"7SC59QD" "1KY76" "1PZ21" 
Hypertension 
OHIP diagnosis codes "401" "402" "403" "404" "405" 
CIHI ICD-9 "401" "402" "403" "404" "405" 
ICD-10 "I10" "I11" "I12" "I13" "I15" 
Cancer 
OHIP diagnosis codes "140" "141" "142" "143" "144" "145" "146" "147" 
"148" "149" "150" "151" "152" "153" "154" "155" 
"156" "157" "158" "159" "160" "161" "162" "163" 
"164" "165" "170" "171" "172" "173" "174" "175" 
"179" "180" "181" "182" "183" "184" "185" "186" 
"187" "188" "189" "190" "191" "192" "193" "194" 
"195" "196" "197" "198" "199" "200" "201" "202" 
"203" "204" "205" "206" "207" "208" 
CIHI ICD-9 "V10" "140" "141" "142" "143" "144" "145" "146" 
"147" "148" "149" "150" "151" "152" "153" "154" 
"155" "156" "157" "158" "159" "160" "161" "162" 
"163" "164" "165" "170" "171" "172" "173" "174" 
"175" "176" "179" "180" "181" "182" "183" "184" 
"185" "186" "187" "188" "189" "190" "191" "192" 
"193" "194" "1950" "1951" "1952" "1953" "1954" 
"1955" "1958" "196" "197" "198" "1990" "1991" 
"2000" "2001" "2002" "2008" "2010" "2011" "2012" 
"2014" "2015" "2016" "2017" "2019" "2020" "2026" 
"2028" "2029" "203" "204" "205" "206" "207" "208" 
"230" "231" "232" "233" "234" 
ICD-10 "80003" "80006" "80013" "80023" "80033" "80043" 
"80102" "80103" "80106" "80113" "80123" "80203" 
"80213" "83123" "87202" "87203" "959" "965" "966" 
"967" "968" "969" "970" "971" "980" "982" "984" 
"985" "986" "987" "988" "989" "990" "991" "993" 
"C00" "C01" "C02" "C03" "C04" "C05" "C06" "C07" 
"C08" "C09" "C10" "C11" "C12" "C13" "C14" "C15" 
"C16" "C17" "C18" "C19" "C20" "C21" "C22" "C23" 
"C24" "C25" "C26" "C30" "C31" "C32" "C33" "C34" 
"C37" "C38" "C39" "C40" "C41" "C43" "C44" "C45" 
"C46" "C47" "C48" "C49" "C50" "C51" "C52" "C53" 
"C54" "C55" "C56" "C57" "C58" "C60" "C61" "C62" 
"C63" "C64" "C65" "C66" "C67" "C68" "C69" "C70" 
"C71" "C72" "C73" "C74" "C75" "C76" "C77" "C78" 
"C79" "C80" "C81" "C82" "C83" "C84" "C85" "C90" 
"C91" "C92" "C93" "C94" "C95" "C96" "C97" "D00" 




"Z434" "R742" "R743" "N220" "R792" "R802" "R816" 
"R817" "R783" "R784" "R785" "R814" "R787" "R780" 
"R797" "R804" 
CIHI ICD-9 "39" "40" "41" "42" "43" "44" "45" 
ICD-10 "I" 
procedural codes "4802" "4803" "4809" "481" "5024" "5034" "5125" 






CIHI ICD-9 "285" 
ICD-10 "D509" 
Ischemic heart disease/coronary artery disease 
ICD-9 "414" 
ICD-10 "I120" "I121" "I122" "I123" "I124" 
"I125" 
Diabetes 
OHIP fee codes "K045" " K046" " K029" " K030" " Q040" 
CIHI ICD-9 "250" 
ICD-10 "E10" "E11" "E13" "E14" 
Anxiety/depression 
OHIP diagnostic codes "311" 
CIHI ICD-9 "2962" "2963" "2966" "3000" "3002" "3003" "3004" 
"309" "311" 
ICD-10 “F063" "F064" "F204" "F313" "F314" "F315" "F32" 
"F33" "F341" "F400" "F401" "F402" "F408" "F409" 
"F410" "F411" "F412" "F413" "F418" "F419" "F420" 
"F421" "F422" "F428" "F429" "F430" "F431" "F432" 
Heart failure 
OHIP Fee codes "R701" "R702" "Z429" 
diagnostic codes "428" 
CIHI ICD-9 "425" "5184" "514" "428" 
ICD-10 "I099" "I420" "I425" "I426" "I427" "I428" "I429" 
"I43" "I500" "I501" "I509" "I255" "J81" 
procedure codes "4961" "4962" "4963" "4964" 
intervention 
codes 
"IHP53" "IHP55" "1HZ53GRFR" "1HZ53LAFR" "1HZ53SYFR" 
OHIP – Ontario Health Insurance Plan; CIHI – Canadian Institute for Health Information (same-day surgery and 
discharge abstract database); ICD – International Statistical Classification of Diseases and Related Health Problems 






Appendix I: Characterizing the living donor evaluation process 
 
We captured all OHIP physician and laboratory billings for up to four years prior to 
donation (1826 unique billing codes) and obtained the description for each billing code. 
Based on these descriptions and prior validation studies, we grouped these codes into 
procedures based on a priori judgement (Step I in Table below). We categorized 
remaining billing codes (observed >5 times for privacy requirements) based on the 
descriptions (Step II in Table below). We then assigned general billing codes to a 
procedure based on the main speciality of the billing physician (obtained from the ICES 
Physician Database, IPDB) (Step III in Table below). We then assigned remaining 
general billing codes to a procedure based on other procedures performed on the same 
day (Step IV in Table below). Next, we combined similar procedures into a single 
category (Step V in Table below). Finally, we considered similar procedures performed 
on the same day to belong to a single category if we believed the procedures were related 
(i.e., we combined a billing code categorized as “pain management” on the same day as a 
billing code categorized as “anesthesia” as “anesthesia”) (Step VI in Table below). 
In order to identify the date of first contact (the date the donor started the evaluation), we 
set up specific rules independent of the data to decide which procedures would be 
considered part of the living donor evaluation process. For example, all nephrology 
consults and nuclear medicine exams were considered part of the evaluation since a 
healthy non-donor would be unlikely to have these billed if not part of the evaluation. 
Any procedure performed within 14 days of donation was considered part of the pre-
admission visit and not a unique procedure in its own right (i.e., a nephrology consult 
during this time is likely not the main nephrology consult). The only exception to this 
rule is the surgical consult, which is allowed by some transplant programs to occur this 
late in the evaluation process. We provide the full list of rules in Appendix J. 
Step I – procedures defined a priori (n=1726) 
Procedure OHIP billing codes 
Nephrectomy 'S411', 'S423', 'S413', 'S415', 'S416', 'S420', 'S421', 'S436', 
'E694', 'E753', 'E766', 'E767', 'E768', 'E792', 'S412' 
Stress test 'G315', 'G174', 'G111', 'G112', 'G319', 'G582', 'G583', 'G584', 
'J607', 'J608', 'J807', 'J808', 'J809', 'J866', 'J609', 'J666' 
Urinalysis 'L253', 'L254', 'L633', 'L641', 'G001', 'G002', 'G003', 'G004', 
'G481', 'G006', 'G007', 'G008', 'G009', 'G010' 
Biochemistry 'L065', 'L067', 'L068', 'L204', 'L226', 'L004', 'L005', 'L111', 




Renal biopsy 'Z601', 'E820' 
Ultrasound 'J128', 'J135', 'J138', 'J162', 'J163', 'J428', 'J435', 'J438', 
'J462', 'J463', 'J205', 'J505' 
Nephrology consult 'A135', 'A136', 'A138', 'A435', 'C435', 'C135', 'C136', 'A133', 
'A134', 'A131', 'C133', 'C134', 'C131', 'A161', 'A163', 'A164', 
'A165', 'A166', 'A168', 'C132', 'C137', 'C139', 'C101', 'C138', 
'G860', 'G323', 'G333', 'E083', 'H540' 
Urology consult 'A355', 'A356', 'A935', 'A353', 'A354', 'C355', 'C356', 'C935', 
'C353', 'C354' 
Echocardiography 'G560', 'G561', 'G562', 'G566', 'G567', 'G568', 'G570', 'G571', 
'G572', 'G574', 'G575', 'G576', 'G577', 'G578', 'G581' 
Counselling 'K013', 'K014', 'K033', 'K040', 'K041' 
Surgery consultation 'A095', 'A096', 'A935', 'A093', 'A094', 'C095', 'C096', 'C935', 
'C093', 'C094', 'C033', 'C034', 'A033', 'A034', 'A036', 'C035', 'C036' 
Glucose tolerance test 'G498', 'L104' 
Immunohematology 'L471', 'L482', 'L473', 'L490', 'L492', 'L493', 'L494', 'L495' 
Histocompatibility test 'L582', 'L581', 'L583', 'L580' 
Chest x-ray 'X090', 'X091', 'X092' 
CT 'X231', 'X232', 'X233', 'X126', 'X409', 'X410' 
MRI 'X451', 'X461' 
Pyelogram 'X129', 'X130', 'X138' 
Cystoscopy 'Z606', 'Z607' 
Cancer screen (pap) 'G365', 'G394', 'E430', 'L812', 'L713' 
Cancer screen (breast) 'X184', 'X185', 'X186', 'X187', 'X172', 'X178','Z139','Z143' 
Cancer screen (PSA) 'L354', 'L358' 
Cancer screen (FOBT) 'Q150A', 'Q005A', 'Q118A', 'Q119A', 'Q120A', 'Q121A', 'Q122A' 'Q123A', 




'A015', 'A016', 'C015', 'C016', 'A903' 
SUBTOTALS 1726 donors, 1826 unique billing codes, 215,363 rows 
Delete any feecodes that occur <6 times in the cohort 
SUBTOTALS 1726 donors, 777 unique billing codes, 211,942 rows 
  
 
Step II – categorize remaining billing codes not yet assigned after Step I above (n=1726) 
Group A – billing codes that will be discarded later (not relevant to donation) but retained for the 
present (may be needed to explain other codes; for example, a biochemistry test performed on the same 
day as an emergency medicine visit is likely due to the emergency medicine visit, and not the donor 
evaluation) 






STD counselling 'K028' 
Biochemistry 'G871','G872','L718','L719' 









Emergency medicine 'K963','K996','Q090' 










to Ministry of 
Transportation 
'K035' 
MRI (other) 'X421','X425','X471','X475','X490','X492','X493','X495' 
Some paediatric code 'A261','A263','A264','A265' 
Sleep study 'J690','J889','J890','J895','J896' 








Group B – lab tests referred to under the umbrella of “biochemistry” 















Group C – other codes deemed relevant and either started a new procedure category or merged in with 
Step I above 


























General consult 'A001','A003','A004','A005','C003','C004','C933','K131' 














Nephrology consult 'A160','C162','C165','C166' 
Neurology evaluation 'A185','A188','G414','G418','G544','A044','A045' 













Physical medicine 'A315','A318','G455','G456','G457','G466','G999','H312' 
Plastic surgery 'A083','A084','A085' 














Urology consult 'C352','G193','G475','G476','G900' 
Bone mineral density 
test 
'X146','X153','X155' 
Birth control surgery 'S626' 
Home visit 'A901','B994' 
Travel reimbursement 'K036' 
 
Group D – cancer screening codes 
Procedure OHIP codes 
Colorectal 'Q005','Q133','Q142' 
Fecal occult blood test 'Q150' 
Breast 'Q002','Q131','R111','X201','J427','J127' 
Papanicolaou test 'Q001','Q011','Q140' 
 
Step III – categorize remaining billing codes not yet assigned after Step II using the main specialty 
associated with the usage of that code (n=1726) 
OHIP codes Procedure (using main specialty) 
'E082' gastroenterology, urology, nephrology, respirology, 
orthopaedic, general surgery consult, general consult, internal 
medicine 












'Z611' Ob/gyn, otolaryngology 
'A888' General consult 
'A603','A604' Cardiac evaluation 
Any code Nephrectomy (if on donation date) 
 
Step IV – generic billing codes that will be assigned using any procedure already defined on the 
same day (i.e., a general code on the same day as a cardiac evaluation will be considered part of that 
cardiac evaluation) (n=1726) 









NOTE: the first part of this table was repeated in case there was >1 generic code on the same day – 
 
Step V – combining similar procedures (n=1726) 
Rule Procedure 
Nephrectomy codes the day before donation was assigned the donation date Nephrectomy 
Surgeon consult + urology consult Surgeon/ 
urology consult 
Counselling + psychiatry Counselling/ 
psychiatry 
NOTE: The same procedures on the same day are combined (rows are merged) and the 
total costs for the same procedure on the same day are summed 
– 
NOTE: Cancer screening tests are removed from dataset if they occurred >1 year before 
any other test 
– 
 
Step VI – combining similar procedures if done on the same day (n=1403) 
Procedure 1 (to be combined with [renamed as] 
Procedure 2) 
Procedure 2 
Pain management Anesthesia 
CT (discard) CT 
MRI (discard) MRI 
Dermatology Skin lesion 
Diagnostic ultrasound of face Ultrasound 
  
Pulmonary function Allergies (discard) 
Pulmonary function Respirology 
Pulmonary function Smoking cessation 





Smoking cessation General consult 
Smoking cessation Intermediate assessment 
  
Intermediate assessment Gastroenterology 
Intermediate assessment Cardiac evaluation 
Intermediate assessment Pulmonary function 
Intermediate assessment Ophthalmology 
Intermediate assessment Obstetrics/gynaecology 
Intermediate assessment Otology/laryngology 
Intermediate assessment Sclerotherapy 
Intermediate assessment Pathology 




Obstetrics/gynaecology Cancer screen (pap) 
Plastic surgery Skin lesion 
Plastic surgery Orthopaedic 
Plastic surgery Cancer screen (breast) 
Diagnostic radiology Ultrasound 
  
Anaesthesiology Sports medicine/physical medicine (discard) 
Orthopaedic Sports medicine/physical medicine (discard) 
Physical medicine Sports medicine/physical medicine (discard) 
Plastic surgery Sports medicine/physical medicine (discard) 
Pain management Sports medicine/physical medicine (discard) 
  
Sleep study (discard) Cardiac evaluation 
  
Fecal occult blood test Cancer screen (colorectal) 
Gastroenterology Cancer screen (colorectal) 
Anaesthesiology Cancer screen (colorectal) 
Cytology Cancer screen (colorectal) 
Intermediate assessment Cancer screen (colorectal) 
  
Pathology Infectious disease consult 
Pathology Cancer screen (pap) 
Pathology Cancer screen (breast) 
Pathology Cancer screen (colorectal) 





Pathology Skin lesion 
  
Respirology Otology/laryngology 
General consult Cancer screen (pap) 
Cytology Cancer screen (pap) 
General consult Cancer screen (colorectal) 
General consult Cancer screen (breast) 




General consult Birth control surgery (discard) 
Anaesthesiology Birth control surgery (discard) 
Intermediate assessment Birth control surgery (discard) 
  
Diagnostic radiology Cancer screen (breast) 
Diagnostic radiology Cancer screen (colorectal) 
Diagnostic radiology Renal biopsy 
Diagnostic radiology Ultrasound 
Diagnostic radiology Chest x-ray 
Diagnostic radiology Diagnostic ultrasound of face (discard) 
Diagnostic radiology Other surgical radiology (discard) 
Diagnostic radiology Sports medicine (discard) 
Diagnostic radiology Emergency medicine (discard) 
Diagnostic radiology Bone mineral density test 
  
Intermediate assessment Cardiac evaluation 
Intermediate assessment Surgeon/urology consult 
Intermediate assessment Nephrology consult 
Intermediate assessment Counselling/psychiatry 
Intermediate assessment General surgery consult 
Intermediate assessment Neurology 
Intermediate assessment Anaesthesiology 
Intermediate assessment Orthopaedic 
Intermediate assessment Obstetrics/gynaecology 
Intermediate assessment Otology/laryngology 
Intermediate assessment Home visit 
Intermediate assessment Physical medicine 
Intermediate assessment Pain management 
Intermediate assessment Rheumatology 
Intermediate assessment Respirology 
  
Any procedure <14 days prior to donation (except 
Surgeon/urology consult) 
Pre-admission 
Any procedure (verified through quality checks) Fracture/casting 
Any procedure (verified through quality checks) Cholecystectomy 
Any procedure (verified through quality checks) General eye care (discard) 
Any procedure (verified through quality checks) Some paediatric code (discard) 







Appendix J: Steps to identify donor’s point of first contact 
Rules to keep visit Procedures where rules are applied 
No rules (all are kept) Nephrology consults 
Last visit (i.e., most recent before nephrectomy) Surgery/urology consult, preadmission 
No rules (all are kept) Nuclear medicine 
4 months before nephrology consult or anytime 
thereafter 
Cardiac evaluation 
±6 months of any nephrology consult or 
surgeon/urology consult 
- Lab tests (urinalysis, biochemistry test, 
cytology, immunohematology) 
- Diagnostic tests (CT, ultrasound, 
echocardiography, ECG, MRI, chest x-ray, 
stress test, pulmonary function, pyelogram) 
- Consults (general consult, intermediate 
assessment, counselling/psychiatry, 
gastroenterology, surgery/urology consult, 
renal biopsy, cystoscopy, endocrinology, 
hematology, musculoskeletal, neurology, 
pathology, plastic surgery, respirology, 
rheumatology) 
±6 months of any nephrology consult or 
surgeon/urology consult AND associated with a 
physician who previously billed a code related to 
donation or a surgeon/urology consult 
General surgeon consult 
Within 30 days before a previously retained 
procedure 
Counselling/psychiatry, cardiac evaluation 
Within 1 year of nephrectomy Cancer screen (pap, breast) 
Within 3 years of nephrectomy Cancer screen (colorectal) 
  
Rules to delete visit  
No rules (all remaining are discarded) All procedures not kept (as per the above rules) 
If the first test is this procedure, this is deleted 
since this was likely done for another reason (i.e., 
the evaluation should not start with a cancer screen, 
a specialist consultation, etc) (repeated 8× until this 
was no longer observed) 












Appendix L: Specific transitions used in scenario analysis 
 N 
Transition time (days) 
median (IQR) mean (SD) 
Transition times between major consults (nephrology, surgery, psychosocial) – 
for Scenarios 3 and 4a  
Nephrology to surgery 315 23 (3, 66) 45.0 (56.9) 
Counselling to surgery 136 3 (0, 18) 13.8 (26.7) 
Nephrology to counselling 189 0 (0, 14) 14.6 (53.0) 
Surgery to nephrology 80 19 (7, 41) 45.6 (87.6) 
Counselling to nephrology 65 13 (6, 23) 38.2 (99.9) 
Surgery to counselling 36 12 (2, 22) 19.4 (26.8) 
    
Transition times from various major medical consults (nephrology, surgery) to 
a cardiology consult – for Scenario 5a 
Nephrology 43 7 (0, 84) 66.7 (114) 
Surgery 7 16 (3, 45) 69.4 (140) 
    
Transition times from various procedures to a nuclear medicine exam – for 
Scenario 6a,b 
Biochemistry 147 21 (7, 41) 29.4 (28.9) 
Computed tomography 102 7 (3, 13) 17.1 (73.8) 
Chest x-ray 100 7 (2, 18) 14.8 (19.3) 
Intermediate assessment 80 17 (8, 34) 42.7 (100) 
Nephrology 65 20 (8, 29) 33.9 (61.5) 
Stress test 46 0 (0, 0) 0.10 (0.70) 
Electrocardiogram 43 12 (5, 36) 26.7 (48.9) 
Ultrasound 41 0 (0, 6) 7.80 (20.3) 
Cardiology consult 29 7 (6, 20) 29.5 (78.8) 
Counselling 28 16 (5, 32) 23.9 (26.6) 
Surgical consult 27 13 (1, 27) 16.0 (15.3) 
General consult 26 20 (13, 40) 41.8 (60.5) 
Pulmonary function test 25 0 (0, 0) 0.40 (1.70) 
Echocardiography 20 7 (4, 11) 8.80 (8.60) 
Cervical cancer screen 20 7 (4, 19) 14.3 (16.7) 
Nuclear exam 13 22 (8, 49) 25.4 (22.1) 
Colorectal cancer screen 11 18 (3, 130) 59.1 (71.5) 
Cytology 10 33 (18, 41) 38.9 (29.2) 
Breast cancer screen 9 8 (6, 11) 11.6 (10.2) 
a also used for scenarios 1-2 
b nuclear renogram not restricted to a test of total glomerular filtration rate or split 
function 
Mean and median estimates of transition times were tabulated for all donors who 
donated a kidney after March 2004 (n=1256), using a list of procedures deemed 
relevant to the evaluation process. 





Appendix M: Codes for exclusion of potential healthy non-donor controls for 
matching 
Database Type of code Codes 
Dialysis 
OHIP Feecodes 
"R849" "G323" "G336" "G325" "G326" "G860" "G862" "G863" 
"G865" "G866" "R825" "R826" "R827" "R833" "R840" "R851" 
"G330" "G331" "G332" "G861" "G864" "R852" "G082" "G083" 
"G085" "G090" "G091" "G092" "G093" "G094" "G095" "G096" 
"G294" "G295" "G333" "H540" "H740" 
CIHI 
ICD-9 "V451" "V560" "V568" "36104" 
ICD-10 
"T824" "Y602" "Y612" "Y622" "Y841" "Z49" "Z992" "N180" 
"E1022" "E1023" "E1122" "E1123" "E1322" "E1323" "E1422" 
"E1423" 
procedure codes "5127" "5195" "6698" 
intervention 
codes 
"7SC59QD" "1KY76" "1PZ21" 
Hypertension 
OHIP diagnosis codes "401" "402" "403" "404" "405" 
CIHI 
ICD-9 "401" "402" "403" "404" "405" 
ICD-10 "I10" "I11" "I12" "I13" "I15" 
Cancer 
OHIP diagnosis codes 
"140" "141" "142" "143" "144" "145" "146" "147" "148" 
"149" "150" "151" "152" "153" "154" "155" "156" "157" 
"158" "159" "160" "161" "162" "163" "164" "165" "170" 
"171" "172" "173" "174" "175" "179" "180" "181" "182" 
"183" "184" "185" "186" "187" "188" "189" "190" "191" 
"192" "193" "194" "195" "196" "197" "198" "199" "200" 
"201" "202" "203" "204" "205" "206" "207" "208" 
CIHI 
ICD-9 
"V10" "140" "141" "142" "143" "144" "145" "146" "147" 
"148" "149" "150" "151" "152" "153" "154" "155" "156" 
"157" "158" "159" "160" "161" "162" "163" "164" "165" 
"170" "171" "172" "173" "174" "175" "176" "179" "180" 
"181" "182" "183" "184" "185" "186" "187" "188" "189" 
"190" "191" "192" "193" "194" "1950" "1951" "1952" 
"1953" "1954" "1955" "1958" "196" "197" "198" "1990" 
"1991" "2000" "2001" "2002" "2008" "2010" "2011" "2012" 
"2014" "2015" "2016" "2017" "2019" "2020" "2026" "2028" 
"2029" "203" "204" "205" "206" "207" "208" "230" "231" 
"232" "233" "234" 
ICD-10 
"80003" "80006" "80013" "80023" "80033" "80043" "80102" 
"80103" "80106" "80113" "80123" "80203" "80213" "83123" 
"87202" "87203" "959" "965" "966" "967" "968" "969" 
"970" "971" "980" "982" "984" "985" "986" "987" "988" 
"989" "990" "991" "993" "C00" "C01" "C02" "C03" "C04" 
"C05" "C06" "C07" "C08" "C09" "C10" "C11" "C12" "C13" 
"C14" "C15" "C16" "C17" "C18" "C19" "C20" "C21" "C22" 
"C23" "C24" "C25" "C26" "C30" "C31" "C32" "C33" "C34" 
"C37" "C38" "C39" "C40" "C41" "C43" "C44" "C45" "C46" 
"C47" "C48" "C49" "C50" "C51" "C52" "C53" "C54" "C55" 
"C56" "C57" "C58" "C60" "C61" "C62" "C63" "C64" "C65" 
"C66" "C67" "C68" "C69" "C70" "C71" "C72" "C73" "C74" 
"C75" "C76" "C77" "C78" "C79" "C80" "C81" "C82" "C83" 
"C84" "C85" "C90" "C91" "C92" "C93" "C94" "C95" "C96" 






"Z434" "R742" "R743" "N220" "R792" "R802" "R816" "R817" 
"R783" "R784" "R785" "R814" "R787" "R780" "R797" "R804" 
CIHI 
ICD-9 "39" "40" "41" "42" "43" "44" "45" 
ICD-10 "I" 
procedural codes "4802" "4803" "4809" "481" "5024" "5034" "5125" 
intervention 
codes 
"1IJ50" "1IJ76" "1KA76" "1KG76" 
Human immunodeficiency virus 





ICD-9 "042" "043" "044" "V08" "176" 
ICD-10 "B24" "C46" "Z21", 
Nephrectomy 
OHIP feecodes 
"E762" "S435" "E769" "S434" "E771" "Z631" "G347" "G348" 
"G412" "G408" "G409" 
CIHI 
ICD-9 "V420" "99681" 
ICD-10 "T861" "N165" "Z940" 





OHIP feecodes "Z601", 
CIHI 
























ICD-10 "M05" "M06" 
Genitourinary disease 
CIHI 




ICD-9 "303" "3050" 
ICD-10 
"E24" "E512" "F10" "G312" "G621" "G721" "I426" "K292" 
"K70" "K860" "T510" "X45" "X65" "Y15" "Y573" "Z502" 
"Z714" "Z721" 
OHIP – Ontario Health Insurance Plan; CIHI – Canadian Institute for Health Information (same-day surgery and 
discharge abstract database); ICD – International Statistical Classification of Diseases and Related Health Problems 






Appendix N: Healthcare utilization patterns of the most common procedures 
determined from OHIP billing codes 
 
Quantity utilized by living donors who started the evaluation as early as March 31, 
2000 until 1-year follow-up post-donation, entire cohort 
 Evaluation period Perioperative period Follow-up period 
Procedure N (%) mean (SD)a N mean (SD)a N mean (SD)a 
Number of donorsb 1256 (100%) – 1240 (99%) – 1223 (97%) – 
       
Nephrology consult 1256 (100%) 1.91 (1.74) 483 (40%) 4.17 (3.98) 935 (76%) 2.03 (1.70) 
Surgery/urology consult 1256 (100%) 1.40 (1.00) 842 (70%) 2.80 (2.15) 790 (65%) 1.28 (0.76) 
Chest x-ray 1210 (96%) 1.40 (0.70) 164 (14%) 2.24 (2.19) 119 (10%) 3.18 (2.71) 
Electrocardiogram 1177 (94%) 1.61 (0.98) 88 (7%) 1.69 (1.08) 149 (12%) 3.38 (2.72) 
Computed tomography 1163 (93%) 1.08 (0.30) 33 (3%) 2.76 (1.12) 50 (4%) 2.26 (1.10) 
       
Biochemistry (bloodwork) 1038 (83%) 3.32 (2.20) 118 (10%) 5.11 (6.96) 921 (75%) 11.7 (11.3) 
Cytology 1061 (84%) 3.34 (2.18) 228 (19%) 1.67 (1.43) 967 (79%) 3.51 (2.82) 
Urinalysis 954 (76%) 2.55 (2.53) 103 (9%) 1.67 (0.96) 640 (52%) 2.47 (2.18) 
Intermediate assessment 890 (71%) 3.44 (3.36) 434 (36%) 1.37 (0.67) 817 (67%) 3.25 (2.93) 
Ultrasound 875 (70%) 1.42 (0.79) 91 (8%) 2.47 (1.70) 242 (20%) 4.28 (2.83) 
Nuclear medicine 805 (64%) 1.12 (0.37) 0 (0%) – <6 (<1%) – 
       
General consult 646 (51%) 2.19 (2.09) 159 (13%) 1.20 (0.43) 524 (43%) 1.94 (1.70) 
Echocardiogram 578 (46%) 1.09 (0.31) <6 (<1%) – 14 (1%) 4.36 (1.08) 
Cardiology evaluation 527 (42%) 1.89 (1.43) 47 (4%) 1.53 (1.69) 186 (15%) 1.81 (1.33) 
Stress test 498 (40%) 1.11 (0.33) <6 (<1%) – 13 (1%) 3.54 (2.96) 
Counseling/psychiatry 486 (39%) 2.42 (4.81) 60 (5%) 1.23 (0.62) 193 (16%) 3.39 (6.97) 
Cancer screen (pap) 401 (32%) 1.64 (0.64) <6 (<1%) – 235 (19%) 2.62 (1.18) 
       
Immunohematology test 397 (32%) 1.07 (0.27) 0 (0%) – 15 (1%) 2.73 (1.49) 
Cancer screen (breast) 243 (19%) 1.23 (0.52) <6 (<1%) – 118 (10%) 2.57 (1.60) 
Pulmonary function test 224 (18%) 1.09 (0.38) <6 (<1%) – 32 (3%) 6.66 (6.18) 
Cancer screen (colorectal) 207 (16%) 1.51 (0.93) <6 (<1%) – 57 (5%) 1.18 (0.54) 
General surgery consult 111 (9%) 1.22 (0.68) 52 (4%) 2.02 (1.32) 55 (4%) 1.67 (1.50) 
Cystoscopy 78 (6%) 1.03 (0.16) <6 (<1%) – 10 (1%) 1.10 (0.32) 
       
Magnetic resonance 67 (5%) 1.15 (0.40) <6 (<1%) – 29 (2%) 2.62 (2.27) 
Gastroenterology consult 67 (5%) 1.28 (0.57) 29 (2%) 1.21 (0.49) 69 (6%) 3.96 (2.36) 
Renal biopsy 54 (4%) 1.02 (0.14) 0 (0%) – 0 (0%) – 
Pathology consult 39 (3%) 1.05 (0.22) <6 (<1%) – 57 (5%) 2.05 (0.93) 
Pyelogram 31 (2%) 1.03 (0.18) 0 (0%) – 0 (0%) – 
Hematology consult 30 (2%) 1.57 (1.04) <6 (<1%) – <6 (<1%) – 
       
Neurology consult 27 (2%) 1.37 (0.84) <6 (<1%) – 15 (1%) 1.60 (1.55) 
Plastic surgery consult 26 (2%) 2.15 (1.32) <6 (<1%) – 20 (2%) 2.40 (1.93) 
Respirology consult 21 (2%) 1.57 (0.93) <6 (<1%) – 35 (3%) 1.60 (1.26) 
Endocrinology consult 13 (1%) 1.08 (0.28) 0 (0%) 0 (–) <6 (<1%) – 
Musculoskeletal consult 10 (1%) 1.10 (0.32) 0 (0%) 0 (–) <6 (<1%) – 
Rheumatology consult 8 (1%) 1.38 (0.52) 0 (0%) 0 (–) <6 (<1%) – 
costs presented only for more common procedures (present in >10% of donors) 
a mean (standard deviation, SD) number of procedures per donor, restricted to those who had the procedure during the specified 
period of coverage. 
b restricted to donors with an OHIP billing code in the specified period 






Appendix O: Healthcare utilization patterns 
 
Evaluation period 
Common consultations: Several donors had more than one nephrology [mean 1.93 (SD 
1.74)] and surgery [mean 1.40 (SD 1.00)] consultation. Other common consultations 
included intermediate assessments (a detailed donor examination performed by a 
physician in a family practice or pediatric services), which were utilized by 71% of 
donors during the evaluation period, general consultations (51%), cardiology 
consultations (42%), a psychosocial assessment (39%), and a general surgery 
consultation (9%).  
Preliminary and diagnostic tests: Chest x-ray, electrocardiography and computed 
tomography (CT) exams were used by at least 93% of donors. With respect to laboratory 
tests, cytology, biochemistry and urinalysis was used by 76-83% of donors. A nuclear 
medicine exam was used by 64% of donors. CT and nuclear renograms were repeated 
infrequently: mean 1.08 (SD 0.30) and 1.12 (SD 0.37) exams per donor.  
Other diagnostic tests and consultations: Cancer screening was used by 32% of donors 
for a pap smear, 19% for a breast exam, and 16% for a colorectal exam. Other 
procedures, including echocardiograms (46%), stress tests (40%), pulmonary function 
tests (18%), cystoscopy (6%), magnetic resonance (MR) exams (5%), renal biopsy (4%), 
and pyelography (2%), were also considered important parts of the donor evaluation and 
were infrequently used (mean 1.02-1.15 per donor). Other consultations, including 
gastroenterology (5%), pathology (3%), neurology (2%), hematology (2%), plastic 
surgery (2%), respirology (2%), endocrinology (1%), musculoskeletal (1%), and 
rheumatology (1%) were also retained since they may be necessary components of the 







Post-donation follow-up period 
During the follow-up period, some healthcare procedures were utilized by most donors, 
including nephrology consultation (76%), surgery consultation (65%), blood and urine 
tests (52-79%), and intermediate assessments (67%). For small subgroups of donors, the 
frequency of certain healthcare procedures more than doubled after donation. For 
example, a mean 3.18 chest x-rays were conducted for 10% of donors during follow-up 
period compared with a mean 1.40 images among 96% of donors during the evaluation 
period. Similar observations were found for electrocardiograms, CT scans, renal 
ultrasound, echocardiograms, stress tests, immunohematological tests, breast cancer 





Appendix P: Average cost of common procedures calculated from billing codes in 
Apr 1 2010 – Mar 31 2014 
 
Cost per unit for selected procedures  
(2017 Canadian dollars)* 
Procedure** N Median (IQR) Mean (SD) 
Number of donors 589 – – 
donation 511 $2,167 ($1,663-$2,839) $2,168 ($835) 
    
Nephrology consult 739 $165 ($83-$170) $137 ($60) 
Surgery/urology consult 642 $87 ($85-$161) $102 ($47) 
Chest x-ray 541 $36 ($34-$36) $35 ($4) 
Electrocardiogram 649 $18 ($12-$18) $20 ($21) 
Computed tomography 436 $149 ($126-$197) $172 ($57) 
    
Biochemistry test 
(bloodwork) 1069 $25 ($12-$76) $51 ($53) 
Cytology 1139 $8 ($8-$8) $8 ($4) 
Urinalysis 748 $3 ($3-$4) $3 ($1) 
Intermediate assessment 593 $38 ($37-$40) $39 ($10) 
Ultrasound 348 $89 ($84-$149) $120 ($58) 
Nuclear medicine 392 $253 ($203-$272) $220 ($95) 
    
General consult 261 $25 ($23-$32) $38 ($29) 
Echocardiogram 214 $254 ($244-$278) $247 ($53) 
Cardiology evaluation 304 $41 ($10-$88) $72 ($82) 
Stress test 198 $112 ($107-$115) $158 ($138) 
Counseling/psychiatry 262 $85 ($67-$205) $128 ($69) 
Cancer screen (pap) 212 $20 ($20-$49) $42 ($40) 
    
Immunohematology test 146 $11 ($11-$11) $13 ($4) 
Cancer screen (breast) 86 $71 ($67-$77) $76 ($29) 
Pulmonary function test 70 $4 ($4-$4) $33 ($64) 
Cancer screen (colorectal) 73 $44 ($14-$285) $150 ($178) 
General surgery consult 43 $98 ($95-$101) $94 ($19) 
Cystoscopy 27 $77 ($75-$78) $84 ($28) 
    
Magnetic resonance 28 $274 ($246-$329) $267 ($82) 
Gastroenterology consult 36 $169 ($133-$208) $187 ($110) 
Renal biopsy 21 $156 ($152-$156) $155 ($6) 
Pathology consult 7 $83 ($71-$138) $100 ($33) 
Pyelogram <6 – – 
Hematology consult 13 $165 ($162-$168) $140 ($53) 
    
Neurology consult 13 $186 ($79-$193) $144 ($64) 
Plastic surgery consult 15 $29 ($28-$86) $44 ($26) 
Respirology consult 13 $165 ($85-$166) $141 ($75) 
Endocrinology consult <6 – – 
Musculoskeletal consult <6 – – 
Rheumatology consult 9 $126 ($37-$168) $115 ($62) 
costs presented only for more common procedures (present in >10% of donors), 
estimated from costs accrued from April 1, 2010 through March 31, 2014 
IQR – interquartile range; SD – standard deviation 
*costs calculated as of 2010 and later to account for any changes in cost over time 
**the cost for a given procedure was calculated by summing the costs of all relevant 




12 Curriculum Vitae 
 




- Microsoft Office 
- SAS 
- STATA 




- Cohort studies 
- Case-control studies 
- Randomized clinical trials 
- Delphi survey 
- Health economic evaluation  
- Cost-effectiveness analysis 
- Critical appraisal 
 
Statistical expertise 
- Linear and logistic regression 
- Generalised linear models 
- Regression of skewed data 
- Multiple imputation 
- Principal component analysis 
- Survival analysis (censored data) 
- Systematic review 
- Meta analysis 
- Multilevel (hierarchical) modeling 
- Data envelopment analysis 
 
Personal interests 
- Sports (top 3: hockey, badminton, 
table tennis) 
- Reading (top 3: The Count of 
Monte Cristo, Les Misérables, 
Captain Blood) 
MISSION STATEMENT 
I believe that health is more important than wealth. 
Society should strive to promote health equity through 
preventive medicine, improving the built environment, 
changing societal norms, and treating illness. This is 
everyone’s responsibility and I will do my part to produce 




2014-2018 University of Western Ontario 
PhD – Epidemiology and Biostatistics 
Experiences: 
- Analytic epidemiology 
- Biostatistics 
- Clinical epidemiology 
- Health economics 
- Population health surveillance 
- University Teaching and Learning (certificate stream) 
- Dean’s PhD Stipend for Graduate Research award in 
2014 (maximum $25,000/year) 
- Canadian Institutes for Health Research doctoral award 
– Frederick Banting and Charles Best Canada Graduate 
Scholarships ($35,000 over 3 years: May 2015 – April 
2018) 
 
2007-2010 University of Toronto at St. George  
MSc – Institute of Medical Science  
Experiences: 
- Cardiovascular research 
- Biomaterials and biomedical engineering  
- Ethics of experimentation on animals 
- Molecular biology 
- Cytological and histological imaging 
- Ontario Graduate Scholarship (OGS) scholarship 
awarded in 2008 ($15,000) 
 
2003-2007 University of Toronto at Scarborough 




PROFESSIONAL AND LEADERSHIP EXPERIENCE 
 
2018-  Cancer Care Ontario 
Functional Lead – Quality, Measurement, and Evaluation 
- Conduct current state analyses on how cancer patients are diagnosed and 
treated, with focus on regional and socioeconomic variability 
- Develop algorithms to determine the date of suspicion of breast cancer 
- Optimize methods to measure various cancer outcomes, including disease 
recurrence using administrative data 
- Coach analysts on how to analyze, interpret, and report data 
 
2014-2018 University of Western Ontario 
Clinical researcher – Institute for Clinical Evaluative Sciences (ICES) 
- Tasked with understanding the efficiency of the living kidney donor 
evaluation process 
- Performed qualitative and quantitative research to understand the barriers and 
facilitators of an efficient evaluation; supervised junior researchers on 
projects; and engaged various stakeholders including patients, providers, and 
decision-makers. 
- Prepared 10 manuscripts for publication and identified potential solutions to 
improve healthcare delivery. 
- Member of the Canadian National Transplant Research Program 
 
2010-2018 University of Toronto & Western University 
   Teaching assistant  
- Taught seminars and labs for first-year and third-year undergraduate courses 
(30-50 students). 
- Instructed students and created course material for health economics, a 
graduate-level course for 3-10 students. Taught students how to use the 
TreeAge program to conduct cost-effectiveness analyses. 
- Provided ongoing support after the course was completed to students 
interested in pursuing publication of their economic evaluation. 
 
2010-2016 Princess Margaret Cancer Centre 




- Tasked with better understand the epidemiology of human papillomavirus in 
head and neck cancer. 
- Established a large head and neck cancer database, planned and executed a 
multi-centred Canada-wide study, collaborated with experts across 
disciplines, and mentored junior researchers. 
- Advanced 14 reports for publication (8 as lead or co-lead author). The most 
recent publication (Habbous et al., CMAJ 2017) received substantial media 
(television, radio, online) attention due to its high-impact and potential to 
influence public health policy, including CTV, CBC, Global News Calgary 
and Toronto, the Canadian Press, and the Canadian Dental Association 
among others. 
 
2000-2016 City of Toronto – Parks, Forestry and Recreation 
Aquatic supervisor, trainer, instructor, and lifeguard 
- Managed recreational and instructional swimming programs with the City of 
Toronto; facilitated the Toronto Sport Leadership Program, a program 
targeting at-risk youth in Toronto. 
- Ensured facilities are up to standard, staff are certified and qualified to work, 
and liaised with Community Recreation Programmers on issues related to 
staff, public relations, and facility management. 
- Delivered high-quality service to patrons and served as a role model for 
children and adolescents. Helped adolescents prepare resumes and apply for 
jobs with the City of Toronto and the YMCA through the Toronto Sport 
Leadership Program. 
 
2007-2010 Hospital for Sick Children 
   Basic science researcher 
- Challenged with elucidating part of the molecular mechanism behind 
ischemic and pharmacologic preconditioning  
- Performed a series of molecular and biochemical assays to track the 
movement of a specific protein through the rabbit heart after oxygen 
starvation or drug treatment 
- Characterised the spatiotemporal movement of this protein before and after 












1. Lam NN, Garg AG, Habbous S, Lentine KL. “Brenner and Rector's The Kidney”. 
Elsevier Canada. 11th edition [in press; book chapter: “Considerations in living kidney 
donation”]. 
2. Habbous S, Garcia-Ochoa C, Brahm G, Nguan C, Garg AX. “Can split renal volume 
assessment by computed tomography replace nuclear split renal function in living kidney 
donor evaluations? A systematic review and meta analysis”. Am J Kidney Dis [under 
review]. 
3. Habbous S, Subnath M, Giblon R, Dasiewicz A, Wilk P. “Prevalence of food insecurity 
across Canada over time: analysis of nationally representative surveys” Can J Pub Health 
[under review]. 
4. Ren J, Xu W, Su J, Ren X, Cheng D, Chen Z, Bender N, Mirshams M, Habbous S, de 
Almeida J, Perez-Ordonez B, Goldstein D, Want J, Bratman S, Huang SH, Zhao Y, 
Waterboer T, Hung R, Liu G. “Multiple imputation and clinico-serological models to 
predict human papillomavirus (HPV) status in oropharyngeal carcinoma: An alternative 
when tissue is unavailable” Int J Cancer [under review]. 
5. Ren J, Yang W, Su J, Ren X, Fazelzad R, Tiong A, Habbous S, Goldstein D, de Almeida 
J, Hansen A, Jang R, Bratman S, Hope A, Chen Q, Wang J, Xu Y, Cheng D, Zhao Y, Xu 
W, Liu G. “Human Papillomavirus Prevalence and Prognosis of Squamous Carcinoma of 
Unknown Primary in the Head and Neck Region: A Systematic Review and Meta-
Analysis” Clinical Cancer Research [submitted]. 
6. Habbous S, McArthur E, Sarma S, Begen MA, Lam NN, Manns B, Lentine KL, 
Dipchand C, Litchfield K, McKenzie S, Garg AX. “Potential implications of a more 
timely living kidney donor evaluation” Am J Transplant. 2018:18(11):2719-2729. 
7. Habbous S, Sarma S, Barnieh L, McArthur E, Klarenbach S, Manns B, Begen MA, 
Lentine KL, Garg AX. “Healthcare costs for the evaluation, surgery, and follow-up care 
of living kidney donors” Transplantation. 2018:102(8):1367-1374. 
8. Habbous S, Garg, AX, Lam, NN. “Optimizing efficiency in the evaluation of living 
donor candidates: Best practices and implications” Curr Transplant Rep. 2018;5(1):55-
63. 
9. Habbous S, Arnold A, Begen MA, Boudville N, Cooper M, Dipchand C, Dixon SN, 
Feldman LS, Goździk D, Karpinski M, Klarenbach S, Knoll GA, Lam NN, Lentine KL, 
Lok C, McArthur E, McKenzie S, Miller M, Monroy-Cuadros M, Nguan C, Prasad GVR, 
Przech S, Sarma S, Segev D, Storsley L, Garg AX. “Duration of Living Kidney 
Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies” Am J 
Kidney Dis. 2018: 72(4):483-498. 
10. Habbous S, McArthur E, Dixon SN, McKenzie S, Garcia-Ochoa C, Lam NN, Lentine 
KL, Dipchand C, Litchfield K, Begen MA, Sarma S, Garg AX. “Initiating maintenance 
dialysis prior to living kidney donor transplantation when a donor candidate evaluation is 




11. Habbous S, Przech S, Martin J, Garg AX, Sarma S. “Cost-effectiveness of first-line 
sevelamer and lanthanum versus calcium-based binders for hyperphosphatemia of 
chronic kidney disease”. Value Health: 2018;21(3):318-325.  
12. Habbous S, Chu KP, Lau H, Schorr M, Belayneh M, Ha MN, Murray S, O’Sullivan B, 
Huang SH, Snow S, Parliament M, Hao D, Cheung WY, Xu W, Liu G. “The rise of 
human papillomavirus in head and neck cancers in Canada: analysis of five 
comprehensive cancer centres using multiple imputation”. CMAJ (August 14, 2017) 
189(32): E1030-E1040. 
13. Gama RR, Song Y, Zhang Q, Brown MC, Want J, Habbous S, Tong L, Huang SH, 
O’Sullivan B, Waldron J, Xu W, Goldstein D, Liu G. “Body mass index and prognosis in 
patients with head and neck cancer”. Head Neck (June 2017) 39(6): 1226-1233. 
14. Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. The efficacy and safety 
of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating 
hyperphosphatemia in patients with chronic kidney disease: a systematic review and 
meta-analysis. Nephrol Dial Transplant (January 1, 2017) 32(1): 111-125. 
*This article was recommended by the Faculty of 1000. 
15. Chu KP*, Habbous S*, Kuang Q, Boyd K, Mirshams M, Liu FF, Espin-Garcia O, Xu W, 
Goldstein D, Waldron MD, O’Sullivan B, Huang SH, Liu G. “Socioeconomic status, 
human papillomavirus, and overall survival in head and neck squamous cell carcinomas 
in Toronto, Canada”. Cancer Epidemiology. (Dec 2015) 40:102-12.  
*co-first authors 
16. Habbous S, Garg AX, Martin J “Appraisal of a redundant report on lanthanum 
carbonate” International Urology and Nephrology. (Jan 2016) 48(1): 149-50. 
(letter to the editor) 
17. Garg AX, Nevis IF, McArthur E, Sontrop JM, Koval JJ, Lam NN, Hildebrand AM, Reese 
PP, Storsley L, Gill JS, Segev DL, Habbous S, Bugeja A, Knoll GA, Dipchand C, 
Monroy-Caudros M, Lentine KL, DONOR Network “Gestational Hypertension and 
Preeclampsia in Living Kidney Donors” New England Journal of Medicine. (Jan 2015) 
372(2):124-133. 
18. Graham DM, Isaranuwatchai W, Habbous S, de Oliveira C, Liu G, Siu LL, Hoch JS “A 
cost-effectiveness analysis of human papillomavirus vaccination of boys for the 
prevention of oropharyngeal cancer” Cancer. (Jun 2015) 121(11): 1785-1792. 
19. Wang JR, Habbous S, Espin-Garcia O, Chen D, Huang SH, Simpson C, Xu W, Liu F-F, 
Brown DH, Gilbert RB, Gullane PJ, Irish JC, Goldstein DP, Liu G “Comorbidity and 
performance status as independent prognostic factors in head and neck squamous cell 
carcinoma patients” Head Neck (May 2016) 38(5): 736-742. 
20. Habbous S, Pang V, Xu W, Amir E, Liu G “Human Papillomavirus and Host Genetic 
Polymorphisms in Carcinogenesis: A Systematic Review and Meta-Analysis” Journal of 
Clinical Virology. (Oct 2014) 61(2): 220-229. 
21. Wong KM, Qiu X, Cheng D, Azad AK, Habbous S, Palepu PR, Mirshams M, Patel D, 
Chen Z, Roberts H, Knox J, Marquez S, Wong R, Darling G, Waldron J, Goldstein D, 
Leighl NB, Shepherd FA, Tsao M, Der S, Reisman D, Liu G “Two BRM promoter 
insertion polymorphisms increase the risk of early-stage upper aerodigestive tract 
cancers” Cancer Medicine. (Apr 2014) 3(2): 426-33.  
22. Eng L, Su J, Qiu X, Palepu PR, Hon H, Fadhel E, Harland LT, La Delfa A, Habbous S, 




Liu G “Second-hand smoke as a predictor of smoking cessation among lung cancer 
survivors” J Clin Oncol. (Feb 2014) 32(6): 564-70. 
23. Habbous S, Harland LT, La Delfa A, Fadhel E, Xu W, Liu F-F, Goldstein D, Waldron J, 
Huang SH, O’Sullivan B, Liu G “Comorbidity and prognosis in head and neck cancers: 
differences by subsite, stage, and human papillomavirus status” Head and Neck (June 
2014) 36(6): 802-10. 
24. Habbous S, Chu KP, Qiu X, La Delfa A, Harland LT, Fadhel E, Hui A, Perez-Ordonez 
B, Weinreb I, Liu F-F, Waldron J, O’Sullivan B, Goldstein D, Xu W, Huang SH, Liu G 
“The changing incidence of human papillomavirus-associated oropharyngeal cancer 
using multiple imputation from 2000-2010 at a comprehensive Cancer Centre” Cancer 
Epidemiology (Dec 2013) 37(6): 820-9.  
25. Kashigar A*, Habbous S*, Eng L, Irish B, Bissada E, Irish J, Brown D, Gilbert R, 
Gullane P, Xu W, Huang S-H, Witterick I, Freeman J, O’Sullivan B, Waldron J, Liu G, 
Goldstein D “Social environment, secondary smoking exposure, and smoking cessation 
among head and neck cancer patients” Cancer (Aug 2013) 119(15): 2701-2709.  
*co-primary authors 
26. Habbous S, Chu KP, Harland LT, La Delfa A, Fadhel E, Sun B, Xu W, Wong A, Howell 
D, Ringash J, Waldron J, O’Sullivan B, Goldstein D, Huang SH, Liu G “Validation of a 
one-page patient-reported Charlson comorbidity index questionnaire for upper 
aerodigestive tract cancer patients”. Oral Oncology (May 2013) 49(5): 407-412. 
27. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu F-F, Mackay HJ, Amir E, Liu G “p53 
Arg72Pro polymorphism, HPV status and initiation, progression, and development of 
cervical cancer: a systematic review and meta-analysis”. Clinical Cancer Research (Dec 
2012) 18(23): 6407-6415. 
28. Eng L, Azad AK, Habbous S, Pang V, Xu W, van der Zee A-HM, Savas S, Mackay HJ, 
Amir E, Liu G “Vascular Endothelial Growth Factor Pathway Polymorphisms as 
Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-




1. Habbous S, Garg AX “Living Kidney Donor Evaluation Time and Pre-emptive Kidney 
Transplantation.” Canadian National Transplant Research Program, November 8, 2017, 
Mont-Tremblant, Montreal Canada (poster presentation). 
2. Habbous S, Garg AX “Living Kidney Donor Evaluation Time and Pre-emptive Kidney 
Transplantation.” Society for Medical Decision Making, November 2, 2017, New 
Orleans, USA (poster presentation – Abstract #2788155). 
3. Zhe L, Habbous S, Thain J, John-Baptiste A “Cost-effectiveness analysis of frailty 
assessment in older patients undergoing coronary artery bypass grafting surgery.” Society 




4. Habbous S, Garg AX “A multi-centre retrospective study of evaluation times in prior 
living kidney donors.” Canadian Society of Epidemiology and Biostatistics, May 31, 
2017, Banff, Alberta (poster presentation). 
5. Eng L, Alton D, Song Y, Farzanfar D, Krys O, Yoannidis T, Milne R, Habbous S, 
Brown CM, Vennettilli A, Shepherd F, Leighl N, Hope A, Howell D, Jones J, Selby P, 
Xu W, Goldstein DP, Giuliani ME, Liu G “Elimination of second-hand smoke (SHS) 
exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient 
smoking cessation.” Cancer Survivorship Symposium: Advancing Care and Research, 
Jan 2016, San Francisco, CA (poster presentation; Abstract #183). 
6. Seth P, Nicholson K, Habbous S, Ménard J “Implementation of a Hospitalist Medicine 
Model in a Community Hospital: Impact and Patient Satisfaction Two Years Post-
Implementation.” The Canadian Society of Hospitalist Medicine, Sept 24-27, 2015, 
Niagara Falls, ON (poster presentation). 
7. Liu G, Song Y, Alton D, Yoannidis T, Milne R, Sarabia S, Merali Z, Habbous S, Brown 
C, Vinnettilli A, Hope A, Howell D, Jones J, Selby P, Goldstein DP, Giuliani ME, Xu W, 
Eng L “Prediction models of smoking cessation in lung and head and neck cancer 
patients: Role of second-hand smoke (SHS) exposure.” American Society of Clinical 
Oncology, May 29-June 2, 2015, Chicago, IL (poster presentation).  
8. Eng L, Alton D, Yoannidis T, Song Y, Milne, R, Sarabia S, Merali Z, Habbous S, Brown 
C, Vinnettilli A, Shepherd F, Leighl N, Hope A, Howell D, Jones J, Selby P, Xu W, 
Goldstein DP, Giuliani ME, Liu G “Change in second-hand smoke exposure after a lung 
and head and neck cancer diagnosis and subsequent patient smoking cessation” American 
Society of Clinical Oncology, May 29-June 2, 2015, Chicago, IL (poster presentation).  
9. M Safi, Habbous S, A Fung, S Mital “Assessing the impact of early out-of-range 
tacrolimus levels on organ rejection after heart transplant” Canadian Society of 
Transplantation, Feb 28, 2014, Montréal, Canada (Oral presentation; Abstract# 54).  
10. A Fung, T Marvasti, L D’Alessandro, AK Manickaraj, M Safi, Habbous S, S Mital 
“Influence of CYP3A Genetic Polymorphisms on Tacrolimus-Amlodipine Drug 
Interaction in Pediatric Heart Transplant Recipients” Canadian Society of 
Transplantation, Feb 28, 2014, Montréal, Canada (oral presentation; Abstract# 71). 
11. Habbous S, M Safi M, A Fung, S Mital “Influence of concomitant medications on 
tacrolimus levels after pediatric solid organ transplantation” Canadian Society of 
Transplantation, Feb 28, 2014, Montréal, Canada (poster abstract# 45). 
12. Eng L, Habbous S, X Qin, Prakruthi P, H Hon, D Pringle, CE Niu, V Ballarino, Liu G 
“Differences in use of pharmacologic smoking cessation aids between lung and other 
cancer patients” International Conference on Pharmacoepidemiology, August 28, 2013, 
Montréal, Canada (poster abstract #766).  
13. Habbous S, Pang V, Eng L, E Amir, Liu G “Interactions of Human Papillomavirus and 




Analysis” International Conference on Pharmacoepidemiology, August 27, 2013, 
Montréal, Canada (poster abstract #870). 
14. W Isaranuwatchai, DM Graham, Habbous S, C de Oliveira, Liu G, LL Siu, JS Hoch “A 
case study of human papillomavirus vaccination in males: Mixed messages from negative 
cost-effectiveness ratios” Canada’s 2nd Applied Research in Cancer Control Conference, 
May 27, 2013, Vancouver, BC (poster abstract #038). 
15. DM Graham, W Isaranuwatchai, Habbous S, C de Oliveira, Liu G, LL Siu, JS Hoch “A 
preliminary cost-effectiveness analysis of human papillomavirus vaccination in males for 
the prevention of oropharyngeal cancer” Journal of Clinical Oncology, (June 2013) 31 
(suppl; poster abstract #6033), Chicago IL. 
16. Eng L, J Su, X Qiu, PR Palepu, H Hon, E Fadhel, L Harland, La Delfa A, Habbous S, A 
Kashigar, S Cuffe, N B Leighl, A Pierre, P Selby, DP Goldstein, Liu G, Xu W 
“Developing a comprehensive smoking cessation program in lung cancer patients: the 
role of social smoking environments” American Society of Clinical Oncology Quality 
Care Symposium, San Diego, California, November 2012; J Clin Oncol 30, 2012 (suppl 
34; abstract #75; poster). 
17. S. Habbous, KP. Chu, A. La Delfa, L. Harland, X. Qiu, W. Xu, DaviGoldstein D, John 
Waldron, Brian O’Sullivan, S-H. Huang, G. Liu “The rise of Human Papillomavirus 
(HPV)-Associated Oropharyngeal Cancer (OPC) in Toronto, Canada: A Case for 
Vaccinating Males”. International Society for Pharmacoepidemiology, Conference, 
Barcelona, Spain, August 24, 2012 (abstract #902, oral presentation #14). 
18. E. Fadhel, YB Brhane, P Palepu, GP Joshi, H Hon, L Harland, La Delfa A, S. Habbous, 
S Cuffe, J Dong, A Pierre, A Brade, NB Leighl, FA Shepherd, Xu W, Liu G. “Socio-
demographic factors influencing the rates of alcohol cessation and relapse in lung cancer 
survivors” Trillium Primary Health Care Research Day, Toronto CA, June 6, 2012 
(poster presentation #21). 
19. L. Eng, J. Su, P.R. Palepu, H. Hon, E. Fadhel, L. Harland, A. La Delfa, S. Habbous, A. 
Kashigar, S. Cuffe, N. B. Leighl, A. Pierre, D.P, Goldstein, G. Liu, W. Xu “Social 
Environment as Predictors of Smoking Cessation and Recidivism in Lung Cancer 
Survivors”. American Society of Clinical Oncology, Conference, Chicago, June 4, 2012; 
J Clin Oncol 30, 2012 (suppl; abstract #9032; poster). 
20. S. Habbous, V. Pang, L. Eng, H. Mackay, E. Amir, G. Liu “Association of p53 
Arg72Pro Polymorphism and HPV Status in the Initiation, Progression, and Development 
of Cervical Cancer (CC): A Meta-Analysis”. American Society of Clinical Oncology, 
Conference, Chicago, June 2, 2012; J Clin Oncol 30, 2012 (suppl; abstr 1597; poster). 
21. A. Kashigar, D. Goldstein, C. Simpson, S. Habbous, S-H. Huang, J. Waldron, G. Liu, D. 
Goldstein “Smoking and Alcohol Cessation in Head and Neck Cancer Patients” Canadian 





22. S. Habbous, KP. Chu, J. Waldron, L. Harland, A. La Delfa, S. Su, W. Xu, A. Hui, F-F. 
Liu, D. Goldstein, B. O`Sullivan, S-H. Huang, G. Liu “The Effect of Comorbidity, 
Smoking and Alcohol on Survival of Head and Neck Cancer Anatomic Subsites: A 
Retrospective Analysis of 4689 Patients” American Association for Cancer Research, 
Conference, Chicago, April 2012 (abstract #666; poster). 
23. L. Eng, E. Amir, A.K. Azad, S. Habbous, V. Pang, A.-H.M. van der Zee, S. Savas, H. 
Mackay, G. Liu “Polymorphisms in vascular endothelial growth factor (VEGF) and 
associated receptors as prognostic and predictive factors in advanced solid tumors”. 
American Association for Cancer Research, Conference, Chicago, April 2012 (poster, 
abstract #4505). 
24. JR Wang, Habbous S, O Espin-Garcia, Liu F-F, DP Goldstein, Liu G “Comorbidity and 
performance status are independent prognostic factors in head and neck squamous cell 
carcinoma patients” Triological Society 116th Annual Meeting at COSM, Orlando, 
Florida, April 12, 2012 (abstract # A229; 2nd place for best poster). 
25. K. P. Chu, S. Habbous, S-H. Huang, L. Cheng, A. Hope, W. Xu, B. O'Sullivan, J. 
Waldron, E. T. Chang, G. Liu. “Impact of Socioeconomic Status (SES) on Head and 
Neck Cancer (HNC) Survival in an Equal Access Health Care System” International 
Journal of Radiation Oncology, (Oct 5, 2011), 81(2 Suppl 1): S107-S108 (oral 
presentation #214, Miami FL).  
26. S. Habbous*, K. P. Chu*, S-H. Huang, L. Cheng, W. Xu, G. Liu, A. Hope, F. Liu, J. 
Waldron, B. O'Sullivan. “Epidemiological Changes of Oropharyngeal Cancer and other 
Head and Neck Squamous Cell Carcinomas Treated from 2003-2010” International 
Journal of Radiation Oncology (Oct 3, 2011) 81(2 , Suppl 1): S18 (oral presentation #35, 
Miami FL; *co-primary authors). 
27. S. Habbous, Chu KP, HSH. Huang, W. Xu, B. Sun, L. Cheng, A. Tse, DP. Goldstein, J. 
Waldron, B. O’Sullivan, G. Liu. “Comparing Epidemiologic Survey Data To Abstracted 
Data From A Head And Neck Cancer (HNC) Radiation Oncology Administrative 
Database” International Journal of Radiation Oncology (Oct 1, 2011) 81(2, Suppl 1): 
S501-S502 (Miami, FL; poster presentation).  
 
